{
    "63f57d9b33942b094c000004_001": [
        {
            "text": "tryptophan",
            "probability": 0.9999568037021133,
            "start_logit": 9.072176933288574,
            "end_logit": 9.32464599609375
        },
        {
            "text": "try",
            "probability": 2.9226903811400637e-05,
            "start_logit": 9.072176933288574,
            "end_logit": -1.1157317161560059
        },
        {
            "text": "tryptophan absorption",
            "probability": 6.254229261155984e-06,
            "start_logit": 9.072176933288574,
            "end_logit": -2.6575634479522705
        },
        {
            "text": "tryptophan absorption was postulated as the underlying pathology.",
            "probability": 6.1141194517797014e-06,
            "start_logit": 9.072176933288574,
            "end_logit": -2.680220603942871
        },
        {
            "text": "An intestinal defect of tryptophan",
            "probability": 6.013206647320839e-07,
            "start_logit": -5.251917362213135,
            "end_logit": 9.32464599609375
        },
        {
            "text": "nephrocalcinosis. An intestinal defect of tryptophan",
            "probability": 5.104515263034505e-07,
            "start_logit": -5.415750026702881,
            "end_logit": 9.32464599609375
        },
        {
            "text": "hypercalcemia, and nephrocalcinosis. An intestinal defect of tryptophan",
            "probability": 1.5790543909669703e-07,
            "start_logit": -6.589049339294434,
            "end_logit": 9.32464599609375
        },
        {
            "text": "intestinal defect of tryptophan",
            "probability": 1.378264461474086e-07,
            "start_logit": -6.725050449371338,
            "end_logit": 9.32464599609375
        },
        {
            "text": "trypt",
            "probability": 1.0946378249715528e-07,
            "start_logit": 9.072176933288574,
            "end_logit": -6.7029829025268555
        },
        {
            "text": "tryptop",
            "probability": 8.400222280378943e-08,
            "start_logit": 9.072176933288574,
            "end_logit": -6.967733383178711
        },
        {
            "text": "An intestinal defect of try",
            "probability": 1.757550042448395e-11,
            "start_logit": -5.251917362213135,
            "end_logit": -1.1157317161560059
        },
        {
            "text": "nephrocalcinosis. An intestinal defect of try",
            "probability": 1.4919562129503676e-11,
            "start_logit": -5.415750026702881,
            "end_logit": -1.1157317161560059
        },
        {
            "text": "Blue diaper syndrome (BDS) (Online Mendelian Inheritance in Man number 211000",
            "probability": 7.0387181939490025e-12,
            "start_logit": -0.6494863033294678,
            "end_logit": -6.633242607116699
        },
        {
            "text": "The characteristic finding is a bluish discoloration of urine spots in the diapers of affected infants.",
            "probability": 6.959772133080615e-12,
            "start_logit": -4.616976261138916,
            "end_logit": -2.677031993865967
        },
        {
            "text": "Blue diaper syndrome",
            "probability": 6.451358726716019e-12,
            "start_logit": -0.6494863033294678,
            "end_logit": -6.7203779220581055
        },
        {
            "text": "Blue diaper syndrome (BDS",
            "probability": 5.3890192704832525e-12,
            "start_logit": -0.6494863033294678,
            "end_logit": -6.900305271148682
        },
        {
            "text": "hypercalcemia, and nephrocalcinosis. An intestinal defect of try",
            "probability": 4.615286443064173e-12,
            "start_logit": -6.589049339294434,
            "end_logit": -1.1157317161560059
        },
        {
            "text": "diarrhea, inadequate weight gain, hypercalcemia, and nephrocalcinosis. An intestinal defect of try",
            "probability": 4.5419892639473525e-12,
            "start_logit": -6.605058193206787,
            "end_logit": -1.1157317161560059
        },
        {
            "text": "intestinal defect of try",
            "probability": 4.028414296801476e-12,
            "start_logit": -6.725050449371338,
            "end_logit": -1.1157317161560059
        },
        {
            "text": "An intestinal defect of tryptophan absorption",
            "probability": 3.760959756243137e-12,
            "start_logit": -5.251917362213135,
            "end_logit": -2.6575634479522705
        }
    ],
    "63f57d9b33942b094c000004_002": [
        {
            "text": "tryptophan",
            "probability": 0.9997520145220714,
            "start_logit": 9.430766105651855,
            "end_logit": 9.562413215637207
        },
        {
            "text": "try",
            "probability": 0.00011818120794704928,
            "start_logit": 9.430766105651855,
            "end_logit": 0.5193697810173035
        },
        {
            "text": "tryptophan.",
            "probability": 0.00010538065494370888,
            "start_logit": 9.430766105651855,
            "end_logit": 0.4047297537326813
        },
        {
            "text": "We describe the ocular abnormalities seen in a new metabolic disease which is deficient in the transport of tryptophan",
            "probability": 1.9839782182972002e-05,
            "start_logit": -1.396807312965393,
            "end_logit": 9.562413215637207
        },
        {
            "text": "a new metabolic disease which is deficient in the transport of tryptophan",
            "probability": 1.6960195400051418e-06,
            "start_logit": -3.8562123775482178,
            "end_logit": 9.562413215637207
        },
        {
            "text": "deficient in the transport of tryptophan",
            "probability": 7.333975018709903e-07,
            "start_logit": -4.694563865661621,
            "end_logit": 9.562413215637207
        },
        {
            "text": "the ocular abnormalities seen in a new metabolic disease which is deficient in the transport of tryptophan",
            "probability": 4.6299375249371067e-07,
            "start_logit": -5.154538154602051,
            "end_logit": 9.562413215637207
        },
        {
            "text": "ocular abnormalities seen in a new metabolic disease which is deficient in the transport of tryptophan",
            "probability": 4.207837965283627e-07,
            "start_logit": -5.2501325607299805,
            "end_logit": 9.562413215637207
        },
        {
            "text": "trypt",
            "probability": 2.621733940821418e-07,
            "start_logit": 9.430766105651855,
            "end_logit": -5.5915985107421875
        },
        {
            "text": "new metabolic disease which is deficient in the transport of tryptophan",
            "probability": 2.6176179633022245e-07,
            "start_logit": -5.724816799163818,
            "end_logit": 9.562413215637207
        },
        {
            "text": "tryptop",
            "probability": 2.5189391831887644e-07,
            "start_logit": 9.430766105651855,
            "end_logit": -5.631596565246582
        },
        {
            "text": "describe the ocular abnormalities seen in a new metabolic disease which is deficient in the transport of tryptophan",
            "probability": 1.5374965385588317e-07,
            "start_logit": -6.2569260597229,
            "end_logit": 9.562413215637207
        },
        {
            "text": "which is deficient in the transport of tryptophan",
            "probability": 1.275521948611041e-07,
            "start_logit": -6.443726062774658,
            "end_logit": 9.562413215637207
        },
        {
            "text": "metabolic disease which is deficient in the transport of tryptophan",
            "probability": 1.0462042266108946e-07,
            "start_logit": -6.641912937164307,
            "end_logit": 9.562413215637207
        },
        {
            "text": "in a new metabolic disease which is deficient in the transport of tryptophan",
            "probability": 1.0398441002716296e-07,
            "start_logit": -6.648010730743408,
            "end_logit": 9.562413215637207
        },
        {
            "text": "We describe the ocular abnormalities seen in a new metabolic disease which is deficient in the transport of try",
            "probability": 2.3452710169439867e-09,
            "start_logit": -1.396807312965393,
            "end_logit": 0.5193697810173035
        },
        {
            "text": "We describe the ocular abnormalities seen in a new metabolic disease which is deficient in the transport of tryptophan.",
            "probability": 2.0912478394770557e-09,
            "start_logit": -1.396807312965393,
            "end_logit": 0.4047297537326813
        },
        {
            "text": "a new metabolic disease which is deficient in the transport of try",
            "probability": 2.0048735589237615e-10,
            "start_logit": -3.8562123775482178,
            "end_logit": 0.5193697810173035
        },
        {
            "text": "a new metabolic disease which is deficient in the transport of tryptophan.",
            "probability": 1.787719827786593e-10,
            "start_logit": -3.8562123775482178,
            "end_logit": 0.4047297537326813
        },
        {
            "text": "deficient in the transport of try",
            "probability": 8.669530185232598e-11,
            "start_logit": -4.694563865661621,
            "end_logit": 0.5193697810173035
        }
    ],
    "6450ec0c57b1c7a31500008f_001": [
        {
            "text": "frataxin",
            "probability": 0.5146545233398306,
            "start_logit": 3.675513982772827,
            "end_logit": 3.4864892959594727
        },
        {
            "text": "FXN gene, which leads to decreased levels of the frataxin",
            "probability": 0.4526309724261659,
            "start_logit": 3.54709529876709,
            "end_logit": 3.4864892959594727
        },
        {
            "text": "frataxin protein.",
            "probability": 0.010866153189266915,
            "start_logit": 3.675513982772827,
            "end_logit": -0.37135380506515503
        },
        {
            "text": "FXN gene, which leads to decreased levels of the frataxin protein.",
            "probability": 0.009556619560384075,
            "start_logit": 3.54709529876709,
            "end_logit": -0.37135380506515503
        },
        {
            "text": "FXN gene,",
            "probability": 0.007468639747286567,
            "start_logit": 3.54709529876709,
            "end_logit": -0.6178749799728394
        },
        {
            "text": "FXN gene",
            "probability": 0.001654227594738101,
            "start_logit": 3.54709529876709,
            "end_logit": -2.125253677368164
        },
        {
            "text": "a triplet guanine-adenine-adenine (GAA) repeat expansion",
            "probability": 0.0009002502607932552,
            "start_logit": -1.2903777360916138,
            "end_logit": 2.1038026809692383
        },
        {
            "text": "FXN",
            "probability": 0.0006708603172859435,
            "start_logit": 3.54709529876709,
            "end_logit": -3.0277822017669678
        },
        {
            "text": "GAA) repeat expansion in intron 1 of the FXN gene, which leads to decreased levels of the frataxin",
            "probability": 0.000657822907406439,
            "start_logit": -2.9868013858795166,
            "end_logit": 3.4864892959594727
        },
        {
            "text": "GAA) repeat expansion",
            "probability": 0.00016505011291596775,
            "start_logit": -2.9868013858795166,
            "end_logit": 2.1038026809692383
        },
        {
            "text": "expansion in intron 1 of the FXN gene, which leads to decreased levels of the frataxin",
            "probability": 0.0001648050987913186,
            "start_logit": -4.370973587036133,
            "end_logit": 3.4864892959594727
        },
        {
            "text": "which leads to decreased levels of the frataxin",
            "probability": 0.00013728114470479088,
            "start_logit": -4.553706169128418,
            "end_logit": 3.4864892959594727
        },
        {
            "text": "the FXN gene, which leads to decreased levels of the frataxin",
            "probability": 0.00012831729505328326,
            "start_logit": -4.6212310791015625,
            "end_logit": 3.4864892959594727
        },
        {
            "text": "guanine-adenine-adenine (GAA) repeat expansion",
            "probability": 5.9759562428360844e-05,
            "start_logit": -4.002721309661865,
            "end_logit": 2.1038026809692383
        },
        {
            "text": "FRDA",
            "probability": 5.9403931409329736e-05,
            "start_logit": 0.89591383934021,
            "end_logit": -2.8008012771606445
        },
        {
            "text": "a triplet guanine-adenine-adenine (GAA) repeat expansion in intron 1 of the FXN gene,",
            "probability": 5.920435665199348e-05,
            "start_logit": -1.2903777360916138,
            "end_logit": -0.6178749799728394
        },
        {
            "text": "decreased levels of the frataxin",
            "probability": 4.66497750363353e-05,
            "start_logit": -5.633069038391113,
            "end_logit": 3.4864892959594727
        },
        {
            "text": "leads to decreased levels of the frataxin",
            "probability": 4.384048391858559e-05,
            "start_logit": -5.695179462432861,
            "end_logit": 3.4864892959594727
        },
        {
            "text": "expansion",
            "probability": 4.1350186894339986e-05,
            "start_logit": -4.370973587036133,
            "end_logit": 2.1038026809692383
        },
        {
            "text": "the frataxin",
            "probability": 3.4268709037758077e-05,
            "start_logit": -5.94150447845459,
            "end_logit": 3.4864892959594727
        }
    ],
    "644ef46557b1c7a315000083_001": [
        {
            "text": "Oncogenes",
            "probability": 0.969880914396585,
            "start_logit": 4.917050838470459,
            "end_logit": 2.270400047302246
        },
        {
            "text": "Oncogenes are gain-of-function mutations of normal regulatory genes or proto-oncogenes.",
            "probability": 0.014340486529079079,
            "start_logit": 4.917050838470459,
            "end_logit": -1.9436864852905273
        },
        {
            "text": "Oncogenes are gain-of-function mutations of normal regulatory genes or proto-oncogenes",
            "probability": 0.010843773525135023,
            "start_logit": 4.917050838470459,
            "end_logit": -2.223182201385498
        },
        {
            "text": "Oncogenes are gain-of-function mutations of normal regulatory genes",
            "probability": 0.0027350771774995643,
            "start_logit": 4.917050838470459,
            "end_logit": -3.600613594055176
        },
        {
            "text": "Oncogene",
            "probability": 0.0018463761029638983,
            "start_logit": 4.917050838470459,
            "end_logit": -3.9935483932495117
        },
        {
            "text": "On",
            "probability": 0.00022045257388718796,
            "start_logit": 4.917050838470459,
            "end_logit": -6.1188459396362305
        },
        {
            "text": "oncogenes",
            "probability": 4.3825538046924554e-05,
            "start_logit": -1.2042502164840698,
            "end_logit": -1.6130107641220093
        },
        {
            "text": "Proto-oncogenes are altered by point mutation, amplification or rearrangement.",
            "probability": 3.351787955438765e-05,
            "start_logit": -1.1399359703063965,
            "end_logit": -1.945462703704834
        },
        {
            "text": "oncogenes are believed to be important contributors to human carcinogenesis.",
            "probability": 3.140867357504066e-05,
            "start_logit": -1.2042502164840698,
            "end_logit": -1.946143388748169
        },
        {
            "text": "Proto-oncogenes",
            "probability": 6.95226411009607e-06,
            "start_logit": -1.1399359703063965,
            "end_logit": -3.5184743404388428
        },
        {
            "text": "oncogenes are believed to be important contributors to human carcinogenesis. Proto-oncogenes",
            "probability": 6.519209534728589e-06,
            "start_logit": -1.2042502164840698,
            "end_logit": -3.5184743404388428
        },
        {
            "text": "proto-oncogenes.",
            "probability": 3.1923446548329857e-06,
            "start_logit": -3.4930355548858643,
            "end_logit": -1.9436864852905273
        },
        {
            "text": "proto-oncogenes",
            "probability": 2.4139391910441193e-06,
            "start_logit": -3.4930355548858643,
            "end_logit": -2.223182201385498
        },
        {
            "text": "gain-of-function mutations of normal regulatory genes or proto-oncogenes.",
            "probability": 1.1868645154250457e-06,
            "start_logit": -4.482476234436035,
            "end_logit": -1.9436864852905273
        },
        {
            "text": "Originally discovered in retroviruses initiating a variety of animal and avian cancers, oncogenes",
            "probability": 1.1225467680053559e-06,
            "start_logit": -4.868866920471191,
            "end_logit": -1.6130107641220093
        },
        {
            "text": "retroviruses initiating a variety of animal and avian cancers, oncogenes",
            "probability": 9.683794252660015e-07,
            "start_logit": -5.016598224639893,
            "end_logit": -1.6130107641220093
        },
        {
            "text": "gain-of-function mutations of normal regulatory genes or proto-oncogenes",
            "probability": 8.974653673144808e-07,
            "start_logit": -4.482476234436035,
            "end_logit": -2.223182201385498
        },
        {
            "text": "Proto-oncogenes are altered by point mutation, amplification or rearrangement",
            "probability": 3.2319785150942173e-07,
            "start_logit": -1.1399359703063965,
            "end_logit": -6.587032318115234
        },
        {
            "text": "normal regulatory genes or proto-oncogenes.",
            "probability": 3.045391796211238e-07,
            "start_logit": -5.842746734619141,
            "end_logit": -1.9436864852905273
        },
        {
            "text": "oncogenes are believed to be important contributors to human carcinogenesis",
            "probability": 2.868530761461751e-07,
            "start_logit": -1.2042502164840698,
            "end_logit": -6.642012596130371
        }
    ],
    "6432fdd857b1c7a315000020_001": [
        {
            "text": "autosomal dominant",
            "probability": 0.9979271306585129,
            "start_logit": 7.6667046546936035,
            "end_logit": 8.875371932983398
        },
        {
            "text": "Hereditary angioedema (HAE) is a rare autosomal dominant",
            "probability": 0.0012244211913676015,
            "start_logit": 0.9634926319122314,
            "end_logit": 8.875371932983398
        },
        {
            "text": "dominant",
            "probability": 0.0006736230681012329,
            "start_logit": 0.36593982577323914,
            "end_logit": 8.875371932983398
        },
        {
            "text": "auto",
            "probability": 0.00010134376335226051,
            "start_logit": 7.6667046546936035,
            "end_logit": -0.31954526901245117
        },
        {
            "text": "autosomal dominant disorder caused by mutations of the SERPING1 or the Factor 12 genes.",
            "probability": 4.9313376294759845e-05,
            "start_logit": 7.6667046546936035,
            "end_logit": -1.0398682355880737
        },
        {
            "text": "autosomal",
            "probability": 7.244770550599575e-06,
            "start_logit": 7.6667046546936035,
            "end_logit": -2.9577836990356445
        },
        {
            "text": "autosomal dominant disorder caused by mutations of the SERPING1 or the Factor 12 genes",
            "probability": 3.7832071831671166e-06,
            "start_logit": 7.6667046546936035,
            "end_logit": -3.6074914932250977
        },
        {
            "text": "rare autosomal dominant",
            "probability": 2.491074110812992e-06,
            "start_logit": -5.2340168952941895,
            "end_logit": 8.875371932983398
        },
        {
            "text": "autosomal dominant disorder caused by mutations of the SERPING1",
            "probability": 2.193593442268881e-06,
            "start_logit": 7.6667046546936035,
            "end_logit": -4.152522563934326
        },
        {
            "text": "a rare autosomal dominant",
            "probability": 1.839101672866338e-06,
            "start_logit": -5.537453651428223,
            "end_logit": 8.875371932983398
        },
        {
            "text": "HAE) is a rare autosomal dominant",
            "probability": 1.7404387083296802e-06,
            "start_logit": -5.592593669891357,
            "end_logit": 8.875371932983398
        },
        {
            "text": "autoso",
            "probability": 1.4540106955153146e-06,
            "start_logit": 7.6667046546936035,
            "end_logit": -4.563737869262695
        },
        {
            "text": "autosomal dominant disorder caused by mutations of the SERPING1 or the Factor 12",
            "probability": 9.402613931942962e-07,
            "start_logit": 7.6667046546936035,
            "end_logit": -4.999660968780518
        },
        {
            "text": "(HAE) is a rare autosomal dominant",
            "probability": 8.346424764110486e-07,
            "start_logit": -6.3274827003479,
            "end_logit": 8.875371932983398
        },
        {
            "text": "autosomal dominant disorder",
            "probability": 6.439826327815564e-07,
            "start_logit": 7.6667046546936035,
            "end_logit": -5.378147125244141
        },
        {
            "text": "angioedema (HAE) is a rare autosomal dominant",
            "probability": 5.867080526707719e-07,
            "start_logit": -6.679958820343018,
            "end_logit": 8.875371932983398
        },
        {
            "text": "autosomal dominant disorder caused by mutations of",
            "probability": 1.5021100096280342e-07,
            "start_logit": 7.6667046546936035,
            "end_logit": -6.833777904510498
        },
        {
            "text": "Hereditary angioedema (HAE) is a rare auto",
            "probability": 1.2434520282013797e-07,
            "start_logit": 0.9634926319122314,
            "end_logit": -0.31954526901245117
        },
        {
            "text": "autosomal dominant disorder caused",
            "probability": 1.0830761992058815e-07,
            "start_logit": 7.6667046546936035,
            "end_logit": -7.160843372344971
        },
        {
            "text": "dominant disorder caused by mutations of the SERPING1 or the Factor 12 genes.",
            "probability": 3.328762874317927e-08,
            "start_logit": 0.36593982577323914,
            "end_logit": -1.0398682355880737
        }
    ],
    "6450ede757b1c7a315000090_001": [
        {
            "text": "first or second decade",
            "probability": 0.9722577072342605,
            "start_logit": 5.8353142738342285,
            "end_logit": 5.6316237449646
        },
        {
            "text": "second decade",
            "probability": 0.013951931562562208,
            "start_logit": 1.5913113355636597,
            "end_logit": 5.6316237449646
        },
        {
            "text": "the first or second decade",
            "probability": 0.005152640546683341,
            "start_logit": 0.5952026844024658,
            "end_logit": 5.6316237449646
        },
        {
            "text": "Friedreich's ataxia is classically considered a disease with onset in the first or second decade",
            "probability": 0.004420262315247915,
            "start_logit": 0.4418924152851105,
            "end_logit": 5.6316237449646
        },
        {
            "text": "first or second decade.",
            "probability": 0.001972422317504189,
            "start_logit": 5.8353142738342285,
            "end_logit": -0.5687347650527954
        },
        {
            "text": "decade",
            "probability": 0.0013974524000304417,
            "start_logit": -0.70965576171875,
            "end_logit": 5.6316237449646
        },
        {
            "text": "first",
            "probability": 0.00040455467271229543,
            "start_logit": 5.8353142738342285,
            "end_logit": -2.152965545654297
        },
        {
            "text": "in the first or second decade",
            "probability": 0.0002854652938650688,
            "start_logit": -2.2979414463043213,
            "end_logit": 5.6316237449646
        },
        {
            "text": "first or second",
            "probability": 6.285462813803061e-05,
            "start_logit": 5.8353142738342285,
            "end_logit": -4.014927864074707
        },
        {
            "text": "second decade.",
            "probability": 2.830432814420282e-05,
            "start_logit": 1.5913113355636597,
            "end_logit": -0.5687347650527954
        },
        {
            "text": "or second decade",
            "probability": 2.0578443253052127e-05,
            "start_logit": -4.9278178215026855,
            "end_logit": 5.6316237449646
        },
        {
            "text": "the first or second decade.",
            "probability": 1.0453178342258631e-05,
            "start_logit": 0.5952026844024658,
            "end_logit": -0.5687347650527954
        },
        {
            "text": "Friedreich's ataxia is classically considered a disease with onset in the first or second decade.",
            "probability": 8.967400283839575e-06,
            "start_logit": 0.4418924152851105,
            "end_logit": -0.5687347650527954
        },
        {
            "text": "onset in the first or second decade",
            "probability": 8.451652599536147e-06,
            "start_logit": -5.817699909210205,
            "end_logit": 5.6316237449646
        },
        {
            "text": "classically considered a disease with onset in the first or second decade",
            "probability": 5.4950917786038605e-06,
            "start_logit": -6.248206615447998,
            "end_logit": 5.6316237449646
        },
        {
            "text": "decade.",
            "probability": 2.835016149484431e-06,
            "start_logit": -0.70965576171875,
            "end_logit": -0.5687347650527954
        },
        {
            "text": "a disease with onset in the first or second decade",
            "probability": 2.7118546018103054e-06,
            "start_logit": -6.9544291496276855,
            "end_logit": 5.6316237449646
        },
        {
            "text": "with onset in the first or second decade",
            "probability": 2.4012643505807663e-06,
            "start_logit": -7.076066493988037,
            "end_logit": 5.6316237449646
        },
        {
            "text": "disease with onset in the first or second decade",
            "probability": 2.3667950847468907e-06,
            "start_logit": -7.090525150299072,
            "end_logit": 5.6316237449646
        },
        {
            "text": "the first",
            "probability": 2.1440044079437947e-06,
            "start_logit": 0.5952026844024658,
            "end_logit": -2.152965545654297
        }
    ],
    "63f03d58f36125a42600001f_001": [
        {
            "text": "hip fractures",
            "probability": 0.9210564373371571,
            "start_logit": 9.366989135742188,
            "end_logit": 9.697088241577148
        },
        {
            "text": "hip fracture",
            "probability": 0.04378966401159739,
            "start_logit": 9.366989135742188,
            "end_logit": 6.650964736938477
        },
        {
            "text": "displaced intracapsular hip fractures",
            "probability": 0.028181461701359996,
            "start_logit": 5.88013219833374,
            "end_logit": 9.697088241577148
        },
        {
            "text": "fractures",
            "probability": 0.0039898794248635645,
            "start_logit": 3.9252288341522217,
            "end_logit": 9.697088241577148
        },
        {
            "text": "displaced intracapsular hip fracture",
            "probability": 0.0013398274950729447,
            "start_logit": 5.88013219833374,
            "end_logit": 6.650964736938477
        },
        {
            "text": "intracapsular hip fractures",
            "probability": 0.0011475982890484415,
            "start_logit": 2.6791391372680664,
            "end_logit": 9.697088241577148
        },
        {
            "text": "hip",
            "probability": 0.00023924069701073252,
            "start_logit": 9.366989135742188,
            "end_logit": 1.441281795501709
        },
        {
            "text": "fracture",
            "probability": 0.0001896903081929229,
            "start_logit": 3.9252288341522217,
            "end_logit": 6.650964736938477
        },
        {
            "text": "intracapsular hip fracture",
            "probability": 5.456011321412648e-05,
            "start_logit": 2.6791391372680664,
            "end_logit": 6.650964736938477
        },
        {
            "text": "displaced intracapsular hip",
            "probability": 7.3200210832972354e-06,
            "start_logit": 5.88013219833374,
            "end_logit": 1.441281795501709
        },
        {
            "text": "hip fractures : the World Hip Trauma Evaluation 5 (WHiTE 5) trial.",
            "probability": 2.8578737413868083e-06,
            "start_logit": 9.366989135742188,
            "end_logit": -2.9861104488372803
        },
        {
            "text": "intracapsular hip",
            "probability": 2.980840298494891e-07,
            "start_logit": 2.6791391372680664,
            "end_logit": 1.441281795501709
        },
        {
            "text": "hydroxyapatite-coated uncemented hemiarthroplasty for the treatment of displaced intracapsular hip fractures",
            "probability": 2.451625121340198e-07,
            "start_logit": -5.772121429443359,
            "end_logit": 9.697088241577148
        },
        {
            "text": "hip fractures : the World Hip Trauma Evaluation 5",
            "probability": 2.264318451666399e-07,
            "start_logit": 9.366989135742188,
            "end_logit": -5.5214996337890625
        },
        {
            "text": "hip fractures : the World Hip Trauma Evaluation 5 (WHiTE 5",
            "probability": 2.219095727223825e-07,
            "start_logit": 9.366989135742188,
            "end_logit": -5.54167366027832
        },
        {
            "text": "treatment of displaced intracapsular hip fractures",
            "probability": 1.193627962565497e-07,
            "start_logit": -6.491875171661377,
            "end_logit": 9.697088241577148
        },
        {
            "text": "the treatment of displaced intracapsular hip fractures",
            "probability": 1.1089417087294675e-07,
            "start_logit": -6.565466403961182,
            "end_logit": 9.697088241577148
        },
        {
            "text": "of displaced intracapsular hip fractures",
            "probability": 9.493063726551947e-08,
            "start_logit": -6.720896244049072,
            "end_logit": 9.697088241577148
        },
        {
            "text": "displaced intracapsular hip fractures : the World Hip Trauma Evaluation 5 (WHiTE 5) trial.",
            "probability": 8.744204603038134e-08,
            "start_logit": 5.88013219833374,
            "end_logit": -2.9861104488372803
        },
        {
            "text": "displaced",
            "probability": 5.851004790512454e-08,
            "start_logit": 5.88013219833374,
            "end_logit": -3.387888193130493
        }
    ],
    "63f03d58f36125a42600001f_002": [
        {
            "text": "fracture",
            "probability": 0.9995729818577934,
            "start_logit": 4.565885543823242,
            "end_logit": 5.6213483810424805
        },
        {
            "text": "fracture: A protocol for the WHiTE 8 COPAL study.",
            "probability": 0.00011976693886741433,
            "start_logit": 4.565885543823242,
            "end_logit": -3.4081873893737793
        },
        {
            "text": "fracture: A protocol for the WHiTE 8 COPAL",
            "probability": 6.719325576900975e-05,
            "start_logit": 4.565885543823242,
            "end_logit": -3.9861621856689453
        },
        {
            "text": "hip hemiarthroplasty after fracture",
            "probability": 5.492043744199396e-05,
            "start_logit": -5.243312358856201,
            "end_logit": 5.6213483810424805
        },
        {
            "text": "after fracture",
            "probability": 3.736431258333097e-05,
            "start_logit": -5.628481864929199,
            "end_logit": 5.6213483810424805
        },
        {
            "text": "low dose single antibiotic-loaded cement versus high dose dual antibiotic-loaded cement in patients receiving a hip hemiarthroplasty after fracture",
            "probability": 3.4908089189126345e-05,
            "start_logit": -5.696479320526123,
            "end_logit": 5.6213483810424805
        },
        {
            "text": "high dose dual antibiotic-loaded cement in patients receiving a hip hemiarthroplasty after fracture",
            "probability": 2.3099059684149113e-05,
            "start_logit": -6.109405994415283,
            "end_logit": 5.6213483810424805
        },
        {
            "text": "hemiarthroplasty after fracture",
            "probability": 1.713888782686394e-05,
            "start_logit": -6.407847881317139,
            "end_logit": 5.6213483810424805
        },
        {
            "text": "a hip hemiarthroplasty after fracture",
            "probability": 1.594228802302551e-05,
            "start_logit": -6.480222702026367,
            "end_logit": 5.6213483810424805
        },
        {
            "text": "fracture:",
            "probability": 1.3364465240255988e-05,
            "start_logit": 4.565885543823242,
            "end_logit": -5.601135730743408
        },
        {
            "text": "fracture: A protocol for the WHiTE 8 COPAL study",
            "probability": 1.0838082858180988e-05,
            "start_logit": 4.565885543823242,
            "end_logit": -5.8106689453125
        },
        {
            "text": "patients receiving a hip hemiarthroplasty after fracture",
            "probability": 9.780011074812682e-06,
            "start_logit": -6.968857288360596,
            "end_logit": 5.6213483810424805
        },
        {
            "text": "single antibiotic-loaded cement versus high dose dual antibiotic-loaded cement in patients receiving a hip hemiarthroplasty after fracture",
            "probability": 9.471787690008791e-06,
            "start_logit": -7.000880241394043,
            "end_logit": 5.6213483810424805
        },
        {
            "text": "antibiotic-loaded cement versus high dose dual antibiotic-loaded cement in patients receiving a hip hemiarthroplasty after fracture",
            "probability": 9.361406773839082e-06,
            "start_logit": -7.01260232925415,
            "end_logit": 5.6213483810424805
        },
        {
            "text": "fracture: A protocol for the WHiTE 8",
            "probability": 2.1761708786258875e-06,
            "start_logit": 4.565885543823242,
            "end_logit": -7.416168212890625
        },
        {
            "text": "fracture: A protocol for the WHiTE",
            "probability": 1.6705908057578964e-06,
            "start_logit": 4.565885543823242,
            "end_logit": -7.680557727813721
        },
        {
            "text": "hip hemiarthroplasty after fracture: A protocol for the WHiTE 8 COPAL study.",
            "probability": 6.580462650622872e-09,
            "start_logit": -5.243312358856201,
            "end_logit": -3.4081873893737793
        },
        {
            "text": "A protocol for the WHiTE 8 COPAL study.",
            "probability": 6.41160609245974e-09,
            "start_logit": -5.269307613372803,
            "end_logit": -3.4081873893737793
        },
        {
            "text": "WHiTE 8 COPAL study.",
            "probability": 4.88851064455957e-09,
            "start_logit": -5.540529727935791,
            "end_logit": -3.4081873893737793
        },
        {
            "text": "after fracture: A protocol for the WHiTE 8 COPAL study.",
            "probability": 4.476921067507812e-09,
            "start_logit": -5.628481864929199,
            "end_logit": -3.4081873893737793
        }
    ],
    "63f03d58f36125a42600001f_003": [
        {
            "text": "Hemiarthroplasty Evaluation by Multicentre Investigation - WHITE 3: HEMI - An Abridged Protocol.",
            "probability": 0.6177947932568976,
            "start_logit": 0.5629986524581909,
            "end_logit": -4.067610740661621
        },
        {
            "text": "Hemiarthroplasty",
            "probability": 0.08446778376942407,
            "start_logit": 0.5629986524581909,
            "end_logit": -6.05739688873291
        },
        {
            "text": "Hemiarthroplasty Evaluation by Multicentre Investigation - WHITE 3: HEMI",
            "probability": 0.07896909184058824,
            "start_logit": 0.5629986524581909,
            "end_logit": -6.124710559844971
        },
        {
            "text": "Hemiarthroplasty Evaluation by Multicentre Investigation",
            "probability": 0.06288056230801604,
            "start_logit": 0.5629986524581909,
            "end_logit": -6.352530002593994
        },
        {
            "text": "Hemiarthroplasty Evaluation by Multicentre",
            "probability": 0.02960382340468121,
            "start_logit": 0.5629986524581909,
            "end_logit": -7.105863571166992
        },
        {
            "text": "Hemiarthroplasty Evaluation by Multicentre Investigation -",
            "probability": 0.02486048402309141,
            "start_logit": 0.5629986524581909,
            "end_logit": -7.280487537384033
        },
        {
            "text": "Hemiarthroplasty Evaluation by Multicentre Investigation - WHITE 3",
            "probability": 0.024791622510305252,
            "start_logit": 0.5629986524581909,
            "end_logit": -7.283261299133301
        },
        {
            "text": "Hemiarthroplasty Evaluation by Multicentre Investigation - WHITE 3: HEMI -",
            "probability": 0.023841938578945916,
            "start_logit": 0.5629986524581909,
            "end_logit": -7.322320938110352
        },
        {
            "text": "Hemiarthroplasty Evaluation by Multicentre Investigation - WHITE 3: HEMI - An Abridged Protocol",
            "probability": 0.016979500492238488,
            "start_logit": 0.5629986524581909,
            "end_logit": -7.661760330200195
        },
        {
            "text": "Hemiarthroplasty Evaluation",
            "probability": 0.016635024705548968,
            "start_logit": 0.5629986524581909,
            "end_logit": -7.682256698608398
        },
        {
            "text": "Hemiarthroplasty Evaluation by Multicentre Investigation - WHITE",
            "probability": 0.014245628722418214,
            "start_logit": 0.5629986524581909,
            "end_logit": -7.837316989898682
        },
        {
            "text": "The World Hip Trauma Evaluation Study 3: Hemiarthroplasty",
            "probability": 0.001066541963073152,
            "start_logit": -3.8089499473571777,
            "end_logit": -6.05739688873291
        },
        {
            "text": "The World Hip Trauma Evaluation Study 3: Hemiarthroplasty Evaluation by Multicentre Investigation",
            "probability": 0.0007939684856205662,
            "start_logit": -3.8089499473571777,
            "end_logit": -6.352530002593994
        },
        {
            "text": "HEMI - An Abridged Protocol.",
            "probability": 0.0007570434219072993,
            "start_logit": -6.1414923667907715,
            "end_logit": -4.067610740661621
        },
        {
            "text": "WHITE 3: HEMI - An Abridged Protocol.",
            "probability": 0.0006682592499817151,
            "start_logit": -6.266236782073975,
            "end_logit": -4.067610740661621
        },
        {
            "text": "The World Hip Trauma Evaluation Study 3",
            "probability": 0.00038854217478589585,
            "start_logit": -3.8089499473571777,
            "end_logit": -7.067172050476074
        },
        {
            "text": "The World Hip Trauma Evaluation Study 3: Hemiarthroplasty Evaluation by Multicentre",
            "probability": 0.00037379600268296347,
            "start_logit": -3.8089499473571777,
            "end_logit": -7.105863571166992
        },
        {
            "text": "The World Hip Trauma Evaluation Study 3: Hemiarthroplasty Evaluation by Multicentre Investigation -",
            "probability": 0.00031390369499116106,
            "start_logit": -3.8089499473571777,
            "end_logit": -7.280487537384033
        },
        {
            "text": "The World Hip Trauma Evaluation Study 3: Hemiarthroplasty Evaluation by Multicentre Investigation - WHITE 3",
            "probability": 0.00031303420736227266,
            "start_logit": -3.8089499473571777,
            "end_logit": -7.283261299133301
        },
        {
            "text": "The World Hip Trauma Evaluation Study 3:",
            "probability": 0.0002546571874394612,
            "start_logit": -3.8089499473571777,
            "end_logit": -7.489655494689941
        }
    ],
    "63f03d58f36125a42600001f_004": [
        {
            "text": "hip fracture",
            "probability": 0.9969495041676979,
            "start_logit": 9.795042991638184,
            "end_logit": 9.60455322265625
        },
        {
            "text": "fracture",
            "probability": 0.002894789236573891,
            "start_logit": 3.9532551765441895,
            "end_logit": 9.60455322265625
        },
        {
            "text": "hip",
            "probability": 0.0001531471241912783,
            "start_logit": 9.795042991638184,
            "end_logit": 0.8234968781471252
        },
        {
            "text": "hip fracture.",
            "probability": 1.8883047475099644e-06,
            "start_logit": 9.795042991638184,
            "end_logit": -3.5722227096557617
        },
        {
            "text": "with hip fracture",
            "probability": 3.0226145670205293e-07,
            "start_logit": -5.2138752937316895,
            "end_logit": 9.60455322265625
        },
        {
            "text": "UK patients with hip fracture",
            "probability": 1.2394840042524277e-07,
            "start_logit": -6.105302333831787,
            "end_logit": 9.60455322265625
        },
        {
            "text": "World Hip Trauma Evaluation (WHiTE) was set up to measure outcome in a comprehensive cohort of UK patients with hip fracture",
            "probability": 7.659732376718628e-08,
            "start_logit": -6.586605548858643,
            "end_logit": 9.60455322265625
        },
        {
            "text": "WHiTE) was set up to measure outcome in a comprehensive cohort of UK patients with hip fracture",
            "probability": 6.114015447775668e-08,
            "start_logit": -6.8119988441467285,
            "end_logit": 9.60455322265625
        },
        {
            "text": "a comprehensive cohort of UK patients with hip fracture",
            "probability": 3.699778663629701e-08,
            "start_logit": -7.314309597015381,
            "end_logit": 9.60455322265625
        },
        {
            "text": "patients with hip fracture",
            "probability": 3.415761274722644e-08,
            "start_logit": -7.394182205200195,
            "end_logit": 9.60455322265625
        },
        {
            "text": "measure outcome in a comprehensive cohort of UK patients with hip fracture",
            "probability": 3.0390073710587126e-08,
            "start_logit": -7.511051654815674,
            "end_logit": 9.60455322265625
        },
        {
            "text": "fracture.",
            "probability": 5.482970035705782e-09,
            "start_logit": 3.9532551765441895,
            "end_logit": -3.5722227096557617
        },
        {
            "text": "The World Hip Trauma Evaluation (WHiTE) was set up to measure outcome in a comprehensive cohort of UK patients with hip",
            "probability": 8.878088216682281e-11,
            "start_logit": -4.565695285797119,
            "end_logit": 0.8234968781471252
        },
        {
            "text": "with hip",
            "probability": 4.643211381747116e-11,
            "start_logit": -5.2138752937316895,
            "end_logit": 0.8234968781471252
        },
        {
            "text": "UK patients with hip",
            "probability": 1.9040423806702556e-11,
            "start_logit": -6.105302333831787,
            "end_logit": 0.8234968781471252
        },
        {
            "text": "World Hip Trauma Evaluation (WHiTE) was set up to measure outcome in a comprehensive cohort of UK patients with hip",
            "probability": 1.176655367865011e-11,
            "start_logit": -6.586605548858643,
            "end_logit": 0.8234968781471252
        },
        {
            "text": "WHiTE) was set up to measure outcome in a comprehensive cohort of UK patients with hip",
            "probability": 9.392089360329236e-12,
            "start_logit": -6.8119988441467285,
            "end_logit": 0.8234968781471252
        },
        {
            "text": "a comprehensive cohort of UK patients with hip",
            "probability": 5.683441940744767e-12,
            "start_logit": -7.314309597015381,
            "end_logit": 0.8234968781471252
        },
        {
            "text": "patients with hip",
            "probability": 5.247146560190418e-12,
            "start_logit": -7.394182205200195,
            "end_logit": 0.8234968781471252
        },
        {
            "text": "measure outcome in a comprehensive cohort of UK patients with hip",
            "probability": 4.668393307064134e-12,
            "start_logit": -7.511051654815674,
            "end_logit": 0.8234968781471252
        }
    ],
    "644008a657b1c7a31500003f_001": [
        {
            "text": "Omaveloxolone",
            "probability": 0.9999075531690063,
            "start_logit": 9.694778442382812,
            "end_logit": 9.929123878479004
        },
        {
            "text": "Omaveloxolo",
            "probability": 5.3580373024785064e-05,
            "start_logit": 9.694778442382812,
            "end_logit": 0.0948885977268219
        },
        {
            "text": "O",
            "probability": 3.5818340975704345e-05,
            "start_logit": 9.694778442382812,
            "end_logit": -0.3078341484069824
        },
        {
            "text": "Omavelox",
            "probability": 9.140481577234004e-07,
            "start_logit": 9.694778442382812,
            "end_logit": -3.976166248321533
        },
        {
            "text": "Omaveloxolone (RTA 408) is an activator of Nrf2 and an inhibitor of NF\u03baB",
            "probability": 5.530959519735459e-07,
            "start_logit": 9.694778442382812,
            "end_logit": -4.478518009185791
        },
        {
            "text": "Omaveloxolone (RTA 408) is an activator of Nrf2",
            "probability": 5.34171093120416e-07,
            "start_logit": 9.694778442382812,
            "end_logit": -4.513333320617676
        },
        {
            "text": "Omaveloxolone (RTA 408) is an activator of Nrf2 and an inhibitor of NF\u03baB,",
            "probability": 5.233204906063688e-07,
            "start_logit": 9.694778442382812,
            "end_logit": -4.533855438232422
        },
        {
            "text": "Omaveloxolone (",
            "probability": 1.7972775088358112e-07,
            "start_logit": 9.694778442382812,
            "end_logit": -5.602606296539307
        },
        {
            "text": "Oma",
            "probability": 1.4588266517524483e-07,
            "start_logit": 9.694778442382812,
            "end_logit": -5.811246871948242
        },
        {
            "text": "Omaveloxolone (RTA 408)",
            "probability": 9.997485699076408e-08,
            "start_logit": 9.694778442382812,
            "end_logit": -6.189130783081055
        },
        {
            "text": "Omavel",
            "probability": 4.6110716965384133e-08,
            "start_logit": 9.694778442382812,
            "end_logit": -6.963004112243652
        },
        {
            "text": "Omaveloxolone (RTA 408",
            "probability": 2.970933005971787e-08,
            "start_logit": 9.694778442382812,
            "end_logit": -7.402588367462158
        },
        {
            "text": "Omaveloxolone (RTA 408) is an activator",
            "probability": 2.198922530183155e-08,
            "start_logit": 9.694778442382812,
            "end_logit": -7.703496932983398
        },
        {
            "text": "Nrf2 and an inhibitor of NF\u03baB, possessing antioxidative and anti-inflammatory activities in mitochondrial bioenergetics.",
            "probability": 5.919146954120019e-11,
            "start_logit": -1.6701418161392212,
            "end_logit": -2.2561070919036865
        },
        {
            "text": "Nrf2 and an inhibitor of NF\u03baB",
            "probability": 6.413252282573671e-12,
            "start_logit": -1.6701418161392212,
            "end_logit": -4.478518009185791
        },
        {
            "text": "Nrf2",
            "probability": 6.193814961067069e-12,
            "start_logit": -1.6701418161392212,
            "end_logit": -4.513333320617676
        },
        {
            "text": "Nrf2 and an inhibitor of NF\u03baB,",
            "probability": 6.068000170537123e-12,
            "start_logit": -1.6701418161392212,
            "end_logit": -4.533855438232422
        },
        {
            "text": "Omaveloxolone (RTA",
            "probability": 3.647337886747906e-12,
            "start_logit": -1.1104224920272827,
            "end_logit": -5.602606296539307
        },
        {
            "text": "NF\u03baB, possessing antioxidative and anti-inflammatory activities in mitochondrial bioenergetics.",
            "probability": 3.3502862736639273e-12,
            "start_logit": -4.541873455047607,
            "end_logit": -2.2561070919036865
        },
        {
            "text": "Nrf2 and an inhibitor of NF\u03baB, possessing antioxidative and anti-inflammatory activities in mitochondrial bioenergetics",
            "probability": 1.8908479618519325e-12,
            "start_logit": -1.6701418161392212,
            "end_logit": -5.699859142303467
        }
    ],
    "644640de57b1c7a31500006b_001": [
        {
            "text": "loss of the SMN1 gene in most cases or mutations in rare cases.",
            "probability": 0.7701407598309667,
            "start_logit": 2.181004047393799,
            "end_logit": -0.32349082827568054
        },
        {
            "text": "loss of the SMN1 gene",
            "probability": 0.06506213695497827,
            "start_logit": 2.181004047393799,
            "end_logit": -2.7947213649749756
        },
        {
            "text": "SMN1 gene in most cases or mutations in rare cases.",
            "probability": 0.05728379466138542,
            "start_logit": -0.4175514876842499,
            "end_logit": -0.32349082827568054
        },
        {
            "text": "loss of the SMN1",
            "probability": 0.03896916593291296,
            "start_logit": 2.181004047393799,
            "end_logit": -3.30729341506958
        },
        {
            "text": "SMA is a monogenic pathology that originates from the loss of the SMN1 gene in most cases or mutations in rare cases.",
            "probability": 0.01966296652297442,
            "start_logit": -1.4868322610855103,
            "end_logit": -0.32349082827568054
        },
        {
            "text": "loss",
            "probability": 0.012970113998689298,
            "start_logit": 2.181004047393799,
            "end_logit": -4.407416343688965
        },
        {
            "text": "the loss of the SMN1 gene in most cases or mutations in rare cases.",
            "probability": 0.006054644078408449,
            "start_logit": -2.664743661880493,
            "end_logit": -0.32349082827568054
        },
        {
            "text": "loss of the SMN1 gene in most cases or mutations",
            "probability": 0.00506190398202589,
            "start_logit": 2.181004047393799,
            "end_logit": -5.348321437835693
        },
        {
            "text": "SMN1 gene",
            "probability": 0.004839382990685919,
            "start_logit": -0.4175514876842499,
            "end_logit": -2.7947213649749756
        },
        {
            "text": "loss of the SMN",
            "probability": 0.003206090820652265,
            "start_logit": 2.181004047393799,
            "end_logit": -5.805011749267578
        },
        {
            "text": "SMN1",
            "probability": 0.0028985632443560005,
            "start_logit": -0.4175514876842499,
            "end_logit": -3.30729341506958
        },
        {
            "text": "loss of the SMN1 gene in most cases",
            "probability": 0.0020550431143048034,
            "start_logit": 2.181004047393799,
            "end_logit": -6.249767303466797
        },
        {
            "text": "monogenic pathology that originates from the loss of the SMN1 gene in most cases or mutations in rare cases.",
            "probability": 0.002048749491154852,
            "start_logit": -3.7483396530151367,
            "end_logit": -0.32349082827568054
        },
        {
            "text": "loss of",
            "probability": 0.0018513644282629961,
            "start_logit": 2.181004047393799,
            "end_logit": -6.3541412353515625
        },
        {
            "text": "loss of the",
            "probability": 0.0017845110319559502,
            "start_logit": 2.181004047393799,
            "end_logit": -6.3909196853637695
        },
        {
            "text": "SMA is a monogenic pathology that originates from the loss of the SMN1 gene",
            "probability": 0.0016611438941885157,
            "start_logit": -1.4868322610855103,
            "end_logit": -2.7947213649749756
        },
        {
            "text": "loss of the SMN1 gene in most cases or mutations in rare cases",
            "probability": 0.0015683252974470398,
            "start_logit": 2.181004047393799,
            "end_logit": -6.520055770874023
        },
        {
            "text": "mutations in rare cases.",
            "probability": 0.001018378929243941,
            "start_logit": -4.447357177734375,
            "end_logit": -0.32349082827568054
        },
        {
            "text": "SMA is a monogenic pathology that originates from the loss of the SMN1",
            "probability": 0.0009949472163183288,
            "start_logit": -1.4868322610855103,
            "end_logit": -3.30729341506958
        },
        {
            "text": "a monogenic pathology that originates from the loss of the SMN1 gene in most cases or mutations in rare cases.",
            "probability": 0.0008680135790880574,
            "start_logit": -4.607117176055908,
            "end_logit": -0.32349082827568054
        }
    ],
    "644640de57b1c7a31500006b_002": [
        {
            "text": "defects in the survival motor neuron 1 (SMN1) gene.",
            "probability": 0.564048880996718,
            "start_logit": 0.4819781482219696,
            "end_logit": -1.1341488361358643
        },
        {
            "text": "defects in the survival motor neuron 1 (SMN1)",
            "probability": 0.11983755012570607,
            "start_logit": 0.4819781482219696,
            "end_logit": -2.683152675628662
        },
        {
            "text": "defects in the survival motor neuron 1",
            "probability": 0.08495303634438413,
            "start_logit": 0.4819781482219696,
            "end_logit": -3.027191162109375
        },
        {
            "text": "survival motor neuron 1 (SMN1) gene.",
            "probability": 0.06459331801471938,
            "start_logit": -1.6850517988204956,
            "end_logit": -1.1341488361358643
        },
        {
            "text": "defects in the survival motor neuron 1 (SMN1) gene",
            "probability": 0.05090347215404438,
            "start_logit": 0.4819781482219696,
            "end_logit": -3.539358615875244
        },
        {
            "text": "defects in the survival motor neuron 1 (SMN1",
            "probability": 0.02758803897478251,
            "start_logit": 0.4819781482219696,
            "end_logit": -4.151907444000244
        },
        {
            "text": "survival motor neuron 1 (SMN1)",
            "probability": 0.013723464838182433,
            "start_logit": -1.6850517988204956,
            "end_logit": -2.683152675628662
        },
        {
            "text": "defects",
            "probability": 0.011025095832434257,
            "start_logit": 0.4819781482219696,
            "end_logit": -5.06911563873291
        },
        {
            "text": "survival motor neuron 1",
            "probability": 0.009728586790584817,
            "start_logit": -1.6850517988204956,
            "end_logit": -3.027191162109375
        },
        {
            "text": "SMN1) gene.",
            "probability": 0.009054186831292166,
            "start_logit": -3.649935483932495,
            "end_logit": -1.1341488361358643
        },
        {
            "text": "Spinal muscular atrophy (SMA) is an autosomal recessive",
            "probability": 0.0071521456294037005,
            "start_logit": -0.2208750993013382,
            "end_logit": -4.7990241050720215
        },
        {
            "text": "survival motor neuron 1 (SMN1) gene",
            "probability": 0.005829324861152828,
            "start_logit": -1.6850517988204956,
            "end_logit": -3.539358615875244
        },
        {
            "text": "Spinal muscular atrophy (SMA) is an autosomal recessive neurodegenerative disorder caused by defects",
            "probability": 0.005459301581267268,
            "start_logit": -0.2208750993013382,
            "end_logit": -5.06911563873291
        },
        {
            "text": "autosomal recessive neurodegenerative disorder caused by defects in the survival motor neuron 1 (SMN1) gene.",
            "probability": 0.00464874926438571,
            "start_logit": -4.316564559936523,
            "end_logit": -1.1341488361358643
        },
        {
            "text": "(SMN1) gene.",
            "probability": 0.004487633980517211,
            "start_logit": -4.351837158203125,
            "end_logit": -1.1341488361358643
        },
        {
            "text": "defects in",
            "probability": 0.0044435288726006154,
            "start_logit": 0.4819781482219696,
            "end_logit": -5.977840900421143
        },
        {
            "text": "the survival motor neuron 1 (SMN1) gene.",
            "probability": 0.003797809670879894,
            "start_logit": -4.518738269805908,
            "end_logit": -1.1341488361358643
        },
        {
            "text": "survival motor neuron 1 (SMN1",
            "probability": 0.003159305930634349,
            "start_logit": -1.6850517988204956,
            "end_logit": -4.151907444000244
        },
        {
            "text": "Spinal muscular atrophy (SMA) is an autosomal recessive neurodegenerative disorder",
            "probability": 0.00278385600135805,
            "start_logit": -0.2208750993013382,
            "end_logit": -5.7425994873046875
        },
        {
            "text": "Spinal muscular atrophy",
            "probability": 0.002782713304952302,
            "start_logit": -0.2208750993013382,
            "end_logit": -5.7430100440979
        }
    ],
    "644640de57b1c7a31500006b_003": [
        {
            "text": "Loss or deletion of survival motor neuron 1 gene (SMN1)",
            "probability": 0.6683371649785879,
            "start_logit": 3.059049606323242,
            "end_logit": 3.58774471282959
        },
        {
            "text": "Loss or deletion of survival motor neuron 1 gene",
            "probability": 0.31703232273255283,
            "start_logit": 3.059049606323242,
            "end_logit": 2.8419556617736816
        },
        {
            "text": "SMN1)",
            "probability": 0.00515508695984049,
            "start_logit": -1.8057591915130615,
            "end_logit": 3.58774471282959
        },
        {
            "text": "(SMN1)",
            "probability": 0.004643999520635402,
            "start_logit": -1.9101672172546387,
            "end_logit": 3.58774471282959
        },
        {
            "text": "Loss or deletion of survival motor neuron 1 gene (SMN1",
            "probability": 0.0021638283814332947,
            "start_logit": 3.059049606323242,
            "end_logit": -2.1451690196990967
        },
        {
            "text": "Loss or deletion of survival motor neuron 1",
            "probability": 0.0006426630222532082,
            "start_logit": 3.059049606323242,
            "end_logit": -3.359182834625244
        },
        {
            "text": "survival motor neuron 1 gene (SMN1)",
            "probability": 0.0005097495968119244,
            "start_logit": -4.119578838348389,
            "end_logit": 3.58774471282959
        },
        {
            "text": "deletion of survival motor neuron 1 gene (SMN1)",
            "probability": 0.00046561858490208884,
            "start_logit": -4.210131645202637,
            "end_logit": 3.58774471282959
        },
        {
            "text": "survival motor neuron 1 gene",
            "probability": 0.00024180474640287923,
            "start_logit": -4.119578838348389,
            "end_logit": 2.8419556617736816
        },
        {
            "text": "deletion of survival motor neuron 1 gene",
            "probability": 0.0002208707658561572,
            "start_logit": -4.210131645202637,
            "end_logit": 2.8419556617736816
        },
        {
            "text": ")",
            "probability": 0.00011865061027344502,
            "start_logit": -5.577315330505371,
            "end_logit": 3.58774471282959
        },
        {
            "text": "Loss or deletion",
            "probability": 8.813253663756056e-05,
            "start_logit": 3.059049606323242,
            "end_logit": -5.345961570739746
        },
        {
            "text": "gene (SMN1)",
            "probability": 8.618743230276788e-05,
            "start_logit": -5.896974086761475,
            "end_logit": 3.58774471282959
        },
        {
            "text": "Loss",
            "probability": 7.922255513632436e-05,
            "start_logit": 3.059049606323242,
            "end_logit": -5.452542304992676
        },
        {
            "text": "Spinal Muscular Atrophy (SMA).",
            "probability": 7.08600651423377e-05,
            "start_logit": -0.972326397895813,
            "end_logit": -1.5327203273773193
        },
        {
            "text": "Loss or deletion of survival motor neuron 1 gene (",
            "probability": 4.8659574484656836e-05,
            "start_logit": 3.059049606323242,
            "end_logit": -5.93995475769043
        },
        {
            "text": "gene",
            "probability": 4.0883858155900346e-05,
            "start_logit": -5.896974086761475,
            "end_logit": 2.8419556617736816
        },
        {
            "text": "or deletion of survival motor neuron 1 gene (SMN1)",
            "probability": 2.0562341902126915e-05,
            "start_logit": -7.3300371170043945,
            "end_logit": 3.58774471282959
        },
        {
            "text": "Loss or deletion of",
            "probability": 1.7041473065682264e-05,
            "start_logit": 3.059049606323242,
            "end_logit": -6.9891533851623535
        },
        {
            "text": "SMN1",
            "probability": 1.669026362287799e-05,
            "start_logit": -1.8057591915130615,
            "end_logit": -2.1451690196990967
        }
    ],
    "644640de57b1c7a31500006b_004": [
        {
            "text": "mutations",
            "probability": 0.24756300192704134,
            "start_logit": 4.05885648727417,
            "end_logit": -1.2934406995773315
        },
        {
            "text": "mutations in SMN1",
            "probability": 0.2139520871177035,
            "start_logit": 4.05885648727417,
            "end_logit": -1.4393537044525146
        },
        {
            "text": "mutations in SMN1 (encoding survival motor neuron protein (SMN))",
            "probability": 0.2104582190979852,
            "start_logit": 4.05885648727417,
            "end_logit": -1.4558186531066895
        },
        {
            "text": "mutations in SMN1 (encoding survival motor neuron protein (SMN)).",
            "probability": 0.18468459969118306,
            "start_logit": 4.05885648727417,
            "end_logit": -1.586456298828125
        },
        {
            "text": "mutations in SMN1 (",
            "probability": 0.061829123400487504,
            "start_logit": 4.05885648727417,
            "end_logit": -2.6807312965393066
        },
        {
            "text": "mutations in SMN1 (encoding survival motor neuron protein",
            "probability": 0.04212005240299791,
            "start_logit": 4.05885648727417,
            "end_logit": -3.064581871032715
        },
        {
            "text": "mutations in",
            "probability": 0.00892289286943053,
            "start_logit": 4.05885648727417,
            "end_logit": -4.616485595703125
        },
        {
            "text": "mutations in SMN1 (encoding survival motor neuron protein (SMN",
            "probability": 0.007658362507710367,
            "start_logit": 4.05885648727417,
            "end_logit": -4.769307613372803
        },
        {
            "text": "mutations in SMN1 (encoding survival motor neuron protein (SMN)",
            "probability": 0.006501071146423574,
            "start_logit": 4.05885648727417,
            "end_logit": -4.933138847351074
        },
        {
            "text": "Spinal muscular atrophy (SMA) is a neurodegenerative disorder caused by mutations",
            "probability": 0.0033342123999770463,
            "start_logit": -0.24857212603092194,
            "end_logit": -1.2934406995773315
        },
        {
            "text": "Spinal muscular atrophy (SMA) is a neurodegenerative disorder caused by mutations in SMN1",
            "probability": 0.002881535998174111,
            "start_logit": -0.24857212603092194,
            "end_logit": -1.4393537044525146
        },
        {
            "text": "SMN1",
            "probability": 0.0021098641736196242,
            "start_logit": -0.5602720379829407,
            "end_logit": -1.4393537044525146
        },
        {
            "text": "SMN1 (encoding survival motor neuron protein (SMN))",
            "probability": 0.002075409791512552,
            "start_logit": -0.5602720379829407,
            "end_logit": -1.4558186531066895
        },
        {
            "text": "SMN1 (encoding survival motor neuron protein (SMN)).",
            "probability": 0.0018212461750529315,
            "start_logit": -0.5602720379829407,
            "end_logit": -1.586456298828125
        },
        {
            "text": "mutations in SMN",
            "probability": 0.0013833028014989732,
            "start_logit": 4.05885648727417,
            "end_logit": -6.4806318283081055
        },
        {
            "text": "Spinal muscular atrophy (SMA) is a neurodegenerative disorder caused by mutations in SMN1 (",
            "probability": 0.0008327230980272681,
            "start_logit": -0.24857212603092194,
            "end_logit": -2.6807312965393066
        },
        {
            "text": "mutations in SMN1 (encoding survival motor neuron protein (SMN)). Reduced expression of SMN",
            "probability": 0.0007270376838175414,
            "start_logit": 4.05885648727417,
            "end_logit": -7.12388277053833
        },
        {
            "text": "SMN1 (",
            "probability": 0.0006097208683794193,
            "start_logit": -0.5602720379829407,
            "end_logit": -2.6807312965393066
        },
        {
            "text": "SMN1 (encoding survival motor neuron protein",
            "probability": 0.0004153621063167141,
            "start_logit": -0.5602720379829407,
            "end_logit": -3.064581871032715
        },
        {
            "text": "Spinal muscular atrophy (SMA) is a neurodegenerative disorder caused by mutations in",
            "probability": 0.00012017474266081904,
            "start_logit": -0.24857212603092194,
            "end_logit": -4.616485595703125
        }
    ],
    "64403a5857b1c7a31500004c_001": [
        {
            "text": "phase III trial with two suprachoroidal injections of CLS-TA at 0 and 12 weeks",
            "probability": 0.8492575735402599,
            "start_logit": 3.570255756378174,
            "end_logit": -0.1785709112882614
        },
        {
            "text": "phase III trial with two suprachoroidal injections",
            "probability": 0.06082272099419118,
            "start_logit": 3.570255756378174,
            "end_logit": -2.814970016479492
        },
        {
            "text": "phase III trial with two suprachoroidal injections of CLS-TA at 0 and 12 weeks with follow up lasting 24 weeks,",
            "probability": 0.021207133218585483,
            "start_logit": 3.570255756378174,
            "end_logit": -3.868595838546753
        },
        {
            "text": "phase III trial with two suprachoroidal injections of CLS-TA",
            "probability": 0.01920990581473652,
            "start_logit": 3.570255756378174,
            "end_logit": -3.9675073623657227
        },
        {
            "text": "phase III trial with two suprachoroidal injections of CLS-TA at 0 and 12 weeks with follow up lasting 24 weeks",
            "probability": 0.01246969102958619,
            "start_logit": 3.570255756378174,
            "end_logit": -4.399632453918457
        },
        {
            "text": "phase III",
            "probability": 0.011445189101971414,
            "start_logit": 3.570255756378174,
            "end_logit": -4.485363960266113
        },
        {
            "text": "suprachoroidal injections of CLS-TA at 0 and 12 weeks",
            "probability": 0.007171950844269921,
            "start_logit": -1.20392906665802,
            "end_logit": -0.1785709112882614
        },
        {
            "text": "phase",
            "probability": 0.005048108628026238,
            "start_logit": 3.570255756378174,
            "end_logit": -5.303919792175293
        },
        {
            "text": "phase III trial with two",
            "probability": 0.0030369856186455847,
            "start_logit": 3.570255756378174,
            "end_logit": -5.812067985534668
        },
        {
            "text": "phase III trial with two suprachoroidal",
            "probability": 0.002550556522601136,
            "start_logit": 3.570255756378174,
            "end_logit": -5.986621856689453
        },
        {
            "text": "phase III trial with two suprachoroidal injection",
            "probability": 0.001891322854374502,
            "start_logit": 3.570255756378174,
            "end_logit": -6.285656929016113
        },
        {
            "text": "phase III trial with two suprachoroidal injections of CLS-TA at",
            "probability": 0.0017248072905169602,
            "start_logit": 3.570255756378174,
            "end_logit": -6.3778181076049805
        },
        {
            "text": "two suprachoroidal injections of CLS-TA at 0 and 12 weeks",
            "probability": 0.0010894713475472207,
            "start_logit": -3.088414192199707,
            "end_logit": -0.1785709112882614
        },
        {
            "text": "PEACHTREE trial (ClinicalTrials.gov Identifier: NCT02595398",
            "probability": 0.001015790913968406,
            "start_logit": -2.3193788528442383,
            "end_logit": -1.0176312923431396
        },
        {
            "text": "suprachoroidal injections",
            "probability": 0.0005136457757646409,
            "start_logit": -1.20392906665802,
            "end_logit": -2.814970016479492
        },
        {
            "text": "12 weeks",
            "probability": 0.0004120485272324537,
            "start_logit": -4.060720920562744,
            "end_logit": -0.1785709112882614
        },
        {
            "text": "CLS-TA at 0 and 12 weeks",
            "probability": 0.00040777130872535433,
            "start_logit": -4.071155548095703,
            "end_logit": -0.1785709112882614
        },
        {
            "text": "Recent results from the PEACHTREE trial (ClinicalTrials.gov Identifier: NCT02595398",
            "probability": 0.0003150634352742996,
            "start_logit": -3.490027666091919,
            "end_logit": -1.0176312923431396
        },
        {
            "text": "NCT02595398",
            "probability": 0.00023116972695779302,
            "start_logit": -3.799649477005005,
            "end_logit": -1.0176312923431396
        },
        {
            "text": "suprachoroidal injections of CLS-TA at 0 and 12 weeks with follow up lasting 24 weeks,",
            "probability": 0.00017909350676443344,
            "start_logit": -1.20392906665802,
            "end_logit": -3.868595838546753
        }
    ],
    "64402bb057b1c7a315000043_001": [
        {
            "text": "Randomized",
            "probability": 0.5643480255857944,
            "start_logit": 7.813243389129639,
            "end_logit": 1.1015405654907227
        },
        {
            "text": "Randomized, clinical trial",
            "probability": 0.37596735182166,
            "start_logit": 7.813243389129639,
            "end_logit": 0.6953717470169067
        },
        {
            "text": "Random",
            "probability": 0.05214513726732886,
            "start_logit": 7.813243389129639,
            "end_logit": -1.280099630355835
        },
        {
            "text": "Randomized, clinical trial of RT001: Early signals of efficacy in Friedreich's ataxia.",
            "probability": 0.0028030684486727245,
            "start_logit": 7.813243389129639,
            "end_logit": -4.203415870666504
        },
        {
            "text": "Randomized,",
            "probability": 0.0024089801877920695,
            "start_logit": 7.813243389129639,
            "end_logit": -4.354927062988281
        },
        {
            "text": "Randomized, clinical trial of RT001:",
            "probability": 0.0015556155914422597,
            "start_logit": 7.813243389129639,
            "end_logit": -4.792259216308594
        },
        {
            "text": "Randomized, clinical trial of RT001: Early signals of efficacy in Friedreich's ataxia",
            "probability": 0.0002860987034503964,
            "start_logit": 7.813243389129639,
            "end_logit": -6.485548973083496
        },
        {
            "text": "Randomized, clinical trial of RT001: Early signals of efficacy",
            "probability": 0.00013517671415770154,
            "start_logit": 7.813243389129639,
            "end_logit": -7.235302925109863
        },
        {
            "text": "Randomized, clinical trial of RT001",
            "probability": 0.00012068339377500464,
            "start_logit": 7.813243389129639,
            "end_logit": -7.348715305328369
        },
        {
            "text": "Randomized, clinical",
            "probability": 0.00011968092265983717,
            "start_logit": 7.813243389129639,
            "end_logit": -7.357056617736816
        },
        {
            "text": "Randomized, clinical trial of RT001: Early signals",
            "probability": 0.00010608391486122946,
            "start_logit": 7.813243389129639,
            "end_logit": -7.477655410766602
        },
        {
            "text": "clinical trial",
            "probability": 3.4846372030829893e-06,
            "start_logit": -3.7756502628326416,
            "end_logit": 0.6953717470169067
        },
        {
            "text": "trial",
            "probability": 4.1816990672764616e-07,
            "start_logit": -5.895881652832031,
            "end_logit": 0.6953717470169067
        },
        {
            "text": ", clinical trial",
            "probability": 1.2033310353263107e-07,
            "start_logit": -7.141505718231201,
            "end_logit": 0.6953717470169067
        },
        {
            "text": "clinical trial of RT001: Early signals of efficacy in Friedreich's ataxia.",
            "probability": 2.598011915584199e-08,
            "start_logit": -3.7756502628326416,
            "end_logit": -4.203415870666504
        },
        {
            "text": "Early signals of efficacy in Friedreich's ataxia.",
            "probability": 1.6160459531100694e-08,
            "start_logit": -4.2504143714904785,
            "end_logit": -4.203415870666504
        },
        {
            "text": "clinical trial of RT001:",
            "probability": 1.441815609086977e-08,
            "start_logit": -3.7756502628326416,
            "end_logit": -4.792259216308594
        },
        {
            "text": "RT001: Early signals of efficacy in Friedreich's ataxia.",
            "probability": 8.686303228647855e-09,
            "start_logit": -4.87123441696167,
            "end_logit": -4.203415870666504
        },
        {
            "text": "RT001:",
            "probability": 4.8206274594821775e-09,
            "start_logit": -4.87123441696167,
            "end_logit": -4.792259216308594
        },
        {
            "text": "Friedreich's ataxia.",
            "probability": 4.242526423474624e-09,
            "start_logit": -5.587822914123535,
            "end_logit": -4.203415870666504
        }
    ],
    "64402bb057b1c7a315000043_002": [
        {
            "text": "phase I/II",
            "probability": 0.6726272815274289,
            "start_logit": 5.0511274337768555,
            "end_logit": 0.16512832045555115
        },
        {
            "text": "phase I/II double-blind, comparator-controlled trial",
            "probability": 0.25846917769281125,
            "start_logit": 5.0511274337768555,
            "end_logit": -0.7912865877151489
        },
        {
            "text": "phase",
            "probability": 0.018743518710994857,
            "start_logit": 5.0511274337768555,
            "end_logit": -3.415215015411377
        },
        {
            "text": "phase I/II double-blind, comparator-controlled",
            "probability": 0.01250274758237464,
            "start_logit": 5.0511274337768555,
            "end_logit": -3.8201146125793457
        },
        {
            "text": "double-blind, comparator-controlled trial",
            "probability": 0.01141903177536606,
            "start_logit": 1.931632399559021,
            "end_logit": -0.7912865877151489
        },
        {
            "text": "phase I/II double-blind",
            "probability": 0.010631057664950266,
            "start_logit": 5.0511274337768555,
            "end_logit": -3.982283353805542
        },
        {
            "text": "phase I",
            "probability": 0.0062995627729835815,
            "start_logit": 5.0511274337768555,
            "end_logit": -4.505582809448242
        },
        {
            "text": "phase I/II double-blind,",
            "probability": 0.002046855434998812,
            "start_logit": 5.0511274337768555,
            "end_logit": -5.629758358001709
        },
        {
            "text": "We conducted a phase I/II",
            "probability": 0.0018474335725945368,
            "start_logit": -0.846266508102417,
            "end_logit": 0.16512832045555115
        },
        {
            "text": "phase I/II double-blind, comparator-controlled trial with 2 doses",
            "probability": 0.001543369432335073,
            "start_logit": 5.0511274337768555,
            "end_logit": -5.912095069885254
        },
        {
            "text": "phase I/II double",
            "probability": 0.0013016245345790966,
            "start_logit": 5.0511274337768555,
            "end_logit": -6.082449913024902
        },
        {
            "text": "We conducted a phase I/II double-blind, comparator-controlled trial",
            "probability": 0.0007099097070018718,
            "start_logit": -0.846266508102417,
            "end_logit": -0.7912865877151489
        },
        {
            "text": "double-blind, comparator-controlled",
            "probability": 0.0005523647856078122,
            "start_logit": 1.931632399559021,
            "end_logit": -3.8201146125793457
        },
        {
            "text": "phase I/II double-blind, comparator",
            "probability": 0.0004975507342203445,
            "start_logit": 5.0511274337768555,
            "end_logit": -7.044120788574219
        },
        {
            "text": "double-blind",
            "probability": 0.0004696745134775594,
            "start_logit": 1.931632399559021,
            "end_logit": -3.982283353805542
        },
        {
            "text": "double-blind,",
            "probability": 9.042899219345573e-05,
            "start_logit": 1.931632399559021,
            "end_logit": -5.629758358001709
        },
        {
            "text": "double-blind, comparator-controlled trial with 2 doses of RT001 in Friedreich's ataxia patients",
            "probability": 7.12394124690445e-05,
            "start_logit": 1.931632399559021,
            "end_logit": -5.868277072906494
        },
        {
            "text": "double-blind, comparator-controlled trial with 2 doses",
            "probability": 6.818524648191753e-05,
            "start_logit": 1.931632399559021,
            "end_logit": -5.912095069885254
        },
        {
            "text": "double",
            "probability": 5.750508456222845e-05,
            "start_logit": 1.931632399559021,
            "end_logit": -6.082449913024902
        },
        {
            "text": "We conducted a phase",
            "probability": 5.148082256879692e-05,
            "start_logit": -0.846266508102417,
            "end_logit": -3.415215015411377
        }
    ],
    "63eef8d6f36125a42600000f_001": [
        {
            "text": "malaria",
            "probability": 0.9964350597091401,
            "start_logit": 7.556685924530029,
            "end_logit": 8.279646873474121
        },
        {
            "text": "antimalarial monoclonal antibody, and its protective efficacy against controlled human malaria",
            "probability": 0.003530458907710066,
            "start_logit": 1.91392982006073,
            "end_logit": 8.279646873474121
        },
        {
            "text": "malaria infection in healthy adults who had never had malaria or received a vaccine for malaria.",
            "probability": 9.82329093760841e-06,
            "start_logit": 7.556685924530029,
            "end_logit": -3.2475361824035645
        },
        {
            "text": "L9LS, a next-generation antimalarial monoclonal antibody, and its protective efficacy against controlled human malaria",
            "probability": 7.602210449190118e-06,
            "start_logit": -4.226814270019531,
            "end_logit": 8.279646873474121
        },
        {
            "text": "a next-generation antimalarial monoclonal antibody, and its protective efficacy against controlled human malaria",
            "probability": 5.883865503548002e-06,
            "start_logit": -4.483039379119873,
            "end_logit": 8.279646873474121
        },
        {
            "text": "human malaria",
            "probability": 2.769423279862059e-06,
            "start_logit": -5.236614227294922,
            "end_logit": 8.279646873474121
        },
        {
            "text": "next-generation antimalarial monoclonal antibody, and its protective efficacy against controlled human malaria",
            "probability": 2.4676562726874205e-06,
            "start_logit": -5.35198450088501,
            "end_logit": 8.279646873474121
        },
        {
            "text": "monoclonal antibody, and its protective efficacy against controlled human malaria",
            "probability": 1.935509956847133e-06,
            "start_logit": -5.594882488250732,
            "end_logit": 8.279646873474121
        },
        {
            "text": "antimalaria",
            "probability": 1.309207007171804e-06,
            "start_logit": 1.91392982006073,
            "end_logit": 0.37988534569740295
        },
        {
            "text": "malaria infection",
            "probability": 7.354901978886475e-07,
            "start_logit": 7.556685924530029,
            "end_logit": -5.839510440826416
        },
        {
            "text": "its protective efficacy against controlled human malaria",
            "probability": 6.131897196038879e-07,
            "start_logit": -6.7443342208862305,
            "end_logit": 8.279646873474121
        },
        {
            "text": "antibody, and its protective efficacy against controlled human malaria",
            "probability": 5.326427929651351e-07,
            "start_logit": -6.885157585144043,
            "end_logit": 8.279646873474121
        },
        {
            "text": "controlled human malaria",
            "probability": 5.173282796260621e-07,
            "start_logit": -6.914330959320068,
            "end_logit": 8.279646873474121
        },
        {
            "text": "antimalarial",
            "probability": 1.405448467505449e-07,
            "start_logit": 1.91392982006073,
            "end_logit": -1.8517649173736572
        },
        {
            "text": "malaria infection in healthy adults who had never had malaria",
            "probability": 1.2749452152149015e-07,
            "start_logit": 7.556685924530029,
            "end_logit": -7.591974258422852
        },
        {
            "text": "antimalarial monoclonal antibody,",
            "probability": 1.0580718952971193e-08,
            "start_logit": 1.91392982006073,
            "end_logit": -4.438258171081543
        },
        {
            "text": "We conducted a phase 1 clinical trial to assess the safety and pharmacokinetics of L9LS, a next-generation antimalaria",
            "probability": 4.6047844297305095e-09,
            "start_logit": -3.7361512184143066,
            "end_logit": 0.37988534569740295
        },
        {
            "text": "antimalarial monoclonal antibody",
            "probability": 2.918830429335243e-09,
            "start_logit": 1.91392982006073,
            "end_logit": -5.726108551025391
        },
        {
            "text": "L9LS, a next-generation antimalaria",
            "probability": 2.8191426243026456e-09,
            "start_logit": -4.226814270019531,
            "end_logit": 0.37988534569740295
        },
        {
            "text": "antimalarial monoclonal antibody, and its protective efficacy against controlled human malaria infection",
            "probability": 2.6059078264742797e-09,
            "start_logit": 1.91392982006073,
            "end_logit": -5.839510440826416
        }
    ],
    "63eef8d6f36125a42600000f_002": [
        {
            "text": "malaria",
            "probability": 0.9999700031820685,
            "start_logit": 7.45217752456665,
            "end_logit": 8.440055847167969
        },
        {
            "text": "CONCLUSIONS: In this small trial, L9LS administered intravenously or subcutaneously protected recipients against malaria",
            "probability": 9.667019122620275e-06,
            "start_logit": -4.094583034515381,
            "end_logit": 8.440055847167969
        },
        {
            "text": "malaria after controlled infection, without evident safety concerns.",
            "probability": 7.498171991557094e-06,
            "start_logit": 7.45217752456665,
            "end_logit": -3.3607654571533203
        },
        {
            "text": "L9LS administered intravenously or subcutaneously protected recipients against malaria",
            "probability": 6.555176703716629e-06,
            "start_logit": -4.483047962188721,
            "end_logit": 8.440055847167969
        },
        {
            "text": "malaria after controlled infection,",
            "probability": 3.5948122087384583e-06,
            "start_logit": 7.45217752456665,
            "end_logit": -4.095932960510254
        },
        {
            "text": "In this small trial, L9LS administered intravenously or subcutaneously protected recipients against malaria",
            "probability": 7.3887764248264e-07,
            "start_logit": -6.665925979614258,
            "end_logit": 8.440055847167969
        },
        {
            "text": "this small trial, L9LS administered intravenously or subcutaneously protected recipients against malaria",
            "probability": 4.5626131481354104e-07,
            "start_logit": -7.1479926109313965,
            "end_logit": 8.440055847167969
        },
        {
            "text": "small trial, L9LS administered intravenously or subcutaneously protected recipients against malaria",
            "probability": 3.792483128513228e-07,
            "start_logit": -7.33286714553833,
            "end_logit": 8.440055847167969
        },
        {
            "text": "against malaria",
            "probability": 3.5727488178252455e-07,
            "start_logit": -7.392552852630615,
            "end_logit": 8.440055847167969
        },
        {
            "text": "protected recipients against malaria",
            "probability": 3.468359540580017e-07,
            "start_logit": -7.422206401824951,
            "end_logit": 8.440055847167969
        },
        {
            "text": "malaria after controlled infection, without evident safety concerns",
            "probability": 2.7676286918068603e-07,
            "start_logit": 7.45217752456665,
            "end_logit": -6.6600189208984375
        },
        {
            "text": "malaria after controlled infection",
            "probability": 1.262329234586136e-07,
            "start_logit": 7.45217752456665,
            "end_logit": -7.445051193237305
        },
        {
            "text": "L9LS administered intravenously or subcutaneously protected recipients against malaria after controlled infection, without evident safety concerns.",
            "probability": 4.915331680261044e-11,
            "start_logit": -4.483047962188721,
            "end_logit": -3.3607654571533203
        },
        {
            "text": "CONCLUSION",
            "probability": 3.10212807858715e-11,
            "start_logit": -4.094583034515381,
            "end_logit": -4.209501266479492
        },
        {
            "text": "L9LS administered intravenously or subcutaneously protected recipients against malaria after controlled infection,",
            "probability": 2.3565336130055848e-11,
            "start_logit": -4.483047962188721,
            "end_logit": -4.095932960510254
        },
        {
            "text": "CONCLUSIONS",
            "probability": 1.9578539355713027e-11,
            "start_logit": -4.094583034515381,
            "end_logit": -4.669740676879883
        },
        {
            "text": "CONCLUSIONS:",
            "probability": 6.3224923305441205e-12,
            "start_logit": -4.094583034515381,
            "end_logit": -5.800061225891113
        },
        {
            "text": "CONCL",
            "probability": 4.903441701839755e-12,
            "start_logit": -4.094583034515381,
            "end_logit": -6.054237365722656
        },
        {
            "text": "CONC",
            "probability": 4.75243362576283e-12,
            "start_logit": -4.094583034515381,
            "end_logit": -6.085517883300781
        },
        {
            "text": "CONCLUS",
            "probability": 4.709086434565824e-12,
            "start_logit": -4.094583034515381,
            "end_logit": -6.0946807861328125
        }
    ],
    "63eef8d6f36125a42600000f_003": [
        {
            "text": "antimalarial",
            "probability": 0.6852503338351802,
            "start_logit": 3.1062395572662354,
            "end_logit": 6.243008613586426
        },
        {
            "text": "antimalaria",
            "probability": 0.3055153863568373,
            "start_logit": 2.2984554767608643,
            "end_logit": 6.243008613586426
        },
        {
            "text": "L9LS, a potent and safe antimalaria",
            "probability": 0.008657295219720454,
            "start_logit": -1.2651423215866089,
            "end_logit": 6.243008613586426
        },
        {
            "text": "a potent and safe antimalaria",
            "probability": 0.0002069460603994781,
            "start_logit": -4.998841762542725,
            "end_logit": 6.243008613586426
        },
        {
            "text": "antimalarial monoclonal antibody, demonstrated 88% protective efficacy against infection in a phase 1 trial in healthy adults.1",
            "probability": 0.00012503913833349767,
            "start_logit": 3.1062395572662354,
            "end_logit": -2.3659040927886963
        },
        {
            "text": "potent and safe antimalaria",
            "probability": 7.195162270261475e-05,
            "start_logit": -6.0553059577941895,
            "end_logit": 6.243008613586426
        },
        {
            "text": "antimalarial monoclonal antibody, demonstrated 88% protective efficacy against infection in a phase 1 trial in healthy adults.",
            "probability": 5.5748065738079526e-05,
            "start_logit": 2.2984554767608643,
            "end_logit": -2.3659040927886963
        },
        {
            "text": "L9LS, a potent and safe antimalarial",
            "probability": 5.271791669246411e-05,
            "start_logit": -1.2651423215866089,
            "end_logit": 1.1418063640594482
        },
        {
            "text": "antimalarial monoclonal antibody,",
            "probability": 4.041812320242951e-05,
            "start_logit": 3.1062395572662354,
            "end_logit": -3.4952526092529297
        },
        {
            "text": "antimalarial monoclonal antibody, demonstrated 88% protective efficacy against infection",
            "probability": 1.5950940969013223e-05,
            "start_logit": 3.1062395572662354,
            "end_logit": -4.425013065338135
        },
        {
            "text": "antimalarial monoclonal antibody",
            "probability": 2.081348368872322e-06,
            "start_logit": 2.2984554767608643,
            "end_logit": -5.653730869293213
        },
        {
            "text": "antimal",
            "probability": 1.7373673477769396e-06,
            "start_logit": 2.2984554767608643,
            "end_logit": -5.834375858306885
        },
        {
            "text": "a potent and safe antimalarial",
            "probability": 1.2601817190110342e-06,
            "start_logit": -4.998841762542725,
            "end_logit": 1.1418063640594482
        },
        {
            "text": "antimalarial monoclonal antibody, demonstrated 88%",
            "probability": 8.556336680931922e-07,
            "start_logit": 3.1062395572662354,
            "end_logit": -7.3504438400268555
        },
        {
            "text": "L9LS, a potent and safe antimalarial monoclonal antibody,",
            "probability": 5.106332788370854e-07,
            "start_logit": -1.2651423215866089,
            "end_logit": -3.4952526092529297
        },
        {
            "text": "antimalarial monoclonal antibody, demonstrated 88% protective efficacy",
            "probability": 4.877123102231446e-07,
            "start_logit": 3.1062395572662354,
            "end_logit": -7.91256046295166
        },
        {
            "text": "potent and safe antimalarial",
            "probability": 4.38143733724554e-07,
            "start_logit": -6.0553059577941895,
            "end_logit": 1.1418063640594482
        },
        {
            "text": "antimalarial monoclonal antibody, demonstrated 88% protective efficacy against infection in a phase 1 trial in healthy adults",
            "probability": 3.465179256701776e-07,
            "start_logit": 2.2984554767608643,
            "end_logit": -7.446567535400391
        },
        {
            "text": "anti",
            "probability": 2.9366135045838784e-07,
            "start_logit": 2.2984554767608643,
            "end_logit": -7.612074851989746
        },
        {
            "text": "L9LS, a potent and safe antimalarial monoclonal antibody, demonstrated 88% protective efficacy against infection",
            "probability": 2.015205220378571e-07,
            "start_logit": -1.2651423215866089,
            "end_logit": -4.425013065338135
        }
    ],
    "64121f44201352f04a000037_001": [
        {
            "text": "proteolysis targeting chimeras",
            "probability": 0.9996601447141933,
            "start_logit": 7.275467395782471,
            "end_logit": 8.415224075317383
        },
        {
            "text": "chimeras",
            "probability": 0.00014160122747307655,
            "start_logit": -1.5866883993148804,
            "end_logit": 8.415224075317383
        },
        {
            "text": "Design and synthesis of proteolysis targeting chimeras",
            "probability": 0.00012900742439704246,
            "start_logit": -1.6798332929611206,
            "end_logit": 8.415224075317383
        },
        {
            "text": "proteolysis targeting chimeras (PROTACs) as an EGFR degrader based on CO-1686.",
            "probability": 2.994820812890035e-05,
            "start_logit": 7.275467395782471,
            "end_logit": -2.0004770755767822
        },
        {
            "text": "proteolysis targeting chimeras (PROTACs) as an EGFR degrader",
            "probability": 1.069198417463486e-05,
            "start_logit": 7.275467395782471,
            "end_logit": -3.030452251434326
        },
        {
            "text": "proteolysis targeting chimeras (PROTACs)",
            "probability": 6.6255847944801705e-06,
            "start_logit": 7.275467395782471,
            "end_logit": -3.5090079307556152
        },
        {
            "text": "targeting chimeras",
            "probability": 6.3753944219832096e-06,
            "start_logit": -4.687257289886475,
            "end_logit": 8.415224075317383
        },
        {
            "text": "proteolysis targeting ch",
            "probability": 5.404717537525933e-06,
            "start_logit": 7.275467395782471,
            "end_logit": -3.712674379348755
        },
        {
            "text": "pro",
            "probability": 2.3321813282149083e-06,
            "start_logit": 7.275467395782471,
            "end_logit": -4.553142547607422
        },
        {
            "text": "proteolysis targeting chimeras (",
            "probability": 1.747108782861067e-06,
            "start_logit": 7.275467395782471,
            "end_logit": -4.841984272003174
        },
        {
            "text": "proteolysis targeting chimeras (PROTACs) as an EGFR degrader based on CO-1686",
            "probability": 1.635927286581388e-06,
            "start_logit": 7.275467395782471,
            "end_logit": -4.907736778259277
        },
        {
            "text": "proteolysis targeting chime",
            "probability": 1.191145763708936e-06,
            "start_logit": 7.275467395782471,
            "end_logit": -5.225030899047852
        },
        {
            "text": "of proteolysis targeting chimeras",
            "probability": 1.170005591560961e-06,
            "start_logit": -6.382694721221924,
            "end_logit": 8.415224075317383
        },
        {
            "text": "proteolysis targeting",
            "probability": 7.91668025921334e-07,
            "start_logit": 7.275467395782471,
            "end_logit": -5.633559703826904
        },
        {
            "text": "proteolysis targeting chimeras (PROTACs) as an EGFR",
            "probability": 6.043359445486126e-07,
            "start_logit": 7.275467395782471,
            "end_logit": -5.903571605682373
        },
        {
            "text": "proteolysis targeting chimeras (PROTACs",
            "probability": 3.17692780732812e-07,
            "start_logit": 7.275467395782471,
            "end_logit": -6.546617031097412
        },
        {
            "text": "proteolysis",
            "probability": 1.6058422674183355e-07,
            "start_logit": 7.275467395782471,
            "end_logit": -7.228883266448975
        },
        {
            "text": "proteolysis targeting chimeras (PROTACs) as an EGFR degrader based",
            "probability": 1.3843364255804003e-07,
            "start_logit": 7.275467395782471,
            "end_logit": -7.377310752868652
        },
        {
            "text": "proteolysis targeting chimeras (PROTAC",
            "probability": 1.0741936041786995e-07,
            "start_logit": 7.275467395782471,
            "end_logit": -7.6309614181518555
        },
        {
            "text": "chimeras (PROTACs) as an EGFR degrader based on CO-1686.",
            "probability": 4.2421447469868795e-09,
            "start_logit": -1.5866883993148804,
            "end_logit": -2.0004770755767822
        }
    ],
    "64121f44201352f04a000037_002": [
        {
            "text": "proteolysis targeting chimera",
            "probability": 0.9988042858157089,
            "start_logit": 8.326031684875488,
            "end_logit": 9.2661771774292
        },
        {
            "text": "chimera",
            "probability": 0.0007778371234686138,
            "start_logit": 1.1682347059249878,
            "end_logit": 9.2661771774292
        },
        {
            "text": "The emerging technology proteolysis targeting chimera",
            "probability": 0.00033082165289966133,
            "start_logit": 0.31329697370529175,
            "end_logit": 9.2661771774292
        },
        {
            "text": "proteolysis targeting chimera (PROTAC) could be an alternative strategy to overcome these problems.",
            "probability": 4.325842480062336e-05,
            "start_logit": 8.326031684875488,
            "end_logit": -0.7809449434280396
        },
        {
            "text": "proteolysis targeting ch",
            "probability": 2.451811782370097e-05,
            "start_logit": 8.326031684875488,
            "end_logit": -1.348724603652954
        },
        {
            "text": "emerging technology proteolysis targeting chimera",
            "probability": 6.2690745828824975e-06,
            "start_logit": -3.652653694152832,
            "end_logit": 9.2661771774292
        },
        {
            "text": "proteolysis targeting chimera (PROTAC)",
            "probability": 3.7654699005922474e-06,
            "start_logit": 8.326031684875488,
            "end_logit": -3.222264289855957
        },
        {
            "text": "pro",
            "probability": 2.661506531593401e-06,
            "start_logit": 8.326031684875488,
            "end_logit": -3.569244623184204
        },
        {
            "text": "targeting chimera",
            "probability": 2.193930839830322e-06,
            "start_logit": -4.702587604522705,
            "end_logit": 9.2661771774292
        },
        {
            "text": "proteolysis targeting chime",
            "probability": 1.7681472089700041e-06,
            "start_logit": 8.326031684875488,
            "end_logit": -3.9782047271728516
        },
        {
            "text": "proteolysis targeting chimera (",
            "probability": 7.611047635896385e-07,
            "start_logit": 8.326031684875488,
            "end_logit": -4.8211212158203125
        },
        {
            "text": "technology proteolysis targeting chimera",
            "probability": 7.268734665419563e-07,
            "start_logit": -5.807285308837891,
            "end_logit": 9.2661771774292
        },
        {
            "text": "proteolysis targeting",
            "probability": 4.71563461043446e-07,
            "start_logit": 8.326031684875488,
            "end_logit": -5.299838542938232
        },
        {
            "text": "proteolysis",
            "probability": 1.791679513510633e-07,
            "start_logit": 8.326031684875488,
            "end_logit": -6.267568588256836
        },
        {
            "text": "proteolysis targeting chimera (PROTAC) could be an alternative strategy to overcome these problems",
            "probability": 1.7048563449836272e-07,
            "start_logit": 8.326031684875488,
            "end_logit": -6.317241191864014
        },
        {
            "text": "proteolysis targeting chimera (PROTAC",
            "probability": 1.3192477268245498e-07,
            "start_logit": 8.326031684875488,
            "end_logit": -6.573660373687744
        },
        {
            "text": "prote",
            "probability": 5.231158396103234e-08,
            "start_logit": 8.326031684875488,
            "end_logit": -7.498674392700195
        },
        {
            "text": "proteoly",
            "probability": 5.148227602154288e-08,
            "start_logit": 8.326031684875488,
            "end_logit": -7.514654636383057
        },
        {
            "text": "proteolysis targeting chimera (PROTAC) could be an alternative strategy",
            "probability": 4.213403463332633e-08,
            "start_logit": 8.326031684875488,
            "end_logit": -7.715036392211914
        },
        {
            "text": "chimera (PROTAC) could be an alternative strategy to overcome these problems.",
            "probability": 3.3688290279231614e-08,
            "start_logit": 1.1682347059249878,
            "end_logit": -0.7809449434280396
        }
    ],
    "6451029f57b1c7a315000094_001": [
        {
            "text": "1:40,000",
            "probability": 0.8967703439918314,
            "start_logit": 8.615745544433594,
            "end_logit": 4.838871955871582
        },
        {
            "text": "1:40,000 - 1:77,000 liveborn infants a year",
            "probability": 0.051601100853505825,
            "start_logit": 8.615745544433594,
            "end_logit": 1.9836151599884033
        },
        {
            "text": "1:40,000 - 1:77,000 liveborn infants a year.",
            "probability": 0.0195226938185551,
            "start_logit": 8.615745544433594,
            "end_logit": 1.01164972782135
        },
        {
            "text": "1:40,000 - 1:77,000 liveborn infants",
            "probability": 0.016777832387009344,
            "start_logit": 8.615745544433594,
            "end_logit": 0.8601306676864624
        },
        {
            "text": "1:40,000 - 1:77,000",
            "probability": 0.010162011799081452,
            "start_logit": 8.615745544433594,
            "end_logit": 0.3587285876274109
        },
        {
            "text": "1",
            "probability": 0.0027802665864537063,
            "start_logit": 8.615745544433594,
            "end_logit": -0.9373810291290283
        },
        {
            "text": "1:",
            "probability": 0.0008906275595825725,
            "start_logit": 8.615745544433594,
            "end_logit": -2.075756788253784
        },
        {
            "text": "40,000",
            "probability": 0.0007745567216750277,
            "start_logit": 1.5614813566207886,
            "end_logit": 4.838871955871582
        },
        {
            "text": "50% of cases in this age group. Its estimated incidence is 1:40,000",
            "probability": 0.00030941833488689214,
            "start_logit": 0.6438846588134766,
            "end_logit": 4.838871955871582
        },
        {
            "text": "more than 50% of cases in this age group. Its estimated incidence is 1:40,000",
            "probability": 8.638261505974357e-05,
            "start_logit": -0.6320230960845947,
            "end_logit": 4.838871955871582
        },
        {
            "text": "1:77,000 liveborn infants a year",
            "probability": 7.808251130567017e-05,
            "start_logit": 2.122213363647461,
            "end_logit": 1.9836151599884033
        },
        {
            "text": "Its estimated incidence is 1:40,000",
            "probability": 7.387236831306412e-05,
            "start_logit": -0.7884706854820251,
            "end_logit": 4.838871955871582
        },
        {
            "text": "40,000 - 1:77,000 liveborn infants a year",
            "probability": 4.4568801566299356e-05,
            "start_logit": 1.5614813566207886,
            "end_logit": 1.9836151599884033
        },
        {
            "text": "1:77,000 liveborn infants a year.",
            "probability": 2.9541636430047162e-05,
            "start_logit": 2.122213363647461,
            "end_logit": 1.01164972782135
        },
        {
            "text": "1:77,000 liveborn infants",
            "probability": 2.538812671385653e-05,
            "start_logit": 2.122213363647461,
            "end_logit": 0.8601306676864624
        },
        {
            "text": "50% of cases in this age group. Its estimated incidence is 1:40,000 - 1:77,000 liveborn infants a year",
            "probability": 1.7804253688130213e-05,
            "start_logit": 0.6438846588134766,
            "end_logit": 1.9836151599884033
        },
        {
            "text": "40,000 - 1:77,000 liveborn infants a year.",
            "probability": 1.6862102793291195e-05,
            "start_logit": 1.5614813566207886,
            "end_logit": 1.01164972782135
        },
        {
            "text": "1:77,000",
            "probability": 1.5377102194830826e-05,
            "start_logit": 2.122213363647461,
            "end_logit": 0.3587285876274109
        },
        {
            "text": "40,000 - 1:77,000 liveborn infants",
            "probability": 1.4491316464199934e-05,
            "start_logit": 1.5614813566207886,
            "end_logit": 0.8601306676864624
        },
        {
            "text": "40,000 - 1:77,000",
            "probability": 8.777112888995331e-06,
            "start_logit": 1.5614813566207886,
            "end_logit": 0.3587285876274109
        }
    ],
    "6432f5f257b1c7a31500001c_001": [
        {
            "text": "BTK",
            "probability": 0.8907160209551286,
            "start_logit": 4.188239574432373,
            "end_logit": -1.762467384338379
        },
        {
            "text": "BTK inhibitor",
            "probability": 0.0657760966669162,
            "start_logit": 4.188239574432373,
            "end_logit": -4.368236541748047
        },
        {
            "text": "BTK inhibitor, has been approved for treating adults with mantle cell lymphoma",
            "probability": 0.011832331909087751,
            "start_logit": 4.188239574432373,
            "end_logit": -6.083657264709473
        },
        {
            "text": "BT",
            "probability": 0.010153802812680083,
            "start_logit": 4.188239574432373,
            "end_logit": -6.236644744873047
        },
        {
            "text": "BTK inhibitor,",
            "probability": 0.009974656127166338,
            "start_logit": 4.188239574432373,
            "end_logit": -6.254445552825928
        },
        {
            "text": "BTK inhibitor, has been approved for treating adults with mantle cell lymphoma who have received at least one prior therapy,",
            "probability": 0.008701373178093559,
            "start_logit": 4.188239574432373,
            "end_logit": -6.391012191772461
        },
        {
            "text": "BTK inhibitor, has been approved for treating adults with mantle cell lymphoma who have received at least one prior therapy",
            "probability": 0.0027105264630955814,
            "start_logit": 4.188239574432373,
            "end_logit": -7.557350158691406
        },
        {
            "text": "CD20-based therapy. B",
            "probability": 2.3438049911687184e-05,
            "start_logit": -3.6674013137817383,
            "end_logit": -4.45224666595459
        },
        {
            "text": "In the United States, zanubrutinib, a next-generation BTK",
            "probability": 2.1543806669345698e-05,
            "start_logit": -6.441452980041504,
            "end_logit": -1.762467384338379
        },
        {
            "text": "zanubrutinib, a next-generation BTK",
            "probability": 2.067949959415463e-05,
            "start_logit": -6.482398509979248,
            "end_logit": -1.762467384338379
        },
        {
            "text": "next-generation BTK",
            "probability": 1.928103896802582e-05,
            "start_logit": -6.552419185638428,
            "end_logit": -1.762467384338379
        },
        {
            "text": "CD20",
            "probability": 1.806283514779935e-05,
            "start_logit": -3.6674013137817383,
            "end_logit": -4.7127509117126465
        },
        {
            "text": "a next-generation BTK",
            "probability": 1.466614977188744e-05,
            "start_logit": -6.8259992599487305,
            "end_logit": -1.762467384338379
        },
        {
            "text": "B",
            "probability": 8.689493180143516e-06,
            "start_logit": -4.659647464752197,
            "end_logit": -4.45224666595459
        },
        {
            "text": "CD20-based therapy.",
            "probability": 1.6749100515257288e-06,
            "start_logit": -3.6674013137817383,
            "end_logit": -7.090847969055176
        },
        {
            "text": "In the United States, zanubrutinib, a next-generation BTK inhibitor",
            "probability": 1.5909307531447486e-06,
            "start_logit": -6.441452980041504,
            "end_logit": -4.368236541748047
        },
        {
            "text": "zanubrutinib, a next-generation BTK inhibitor",
            "probability": 1.5271048598294971e-06,
            "start_logit": -6.482398509979248,
            "end_logit": -4.368236541748047
        },
        {
            "text": "next-generation BTK inhibitor",
            "probability": 1.4238336946488288e-06,
            "start_logit": -6.552419185638428,
            "end_logit": -4.368236541748047
        },
        {
            "text": "anti-CD20-based therapy. B",
            "probability": 1.313242876468983e-06,
            "start_logit": -6.549262523651123,
            "end_logit": -4.45224666595459
        },
        {
            "text": "CD20-based therapy",
            "probability": 1.3009923535378179e-06,
            "start_logit": -3.6674013137817383,
            "end_logit": -7.343480110168457
        }
    ],
    "6432f5f257b1c7a31500001c_002": [
        {
            "text": "BTK",
            "probability": 0.9978137303072449,
            "start_logit": 7.486991882324219,
            "end_logit": 3.5449392795562744
        },
        {
            "text": "BT",
            "probability": 0.0009135599707737572,
            "start_logit": 7.486991882324219,
            "end_logit": -3.451033592224121
        },
        {
            "text": "BTK inhibitor, was designed to block BTK more specifically than ibrutinib.",
            "probability": 0.0005361470105989027,
            "start_logit": 7.486991882324219,
            "end_logit": -3.9839742183685303
        },
        {
            "text": "BTK inhibitor",
            "probability": 0.00041901639609215596,
            "start_logit": 7.486991882324219,
            "end_logit": -4.230472564697266
        },
        {
            "text": "BTK inhibitor,",
            "probability": 0.0001515151680095478,
            "start_logit": 7.486991882324219,
            "end_logit": -5.247696876525879
        },
        {
            "text": "BTK inhibitor, was designed to block BTK",
            "probability": 9.522100615595494e-05,
            "start_logit": 7.486991882324219,
            "end_logit": -5.71218204498291
        },
        {
            "text": "BTK inhibitor, was designed to block BTK more specifically than ibrutinib",
            "probability": 3.319600546531024e-05,
            "start_logit": 7.486991882324219,
            "end_logit": -6.765953063964844
        },
        {
            "text": "BTK inhibitor, was designed to block BTK more specifically",
            "probability": 1.9339823724135673e-05,
            "start_logit": 7.486991882324219,
            "end_logit": -7.306216239929199
        },
        {
            "text": "To reduce these side effects, zanubrutinib, a next-generation BTK",
            "probability": 1.3430394940843604e-05,
            "start_logit": -3.7288095951080322,
            "end_logit": 3.5449392795562744
        },
        {
            "text": "zanubrutinib, a next-generation BTK",
            "probability": 1.3167352426516067e-06,
            "start_logit": -6.051174640655518,
            "end_logit": 3.5449392795562744
        },
        {
            "text": "side effects, zanubrutinib, a next-generation BTK",
            "probability": 1.1365216689064522e-06,
            "start_logit": -6.198357582092285,
            "end_logit": 3.5449392795562744
        },
        {
            "text": "reduce these side effects, zanubrutinib, a next-generation BTK",
            "probability": 7.189651455118074e-07,
            "start_logit": -6.6562724113464355,
            "end_logit": 3.5449392795562744
        },
        {
            "text": "next-generation BTK",
            "probability": 6.997411002252667e-07,
            "start_logit": -6.683374881744385,
            "end_logit": 3.5449392795562744
        },
        {
            "text": "a next-generation BTK",
            "probability": 6.462881761304803e-07,
            "start_logit": -6.7628397941589355,
            "end_logit": 3.5449392795562744
        },
        {
            "text": "these side effects, zanubrutinib, a next-generation BTK",
            "probability": 3.0308413710942857e-07,
            "start_logit": -7.520074844360352,
            "end_logit": 3.5449392795562744
        },
        {
            "text": "To reduce these side effects, zanubrutinib, a next-generation BT",
            "probability": 1.2296354356498089e-08,
            "start_logit": -3.7288095951080322,
            "end_logit": -3.451033592224121
        },
        {
            "text": "To reduce these side effects, zanubrutinib, a next-generation BTK inhibitor",
            "probability": 5.639885998034707e-09,
            "start_logit": -3.7288095951080322,
            "end_logit": -4.230472564697266
        },
        {
            "text": "To reduce these side effects, zanubrutinib, a next-generation BTK inhibitor,",
            "probability": 2.0393671524943984e-09,
            "start_logit": -3.7288095951080322,
            "end_logit": -5.247696876525879
        },
        {
            "text": "BTK more specifically than ibrutinib.",
            "probability": 1.3242589277921926e-09,
            "start_logit": -5.424318790435791,
            "end_logit": -3.9839742183685303
        },
        {
            "text": "To reduce these side effects, zanubrutinib, a next-generation BTK inhibitor, was designed to block BTK",
            "probability": 1.2816577688755517e-09,
            "start_logit": -3.7288095951080322,
            "end_logit": -5.71218204498291
        }
    ],
    "6440420857b1c7a315000050_001": [
        {
            "text": "Cabotegravir Extended-Release Injectable Suspension",
            "probability": 0.8000773871097517,
            "start_logit": 3.753086566925049,
            "end_logit": -0.41940590739250183
        },
        {
            "text": "Cabotegravir Extended-Release Injectable Suspension: A Review in HIV-1 Pre-Exposure Prophylaxis",
            "probability": 0.1289613359008379,
            "start_logit": 3.753086566925049,
            "end_logit": -2.2446017265319824
        },
        {
            "text": "Cabotegravir",
            "probability": 0.0227311062532,
            "start_logit": 3.753086566925049,
            "end_logit": -3.980380058288574
        },
        {
            "text": "Cabotegravir Extended-Release Injectable Suspension: A Review",
            "probability": 0.017072271220764334,
            "start_logit": 3.753086566925049,
            "end_logit": -4.266658782958984
        },
        {
            "text": "Cabotegravir Extended-Release Injectable Suspension:",
            "probability": 0.010596219710963882,
            "start_logit": 3.753086566925049,
            "end_logit": -4.743617057800293
        },
        {
            "text": "Cabotegravir Extended-Release",
            "probability": 0.005569588802873384,
            "start_logit": 3.753086566925049,
            "end_logit": -5.38679313659668
        },
        {
            "text": "Cabotegravir Extended-Release Injectable Su",
            "probability": 0.003827639411715342,
            "start_logit": 3.753086566925049,
            "end_logit": -5.761866092681885
        },
        {
            "text": "C",
            "probability": 0.0023885474249580353,
            "start_logit": 3.753086566925049,
            "end_logit": -6.233428955078125
        },
        {
            "text": "Cabotegravir Extended-Release Injectable Suspens",
            "probability": 0.0017215328858064163,
            "start_logit": 3.753086566925049,
            "end_logit": -6.560899257659912
        },
        {
            "text": "Cabotegravir Extended-Release Injectable Suspension: A Review in HIV",
            "probability": 0.0012896538629201073,
            "start_logit": 3.753086566925049,
            "end_logit": -6.849740505218506
        },
        {
            "text": "Cabotegravir Extended-Release Inject",
            "probability": 0.001113655897274892,
            "start_logit": 3.753086566925049,
            "end_logit": -6.996466159820557
        },
        {
            "text": "Cabotegravir Extended-Release Injectable Suspension: A Review in HIV-1 Pre-Exposure",
            "probability": 0.001108496690165641,
            "start_logit": 3.753086566925049,
            "end_logit": -7.001109600067139
        },
        {
            "text": "Cabotegravir Extended-Release Injectable Suspension: A Review in HIV-1",
            "probability": 0.0009102870747148205,
            "start_logit": 3.753086566925049,
            "end_logit": -7.1981096267700195
        },
        {
            "text": "Cabotegravir Extended-Release Injectable Suspension: A Review in HIV-1 Pre-Exposure Prophylax",
            "probability": 0.0008661584526481253,
            "start_logit": 3.753086566925049,
            "end_logit": -7.247801780700684
        },
        {
            "text": "Cab",
            "probability": 0.0007575943974152532,
            "start_logit": 3.753086566925049,
            "end_logit": -7.381721496582031
        },
        {
            "text": "Extended-Release Injectable Suspension",
            "probability": 0.0006984866775330041,
            "start_logit": -3.2904610633850098,
            "end_logit": -0.41940590739250183
        },
        {
            "text": "Injectable Suspension",
            "probability": 0.00012743080645884699,
            "start_logit": -4.9918036460876465,
            "end_logit": -0.41940590739250183
        },
        {
            "text": "Extended-Release Injectable Suspension: A Review in HIV-1 Pre-Exposure Prophylaxis",
            "probability": 0.00011258632789135114,
            "start_logit": -3.2904610633850098,
            "end_logit": -2.2446017265319824
        },
        {
            "text": "A Review in HIV-1 Pre-Exposure Prophylaxis",
            "probability": 3.664493354527375e-05,
            "start_logit": -4.412906169891357,
            "end_logit": -2.2446017265319824
        },
        {
            "text": "Injectable Suspension:",
            "probability": 3.337615856174086e-05,
            "start_logit": -6.331535339355469,
            "end_logit": -0.41940590739250183
        }
    ],
    "6440420857b1c7a315000050_002": [
        {
            "text": "HIV-1 pre-exposure prophylaxis",
            "probability": 0.80348071174679,
            "start_logit": 1.4192657470703125,
            "end_logit": 5.31214714050293
        },
        {
            "text": "approved for HIV-1 pre-exposure prophylaxis",
            "probability": 0.07060141416397435,
            "start_logit": -1.0126372575759888,
            "end_logit": 5.31214714050293
        },
        {
            "text": "pre-exposure prophylaxis",
            "probability": 0.03805103151224193,
            "start_logit": -1.6307592391967773,
            "end_logit": 5.31214714050293
        },
        {
            "text": "for HIV-1 pre-exposure prophylaxis",
            "probability": 0.03688501129033008,
            "start_logit": -1.6618821620941162,
            "end_logit": 5.31214714050293
        },
        {
            "text": "HIV-1 pre-exposure prophylaxis (PrEP)",
            "probability": 0.015493718209360465,
            "start_logit": 1.4192657470703125,
            "end_logit": 1.363628625869751
        },
        {
            "text": "the first long-acting injectable option to be approved for HIV-1 pre-exposure prophylaxis",
            "probability": 0.006452475299220216,
            "start_logit": -3.4052236080169678,
            "end_logit": 5.31214714050293
        },
        {
            "text": "first long-acting injectable option to be approved for HIV-1 pre-exposure prophylaxis",
            "probability": 0.00632086530809306,
            "start_logit": -3.4258313179016113,
            "end_logit": 5.31214714050293
        },
        {
            "text": "Cabotegravir extended-release (ER) injectable suspension",
            "probability": 0.004760739047813024,
            "start_logit": 1.8444420099258423,
            "end_logit": -0.24157938361167908
        },
        {
            "text": "long-acting injectable option to be approved for HIV-1 pre-exposure prophylaxis",
            "probability": 0.0035707951588643794,
            "start_logit": -3.996899127960205,
            "end_logit": 5.31214714050293
        },
        {
            "text": "PrEP)",
            "probability": 0.0034495624538078353,
            "start_logit": -0.08292151987552643,
            "end_logit": 1.363628625869751
        },
        {
            "text": "injectable option to be approved for HIV-1 pre-exposure prophylaxis",
            "probability": 0.002399885018261634,
            "start_logit": -4.394266605377197,
            "end_logit": 5.31214714050293
        },
        {
            "text": "HIV-1 pre-exposure prophylaxis (PrEP).",
            "probability": 0.0015221180113439774,
            "start_logit": 1.4192657470703125,
            "end_logit": -0.956703245639801
        },
        {
            "text": "approved for HIV-1 pre-exposure prophylaxis (PrEP)",
            "probability": 0.0013614246119995166,
            "start_logit": -1.0126372575759888,
            "end_logit": 1.363628625869751
        },
        {
            "text": "prophylaxis",
            "probability": 0.0013117193001884098,
            "start_logit": -4.998348712921143,
            "end_logit": 5.31214714050293
        },
        {
            "text": "(Apretude\u2122) is the first long-acting injectable option to be approved for HIV-1 pre-exposure prophylaxis",
            "probability": 0.00103077395624237,
            "start_logit": -5.239377498626709,
            "end_logit": 5.31214714050293
        },
        {
            "text": "to be approved for HIV-1 pre-exposure prophylaxis",
            "probability": 0.0009690504826798249,
            "start_logit": -5.301126003265381,
            "end_logit": 5.31214714050293
        },
        {
            "text": "pre-exposure prophylaxis (PrEP)",
            "probability": 0.0007337474953748033,
            "start_logit": -1.6307592391967773,
            "end_logit": 1.363628625869751
        },
        {
            "text": "for HIV-1 pre-exposure prophylaxis (PrEP)",
            "probability": 0.0007112628377089809,
            "start_logit": -1.6618821620941162,
            "end_logit": 1.363628625869751
        },
        {
            "text": "HIV",
            "probability": 0.0005548057106677875,
            "start_logit": 1.4192657470703125,
            "end_logit": -1.9659433364868164
        },
        {
            "text": "PrEP).",
            "probability": 0.00033888838503753606,
            "start_logit": -0.08292151987552643,
            "end_logit": -0.956703245639801
        }
    ],
    "6440420857b1c7a315000050_003": [
        {
            "text": "PrEP",
            "probability": 0.6111548449572197,
            "start_logit": 4.828359127044678,
            "end_logit": 7.139703273773193
        },
        {
            "text": "Cabotegravir ER injectable suspension is indicated in the USA for PrEP",
            "probability": 0.3795211790108948,
            "start_logit": 4.351919174194336,
            "end_logit": 7.139703273773193
        },
        {
            "text": "Cabotegravir ER injectable suspension",
            "probability": 0.007571477539282715,
            "start_logit": 4.351919174194336,
            "end_logit": 3.2251811027526855
        },
        {
            "text": "for PrEP",
            "probability": 0.0012131709855988525,
            "start_logit": -1.3937536478042603,
            "end_logit": 7.139703273773193
        },
        {
            "text": "Cabotegravir",
            "probability": 0.00017850511967884406,
            "start_logit": 4.351919174194336,
            "end_logit": -0.5223451256752014
        },
        {
            "text": "suspension is indicated in the USA for PrEP",
            "probability": 0.00011594878869768905,
            "start_logit": -3.741597890853882,
            "end_logit": 7.139703273773193
        },
        {
            "text": "ER injectable suspension is indicated in the USA for PrEP",
            "probability": 6.221573266673106e-05,
            "start_logit": -4.364138603210449,
            "end_logit": 7.139703273773193
        },
        {
            "text": "injectable suspension is indicated in the USA for PrEP",
            "probability": 4.695873384843903e-05,
            "start_logit": -4.645477294921875,
            "end_logit": 7.139703273773193
        },
        {
            "text": "indicated in the USA for PrEP",
            "probability": 4.316437165740464e-05,
            "start_logit": -4.72973108291626,
            "end_logit": 7.139703273773193
        },
        {
            "text": "PrEP to",
            "probability": 2.1331884922258243e-05,
            "start_logit": 4.828359127044678,
            "end_logit": -3.123199462890625
        },
        {
            "text": "to",
            "probability": 2.0233203551798553e-05,
            "start_logit": 4.775481224060059,
            "end_logit": -3.123199462890625
        },
        {
            "text": "Cabotegravir ER injectable suspension is indicated in the USA for PrEP to",
            "probability": 1.3246891819677687e-05,
            "start_logit": 4.351919174194336,
            "end_logit": -3.123199462890625
        },
        {
            "text": "Cabotegravir ER",
            "probability": 1.115653864075478e-05,
            "start_logit": 4.351919174194336,
            "end_logit": -3.2949366569519043
        },
        {
            "text": "is indicated in the USA for PrEP",
            "probability": 1.0728048693556313e-05,
            "start_logit": -6.121884822845459,
            "end_logit": 7.139703273773193
        },
        {
            "text": "P",
            "probability": 3.71545539422133e-06,
            "start_logit": 4.828359127044678,
            "end_logit": -4.870901107788086
        },
        {
            "text": "PrEP to reduce the risk of sexually acquired HIV-1 infection",
            "probability": 2.6110398910482843e-06,
            "start_logit": 4.828359127044678,
            "end_logit": -5.223653793334961
        },
        {
            "text": "to reduce the risk of sexually acquired HIV-1 infection",
            "probability": 2.476560406639076e-06,
            "start_logit": 4.775481224060059,
            "end_logit": -5.223653793334961
        },
        {
            "text": "PrEP to reduce the risk of sexually acquired HIV",
            "probability": 2.4146881827908404e-06,
            "start_logit": 4.828359127044678,
            "end_logit": -5.30183219909668
        },
        {
            "text": "suspension",
            "probability": 2.313187505423481e-06,
            "start_logit": -3.741597890853882,
            "end_logit": 3.2251811027526855
        },
        {
            "text": "Cabotegravir ER injectable suspension is indicated in the USA for P",
            "probability": 2.3072614467712735e-06,
            "start_logit": 4.351919174194336,
            "end_logit": -4.870901107788086
        }
    ],
    "6440420857b1c7a315000050_004": [
        {
            "text": "cabotegravir ER injectable suspension",
            "probability": 0.9248730744583509,
            "start_logit": 0.3548402786254883,
            "end_logit": 2.1739165782928467
        },
        {
            "text": "cabotegravir",
            "probability": 0.023652890283099214,
            "start_logit": 0.3548402786254883,
            "end_logit": -1.492254614830017
        },
        {
            "text": "cabotegravir ER injectable suspension represents a novel and efficacious alternative to daily oral PrEP.",
            "probability": 0.012938100964254007,
            "start_logit": 0.3548402786254883,
            "end_logit": -2.0955634117126465
        },
        {
            "text": "injectable suspension",
            "probability": 0.011574046123110474,
            "start_logit": -4.026051044464111,
            "end_logit": 2.1739165782928467
        },
        {
            "text": "intramuscular administration, cabotegravir ER injectable suspension",
            "probability": 0.0074974430842699325,
            "start_logit": -4.460254192352295,
            "end_logit": 2.1739165782928467
        },
        {
            "text": "suspension",
            "probability": 0.0067771682139200805,
            "start_logit": -4.5612568855285645,
            "end_logit": 2.1739165782928467
        },
        {
            "text": "ER injectable suspension",
            "probability": 0.004425280582437254,
            "start_logit": -4.98748254776001,
            "end_logit": 2.1739165782928467
        },
        {
            "text": "its long-acting formulation enabling intramuscular administration, cabotegravir ER injectable suspension",
            "probability": 0.00266920564310974,
            "start_logit": -5.493035316467285,
            "end_logit": 2.1739165782928467
        },
        {
            "text": "long-acting formulation enabling intramuscular administration, cabotegravir ER injectable suspension",
            "probability": 0.001543797818928704,
            "start_logit": -6.0405707359313965,
            "end_logit": 2.1739165782928467
        },
        {
            "text": "cabotegravir ER",
            "probability": 0.0013023766954848442,
            "start_logit": 0.3548402786254883,
            "end_logit": -4.391549110412598
        },
        {
            "text": "With its convenient, less-frequent dosing schedule and its long-acting formulation enabling intramuscular administration, cabotegravir",
            "probability": 0.0005400279531972952,
            "start_logit": -3.4247794151306152,
            "end_logit": -1.492254614830017
        },
        {
            "text": "cabotegravir ER injectable suspension represents",
            "probability": 0.0004640911521993201,
            "start_logit": 0.3548402786254883,
            "end_logit": -5.42341423034668
        },
        {
            "text": "cabotegravir ER injectable suspension represents a novel and efficacious alternative",
            "probability": 0.00040628615215892533,
            "start_logit": 0.3548402786254883,
            "end_logit": -5.5564374923706055
        },
        {
            "text": "cabotegravir ER injectable suspension represents a novel and efficacious alternative to daily oral PrEP",
            "probability": 0.0003750694473170895,
            "start_logit": 0.3548402786254883,
            "end_logit": -5.636384010314941
        },
        {
            "text": "cabotegravir ER injectable suspension represents a novel and efficacious alternative to daily oral",
            "probability": 0.00019586886303352244,
            "start_logit": 0.3548402786254883,
            "end_logit": -6.286049842834473
        },
        {
            "text": "intramuscular administration, cabotegravir",
            "probability": 0.00019174111948266423,
            "start_logit": -4.460254192352295,
            "end_logit": -1.492254614830017
        },
        {
            "text": "injectable suspension represents a novel and efficacious alternative to daily oral PrEP.",
            "probability": 0.00016190997601853033,
            "start_logit": -4.026051044464111,
            "end_logit": -2.0955634117126465
        },
        {
            "text": "novel and efficacious alternative to daily oral PrEP.",
            "probability": 0.00015200790252728173,
            "start_logit": -4.08915901184082,
            "end_logit": -2.0955634117126465
        },
        {
            "text": "cabotegravir ER injectable suspension represents a novel",
            "probability": 0.00014820178933430092,
            "start_logit": 0.3548402786254883,
            "end_logit": -6.564920425415039
        },
        {
            "text": "oral PrEP.",
            "probability": 0.00011141177776617833,
            "start_logit": -4.399858474731445,
            "end_logit": -2.0955634117126465
        }
    ],
    "63eef4f5f36125a42600000b_001": [
        {
            "text": "multiple sclerosis",
            "probability": 0.9994145313935839,
            "start_logit": 7.098843097686768,
            "end_logit": 9.409309387207031
        },
        {
            "text": "sclerosis:",
            "probability": 0.0003527012601490254,
            "start_logit": -0.850460410118103,
            "end_logit": 9.409309387207031
        },
        {
            "text": "relapsing multiple sclerosis",
            "probability": 0.00020118256333902113,
            "start_logit": -1.4118690490722656,
            "end_logit": 9.409309387207031
        },
        {
            "text": "multiple",
            "probability": 1.0978489761736641e-05,
            "start_logit": 7.098843097686768,
            "end_logit": -2.0096776485443115
        },
        {
            "text": "Teriflunomide for relapsing multiple sclerosis",
            "probability": 4.373513051652017e-06,
            "start_logit": -5.240515232086182,
            "end_logit": 9.409309387207031
        },
        {
            "text": "sclerosis",
            "probability": 3.6806727268515715e-06,
            "start_logit": -5.4129862785339355,
            "end_logit": 9.409309387207031
        },
        {
            "text": "for relapsing multiple sclerosis",
            "probability": 2.7362207848317658e-06,
            "start_logit": -5.709504127502441,
            "end_logit": 9.409309387207031
        },
        {
            "text": "multiple sclerosis: A meta-analysis.",
            "probability": 2.4331984109862638e-06,
            "start_logit": 7.098843097686768,
            "end_logit": -3.516408920288086
        },
        {
            "text": "Outcomes of Ublituximab compared to Teriflunomide for relapsing multiple sclerosis",
            "probability": 2.3455629455991477e-06,
            "start_logit": -5.863556385040283,
            "end_logit": 9.409309387207031
        },
        {
            "text": "Ublituximab compared to Teriflunomide for relapsing multiple sclerosis",
            "probability": 2.0731050331388114e-06,
            "start_logit": -5.987034320831299,
            "end_logit": 9.409309387207031
        },
        {
            "text": "relapsing multiple sclerosis:",
            "probability": 8.460478306620973e-07,
            "start_logit": -6.883261203765869,
            "end_logit": 9.409309387207031
        },
        {
            "text": "compared to Teriflunomide for relapsing multiple sclerosis",
            "probability": 7.540990098820718e-07,
            "start_logit": -6.9983134269714355,
            "end_logit": 9.409309387207031
        },
        {
            "text": "multiple s",
            "probability": 4.727697774723192e-07,
            "start_logit": 7.098843097686768,
            "end_logit": -5.154762268066406
        },
        {
            "text": "multiple scle",
            "probability": 3.36112157504022e-07,
            "start_logit": 7.098843097686768,
            "end_logit": -5.4959259033203125
        },
        {
            "text": "multiple sclerosis:",
            "probability": 2.2867801766727735e-07,
            "start_logit": 7.098843097686768,
            "end_logit": -5.88105583190918
        },
        {
            "text": "multiple sclerosis: A meta-analysis",
            "probability": 2.1255039750109343e-07,
            "start_logit": 7.098843097686768,
            "end_logit": -5.9541916847229
        },
        {
            "text": "multiple sclerosis: A",
            "probability": 7.575603349571486e-08,
            "start_logit": 7.098843097686768,
            "end_logit": -6.9858527183532715
        },
        {
            "text": "multiple sclerosis: A meta-",
            "probability": 3.4938319396316106e-08,
            "start_logit": 7.098843097686768,
            "end_logit": -7.759786605834961
        },
        {
            "text": "relapsing multiple",
            "probability": 2.2099745825964646e-09,
            "start_logit": -1.4118690490722656,
            "end_logit": -2.0096776485443115
        },
        {
            "text": "sclerosis: A meta-analysis.",
            "probability": 8.586948846449111e-10,
            "start_logit": -0.850460410118103,
            "end_logit": -3.516408920288086
        }
    ],
    "63eef4f5f36125a42600000b_002": [
        {
            "text": "multiple sclerosis",
            "probability": 0.9996428000488103,
            "start_logit": 6.784877300262451,
            "end_logit": 9.189192771911621
        },
        {
            "text": "sclerosis",
            "probability": 0.00028389130960150495,
            "start_logit": -1.3816845417022705,
            "end_logit": 9.189192771911621
        },
        {
            "text": "relapsing multiple sclerosis",
            "probability": 2.5900873300604062e-05,
            "start_logit": -3.7759993076324463,
            "end_logit": 9.189192771911621
        },
        {
            "text": "multiple",
            "probability": 1.2406225759334232e-05,
            "start_logit": 6.784877300262451,
            "end_logit": -2.107762098312378
        },
        {
            "text": "multiple sclerosis (MS",
            "probability": 1.1449403932479045e-05,
            "start_logit": 6.784877300262451,
            "end_logit": -2.1880228519439697
        },
        {
            "text": "multiple sclerosis (MS).",
            "probability": 7.420586444165193e-06,
            "start_logit": 6.784877300262451,
            "end_logit": -2.6217024326324463
        },
        {
            "text": "CD20 antibody that immunomodulates B-cells for relapsing multiple sclerosis",
            "probability": 5.700508940497785e-06,
            "start_logit": -5.28972053527832,
            "end_logit": 9.189192771911621
        },
        {
            "text": "anti-CD20 antibody that immunomodulates B-cells for relapsing multiple sclerosis",
            "probability": 3.3230311450216624e-06,
            "start_logit": -5.8293986320495605,
            "end_logit": 9.189192771911621
        },
        {
            "text": "multiple sclerosis (MS)",
            "probability": 1.9850116273132374e-06,
            "start_logit": 6.784877300262451,
            "end_logit": -3.940335750579834
        },
        {
            "text": "B-cells for relapsing multiple sclerosis",
            "probability": 1.573524946121348e-06,
            "start_logit": -6.576957702636719,
            "end_logit": 9.189192771911621
        },
        {
            "text": "an anti-CD20 antibody that immunomodulates B-cells for relapsing multiple sclerosis",
            "probability": 1.2907857003957088e-06,
            "start_logit": -6.775024890899658,
            "end_logit": 9.189192771911621
        },
        {
            "text": "immunomodulates B-cells for relapsing multiple sclerosis",
            "probability": 1.0438372594565965e-06,
            "start_logit": -6.987372398376465,
            "end_logit": 9.189192771911621
        },
        {
            "text": "antibody that immunomodulates B-cells for relapsing multiple sclerosis",
            "probability": 6.542088527698478e-07,
            "start_logit": -7.454604625701904,
            "end_logit": 9.189192771911621
        },
        {
            "text": "multiple s",
            "probability": 3.599720749196097e-07,
            "start_logit": 6.784877300262451,
            "end_logit": -5.647689342498779
        },
        {
            "text": "multiple scle",
            "probability": 1.956352330085369e-07,
            "start_logit": 6.784877300262451,
            "end_logit": -6.2574639320373535
        },
        {
            "text": "sclerosis (MS).",
            "probability": 3.251547729238272e-09,
            "start_logit": -1.3816845417022705,
            "end_logit": -2.1880228519439697
        },
        {
            "text": "MS",
            "probability": 5.674842344704762e-10,
            "start_logit": -3.1273579597473145,
            "end_logit": -2.1880228519439697
        },
        {
            "text": "Ublituximab is an anti-CD20 antibody that immunomodulates B-cells for relapsing multiple",
            "probability": 5.280948375256017e-10,
            "start_logit": -3.2795557975769043,
            "end_logit": -2.107762098312378
        },
        {
            "text": "MS).",
            "probability": 3.677978209540984e-10,
            "start_logit": -3.1273579597473145,
            "end_logit": -2.6217024326324463
        },
        {
            "text": "relapsing multiple",
            "probability": 3.214469023490355e-10,
            "start_logit": -3.7759993076324463,
            "end_logit": -2.107762098312378
        }
    ],
    "63eef4f5f36125a42600000b_003": [
        {
            "text": "MS",
            "probability": 0.9999240331963329,
            "start_logit": 6.37827730178833,
            "end_logit": 8.364032745361328
        },
        {
            "text": "B cells in patients with MS",
            "probability": 6.613708794920972e-05,
            "start_logit": -3.2454276084899902,
            "end_logit": 8.364032745361328
        },
        {
            "text": "In the second part of the review, we summarize medications that have targeted B cells in patients with MS",
            "probability": 2.7618065388053972e-06,
            "start_logit": -6.421272277832031,
            "end_logit": 8.364032745361328
        },
        {
            "text": "patients with MS",
            "probability": 2.646150757897688e-06,
            "start_logit": -6.464051246643066,
            "end_logit": 8.364032745361328
        },
        {
            "text": "we summarize medications that have targeted B cells in patients with MS",
            "probability": 1.7762781414550723e-06,
            "start_logit": -6.862637042999268,
            "end_logit": 8.364032745361328
        },
        {
            "text": "MS and their current position in the therapeutic armamentarium based on clinical trials and real-world data.",
            "probability": 1.672169929009032e-06,
            "start_logit": 6.37827730178833,
            "end_logit": -4.93727970123291
        },
        {
            "text": "with MS",
            "probability": 9.731149942413587e-07,
            "start_logit": -7.464410305023193,
            "end_logit": 8.364032745361328
        },
        {
            "text": "B cells in patients with MS and their current position in the therapeutic armamentarium based on clinical trials and real-world data.",
            "probability": 1.1060085165407714e-10,
            "start_logit": -3.2454276084899902,
            "end_logit": -4.93727970123291
        },
        {
            "text": "B cells",
            "probability": 4.154859897147019e-11,
            "start_logit": -3.2454276084899902,
            "end_logit": -5.916343688964844
        },
        {
            "text": "B cells in patients with",
            "probability": 1.2061180622948237e-11,
            "start_logit": -3.2454276084899902,
            "end_logit": -7.153215408325195
        },
        {
            "text": "CD20",
            "probability": 6.703097354998208e-12,
            "start_logit": -5.706424713134766,
            "end_logit": -5.2796406745910645
        },
        {
            "text": "CD19 (inebilizumab),",
            "probability": 6.191384206876344e-12,
            "start_logit": -6.045755386352539,
            "end_logit": -5.019721031188965
        },
        {
            "text": "patients with MS and their current position in the therapeutic armamentarium based on clinical trials and real-world data.",
            "probability": 4.425149889473825e-12,
            "start_logit": -6.464051246643066,
            "end_logit": -4.93727970123291
        },
        {
            "text": "evobrutinib).",
            "probability": 2.5447013802156983e-12,
            "start_logit": -7.01369047164917,
            "end_logit": -4.94093132019043
        },
        {
            "text": "ublituximab) and CD19 (inebilizumab),",
            "probability": 2.1979814636541007e-12,
            "start_logit": -7.081374645233154,
            "end_logit": -5.019721031188965
        },
        {
            "text": "CD19",
            "probability": 2.0110346622835917e-12,
            "start_logit": -6.045755386352539,
            "end_logit": -6.144230365753174
        },
        {
            "text": "Bruton's Tyrosine Kinase (BTK) (evobrutinib).",
            "probability": 1.8949989243977213e-12,
            "start_logit": -7.308485507965088,
            "end_logit": -4.94093132019043
        },
        {
            "text": "inebilizumab),",
            "probability": 1.814971478603753e-12,
            "start_logit": -7.272844314575195,
            "end_logit": -5.019721031188965
        },
        {
            "text": "In the second part of the review, we summarize medications that have targeted B cells",
            "probability": 1.7350203324000557e-12,
            "start_logit": -6.421272277832031,
            "end_logit": -5.916343688964844
        },
        {
            "text": "with MS and their current position in the therapeutic armamentarium based on clinical trials and real-world data.",
            "probability": 1.627337254447906e-12,
            "start_logit": -7.464410305023193,
            "end_logit": -4.93727970123291
        }
    ],
    "63eef4f5f36125a42600000b_004": [
        {
            "text": "Relapsing Multiple Sclerosis",
            "probability": 0.9914271058232614,
            "start_logit": 6.930022239685059,
            "end_logit": 8.828222274780273
        },
        {
            "text": "Multiple Sclerosis",
            "probability": 0.0083886492733232,
            "start_logit": 2.1577563285827637,
            "end_logit": 8.828222274780273
        },
        {
            "text": "Sclerosis.",
            "probability": 0.00011111670325837063,
            "start_logit": -2.166297435760498,
            "end_logit": 8.828222274780273
        },
        {
            "text": "in Relapsing Multiple Sclerosis",
            "probability": 1.4526382322560605e-05,
            "start_logit": -4.200911998748779,
            "end_logit": 8.828222274780273
        },
        {
            "text": "Relapsing Multiple Sclerosis.",
            "probability": 1.3378843623389731e-05,
            "start_logit": 6.930022239685059,
            "end_logit": -2.3850038051605225
        },
        {
            "text": "Ublituximab versus Teriflunomide in Relapsing Multiple Sclerosis",
            "probability": 1.2452546951841156e-05,
            "start_logit": -4.354953289031982,
            "end_logit": 8.828222274780273
        },
        {
            "text": "Re",
            "probability": 1.2012033639621726e-05,
            "start_logit": 6.930022239685059,
            "end_logit": -2.492769479751587
        },
        {
            "text": "Teriflunomide in Relapsing Multiple Sclerosis",
            "probability": 1.1398713450540823e-05,
            "start_logit": -4.44337797164917,
            "end_logit": 8.828222274780273
        },
        {
            "text": "Relapsing Multiple",
            "probability": 4.373885333829105e-06,
            "start_logit": 6.930022239685059,
            "end_logit": -3.5030267238616943
        },
        {
            "text": "versus Teriflunomide in Relapsing Multiple Sclerosis",
            "probability": 1.3380077691518409e-06,
            "start_logit": -6.585696697235107,
            "end_logit": 8.828222274780273
        },
        {
            "text": "Relapsing Multiple Sc",
            "probability": 9.600766121234017e-07,
            "start_logit": 6.930022239685059,
            "end_logit": -5.019420623779297
        },
        {
            "text": "Sclerosis",
            "probability": 7.570266472343368e-07,
            "start_logit": -7.155235290527344,
            "end_logit": 8.828222274780273
        },
        {
            "text": "Relapsing",
            "probability": 6.403123679096305e-07,
            "start_logit": 6.930022239685059,
            "end_logit": -5.424477577209473
        },
        {
            "text": "Relapsing Multiple Scler",
            "probability": 5.488547198060879e-07,
            "start_logit": 6.930022239685059,
            "end_logit": -5.57859992980957
        },
        {
            "text": "Teriflunomide in Relapsing Multiple Sclerosis.",
            "probability": 4.323592718875815e-07,
            "start_logit": -7.715376853942871,
            "end_logit": 8.828222274780273
        },
        {
            "text": "Relap",
            "probability": 1.461809546109289e-07,
            "start_logit": 6.930022239685059,
            "end_logit": -6.901588439941406
        },
        {
            "text": "Multiple Sclerosis.",
            "probability": 1.1320088605612518e-07,
            "start_logit": 2.1577563285827637,
            "end_logit": -2.3850038051605225
        },
        {
            "text": "Multiple",
            "probability": 3.70082579059174e-08,
            "start_logit": 2.1577563285827637,
            "end_logit": -3.5030267238616943
        },
        {
            "text": "Multiple Sc",
            "probability": 8.123386910968005e-09,
            "start_logit": 2.1577563285827637,
            "end_logit": -5.019420623779297
        },
        {
            "text": "Multiple Scler",
            "probability": 4.643961940740115e-09,
            "start_logit": 2.1577563285827637,
            "end_logit": -5.57859992980957
        }
    ],
    "63eef4f5f36125a42600000b_005": [
        {
            "text": "multiple sclerosis",
            "probability": 0.9996991347144494,
            "start_logit": 7.788674831390381,
            "end_logit": 9.563104629516602
        },
        {
            "text": "sclerosis.",
            "probability": 0.00024647697176077783,
            "start_logit": -0.5192662477493286,
            "end_logit": 9.563104629516602
        },
        {
            "text": "multiple",
            "probability": 2.569230477264588e-05,
            "start_logit": 7.788674831390381,
            "end_logit": -1.005913496017456
        },
        {
            "text": "relapsing multiple sclerosis",
            "probability": 1.3955411825438102e-05,
            "start_logit": -3.39066743850708,
            "end_logit": 9.563104629516602
        },
        {
            "text": "Ublituximab is being evaluated for the treatment of relapsing multiple sclerosis",
            "probability": 5.891286972906742e-06,
            "start_logit": -4.253060340881348,
            "end_logit": 9.563104629516602
        },
        {
            "text": "multiple sclerosis.",
            "probability": 2.493819618876326e-06,
            "start_logit": 7.788674831390381,
            "end_logit": -3.338289499282837
        },
        {
            "text": "the treatment of relapsing multiple sclerosis",
            "probability": 1.426085845724734e-06,
            "start_logit": -5.671601295471191,
            "end_logit": 9.563104629516602
        },
        {
            "text": "treatment of relapsing multiple sclerosis",
            "probability": 1.070462902796196e-06,
            "start_logit": -5.958443641662598,
            "end_logit": 9.563104629516602
        },
        {
            "text": "sclerosis",
            "probability": 1.0398858205877466e-06,
            "start_logit": -5.987423896789551,
            "end_logit": 9.563104629516602
        },
        {
            "text": "being evaluated for the treatment of relapsing multiple sclerosis",
            "probability": 5.649047935871702e-07,
            "start_logit": -6.597632884979248,
            "end_logit": 9.563104629516602
        },
        {
            "text": "evaluated for the treatment of relapsing multiple sclerosis",
            "probability": 4.2077678855917985e-07,
            "start_logit": -6.892187595367432,
            "end_logit": 9.563104629516602
        },
        {
            "text": "for the treatment of relapsing multiple sclerosis",
            "probability": 4.170635355826312e-07,
            "start_logit": -6.9010515213012695,
            "end_logit": 9.563104629516602
        },
        {
            "text": "is being evaluated for the treatment of relapsing multiple sclerosis",
            "probability": 3.647786475042858e-07,
            "start_logit": -7.034999370574951,
            "end_logit": 9.563104629516602
        },
        {
            "text": "relapsing multiple sclerosis.",
            "probability": 3.1615238177933224e-07,
            "start_logit": -7.178065776824951,
            "end_logit": 9.563104629516602
        },
        {
            "text": "multiple s",
            "probability": 2.5700653573365497e-07,
            "start_logit": 7.788674831390381,
            "end_logit": -5.6107587814331055
        },
        {
            "text": "multiple scle",
            "probability": 2.414787030439916e-07,
            "start_logit": 7.788674831390381,
            "end_logit": -5.673079013824463
        },
        {
            "text": "of relapsing multiple sclerosis",
            "probability": 2.363479336111935e-07,
            "start_logit": -7.468985080718994,
            "end_logit": 9.563104629516602
        },
        {
            "text": "relapsing multiple",
            "probability": 3.586546005657554e-10,
            "start_logit": -3.39066743850708,
            "end_logit": -1.005913496017456
        },
        {
            "text": "Ublituximab is being evaluated for the treatment of relapsing multiple",
            "probability": 1.514062933087089e-10,
            "start_logit": -4.253060340881348,
            "end_logit": -1.005913496017456
        },
        {
            "text": "the treatment of relapsing multiple",
            "probability": 3.6650459031138294e-11,
            "start_logit": -5.671601295471191,
            "end_logit": -1.005913496017456
        }
    ],
    "63eef4f5f36125a42600000b_006": [
        {
            "text": "multiple sclerosis",
            "probability": 0.9998273200349425,
            "start_logit": 8.441610336303711,
            "end_logit": 9.795217514038086
        },
        {
            "text": "sclerosis,",
            "probability": 0.000132471724798508,
            "start_logit": -0.48735830187797546,
            "end_logit": 9.795217514038086
        },
        {
            "text": "multiple",
            "probability": 2.8361402163238903e-05,
            "start_logit": 8.441610336303711,
            "end_logit": -0.6750912070274353
        },
        {
            "text": "CONCLUSIONS: Among participants with relapsing multiple sclerosis",
            "probability": 4.3873709202030085e-06,
            "start_logit": -3.8949973583221436,
            "end_logit": 9.795217514038086
        },
        {
            "text": "relapsing multiple sclerosis",
            "probability": 3.5113036280184587e-06,
            "start_logit": -4.117740154266357,
            "end_logit": 9.795217514038086
        },
        {
            "text": "Among participants with relapsing multiple sclerosis",
            "probability": 1.642192051831553e-06,
            "start_logit": -4.877695560455322,
            "end_logit": 9.795217514038086
        },
        {
            "text": "sclerosis",
            "probability": 9.63804373938766e-07,
            "start_logit": -5.410594463348389,
            "end_logit": 9.795217514038086
        },
        {
            "text": "CONCLUSIONS: Among participants with relapsing multiple sclerosis,",
            "probability": 3.776180743008237e-07,
            "start_logit": -6.347599506378174,
            "end_logit": 9.795217514038086
        },
        {
            "text": "multiple s",
            "probability": 3.041962140318744e-07,
            "start_logit": 8.441610336303711,
            "end_logit": -5.210202693939209
        },
        {
            "text": "with relapsing multiple sclerosis",
            "probability": 2.944540830514219e-07,
            "start_logit": -6.596359729766846,
            "end_logit": 9.795217514038086
        },
        {
            "text": "multiple scle",
            "probability": 1.9216278515297816e-07,
            "start_logit": 8.441610336303711,
            "end_logit": -5.669532775878906
        },
        {
            "text": "multiple sclerosis, ublituximab resulted in lower annualized relapse rates and fewer brain lesions on MRI",
            "probability": 8.020412916301562e-08,
            "start_logit": 8.441610336303711,
            "end_logit": -6.543300628662109
        },
        {
            "text": "multiple sclerosis,",
            "probability": 4.9359109938414995e-08,
            "start_logit": 8.441610336303711,
            "end_logit": -7.028753280639648
        },
        {
            "text": "multiple sclerosis, ublituximab resulted in lower annualized relapse rates and fewer brain lesions",
            "probability": 4.387729442818787e-08,
            "start_logit": 8.441610336303711,
            "end_logit": -7.146478652954102
        },
        {
            "text": "CONCLUSIONS: Among participants with relapsing multiple",
            "probability": 1.244534817300535e-10,
            "start_logit": -3.8949973583221436,
            "end_logit": -0.6750912070274353
        },
        {
            "text": "relapsing multiple",
            "probability": 9.960269370113928e-11,
            "start_logit": -4.117740154266357,
            "end_logit": -0.6750912070274353
        },
        {
            "text": "Among participants with relapsing multiple",
            "probability": 4.658291314708366e-11,
            "start_logit": -4.877695560455322,
            "end_logit": -0.6750912070274353
        },
        {
            "text": "sclerosis, ublituximab resulted in lower annualized relapse rates and fewer brain lesions on MRI",
            "probability": 1.0626614329578106e-11,
            "start_logit": -0.48735830187797546,
            "end_logit": -6.543300628662109
        },
        {
            "text": "with relapsing multiple",
            "probability": 8.352572990041188e-12,
            "start_logit": -6.596359729766846,
            "end_logit": -0.6750912070274353
        },
        {
            "text": "sclerosis, ublituximab resulted in lower annualized relapse rates and fewer brain lesions",
            "probability": 5.813504748190791e-12,
            "start_logit": -0.48735830187797546,
            "end_logit": -7.146478652954102
        }
    ],
    "63eef4f5f36125a42600000b_007": [
        {
            "text": "CD20",
            "probability": 0.4808746462980503,
            "start_logit": -0.7585766911506653,
            "end_logit": -4.37757682800293
        },
        {
            "text": "CD20 therapy about to be approved.",
            "probability": 0.3726595104235481,
            "start_logit": -0.7585766911506653,
            "end_logit": -4.632518291473389
        },
        {
            "text": "CD20 therapy",
            "probability": 0.06991488602320392,
            "start_logit": -0.7585766911506653,
            "end_logit": -6.305904865264893
        },
        {
            "text": "anti-CD20",
            "probability": 0.01571385839879283,
            "start_logit": -4.179640293121338,
            "end_logit": -4.37757682800293
        },
        {
            "text": "CD20 therapy about to be approved",
            "probability": 0.01505801105722383,
            "start_logit": -0.7585766911506653,
            "end_logit": -7.841273307800293
        },
        {
            "text": "anti-CD20 therapy about to be approved.",
            "probability": 0.012177640935824146,
            "start_logit": -4.179640293121338,
            "end_logit": -4.632518291473389
        },
        {
            "text": "The glycoengineered antibody ublituximab is the next anti-CD20",
            "probability": 0.00778159512672855,
            "start_logit": -4.882421970367432,
            "end_logit": -4.37757682800293
        },
        {
            "text": "CD20 therapy about",
            "probability": 0.007091409607906939,
            "start_logit": -0.7585766911506653,
            "end_logit": -8.59429931640625
        },
        {
            "text": "The glycoengineered antibody ublituximab is the next anti-CD20 therapy about to be approved.",
            "probability": 0.006030439434820099,
            "start_logit": -4.882421970367432,
            "end_logit": -4.632518291473389
        },
        {
            "text": "ublituximab is the next anti-CD20",
            "probability": 0.002465959383545266,
            "start_logit": -6.031602382659912,
            "end_logit": -4.37757682800293
        },
        {
            "text": "anti-CD20 therapy",
            "probability": 0.002284654904129473,
            "start_logit": -4.179640293121338,
            "end_logit": -6.305904865264893
        },
        {
            "text": "ublituximab is the next anti-CD20 therapy about to be approved.",
            "probability": 0.0019110244710775456,
            "start_logit": -6.031602382659912,
            "end_logit": -4.632518291473389
        },
        {
            "text": "The glycoengineered antibody ublituximab is the next anti-CD20 therapy",
            "probability": 0.0011313745495884163,
            "start_logit": -4.882421970367432,
            "end_logit": -6.305904865264893
        },
        {
            "text": "the next anti-CD20",
            "probability": 0.0011068185622334162,
            "start_logit": -6.832693576812744,
            "end_logit": -4.37757682800293
        },
        {
            "text": "the next anti-CD20 therapy about to be approved.",
            "probability": 0.0008577421719047128,
            "start_logit": -6.832693576812744,
            "end_logit": -4.632518291473389
        },
        {
            "text": "glycoengineered antibody ublituximab is the next anti-CD20",
            "probability": 0.000715513887225765,
            "start_logit": -7.268937587738037,
            "end_logit": -4.37757682800293
        },
        {
            "text": "antibody ublituximab is the next anti-CD20",
            "probability": 0.0006638780503143268,
            "start_logit": -7.3438401222229,
            "end_logit": -4.37757682800293
        },
        {
            "text": "glycoengineered antibody ublituximab is the next anti-CD20 therapy about to be approved.",
            "probability": 0.0005544959730514377,
            "start_logit": -7.268937587738037,
            "end_logit": -4.632518291473389
        },
        {
            "text": "antibody ublituximab is the next anti-CD20 therapy about to be approved.",
            "probability": 0.0005144801688249866,
            "start_logit": -7.3438401222229,
            "end_logit": -4.632518291473389
        },
        {
            "text": "anti-CD20 therapy about to be approved",
            "probability": 0.0004920605720061463,
            "start_logit": -4.179640293121338,
            "end_logit": -7.841273307800293
        }
    ],
    "63eef4f5f36125a42600000b_008": [
        {
            "text": "pathogenic cell populations.",
            "probability": 0.16457047221151747,
            "start_logit": -5.937017440795898,
            "end_logit": -4.787347316741943
        },
        {
            "text": "CD52 monoclonal antibody alemtuzumab and the anti-CD20",
            "probability": 0.1357267590533775,
            "start_logit": -5.499227046966553,
            "end_logit": -5.417832851409912
        },
        {
            "text": "CD52",
            "probability": 0.0838234672781575,
            "start_logit": -5.499227046966553,
            "end_logit": -5.899763584136963
        },
        {
            "text": "CD20",
            "probability": 0.07129361448771718,
            "start_logit": -6.143064022064209,
            "end_logit": -5.417832851409912
        },
        {
            "text": "ublituximab work via eliminating selected pathogenic cell populations.",
            "probability": 0.0474619026609469,
            "start_logit": -7.180428981781006,
            "end_logit": -4.787347316741943
        },
        {
            "text": "alemtuzumab and the anti-CD20",
            "probability": 0.04581527489090142,
            "start_logit": -6.5852532386779785,
            "end_logit": -5.417832851409912
        },
        {
            "text": "anti-CD52 monoclonal antibody alemtuzumab and the anti-CD20",
            "probability": 0.04424480059935291,
            "start_logit": -6.620132923126221,
            "end_logit": -5.417832851409912
        },
        {
            "text": "On the other hand, the anti-CD52 monoclonal antibody alemtuzumab and the anti-CD20",
            "probability": 0.043252610129755,
            "start_logit": -6.642813205718994,
            "end_logit": -5.417832851409912
        },
        {
            "text": "ofatumumab, and ublituximab work via eliminating selected pathogenic cell populations.",
            "probability": 0.03763055535537458,
            "start_logit": -7.412539958953857,
            "end_logit": -4.787347316741943
        },
        {
            "text": "ocrelizumab, ofatumumab, and ublituximab work via eliminating selected pathogenic cell populations.",
            "probability": 0.03708421065948506,
            "start_logit": -7.4271650314331055,
            "end_logit": -4.787347316741943
        },
        {
            "text": "eliminating selected pathogenic cell populations.",
            "probability": 0.0364422406745602,
            "start_logit": -7.44462776184082,
            "end_logit": -4.787347316741943
        },
        {
            "text": "anti-CD20",
            "probability": 0.034633219363721664,
            "start_logit": -6.865057468414307,
            "end_logit": -5.417832851409912
        },
        {
            "text": "CD52 monoclonal antibody alemtuzumab",
            "probability": 0.03322150328934765,
            "start_logit": -5.499227046966553,
            "end_logit": -6.825279235839844
        },
        {
            "text": "CD20 monoclonal antibodies rituximab, ocrelizumab, ofatumumab,",
            "probability": 0.031957522737603106,
            "start_logit": -6.143064022064209,
            "end_logit": -6.220232009887695
        },
        {
            "text": "pathogenic cell populations",
            "probability": 0.03193371378191999,
            "start_logit": -5.937017440795898,
            "end_logit": -6.427023887634277
        },
        {
            "text": "anti-CD52",
            "probability": 0.0273251392808246,
            "start_logit": -6.620132923126221,
            "end_logit": -5.899763584136963
        },
        {
            "text": "On the other hand, the anti-CD52",
            "probability": 0.02671237252840158,
            "start_logit": -6.642813205718994,
            "end_logit": -5.899763584136963
        },
        {
            "text": "the anti-CD52 monoclonal antibody alemtuzumab and the anti-CD20",
            "probability": 0.025426849280754903,
            "start_logit": -7.174065113067627,
            "end_logit": -5.417832851409912
        },
        {
            "text": "CD52 monoclonal antibody alemtuzumab and the anti-CD20 monoclonal antibodies",
            "probability": 0.021983530733551724,
            "start_logit": -5.499227046966553,
            "end_logit": -7.23818302154541
        },
        {
            "text": "other hand, the anti-CD52 monoclonal antibody alemtuzumab and the anti-CD20",
            "probability": 0.01946024100272888,
            "start_logit": -7.441497325897217,
            "end_logit": -5.417832851409912
        }
    ],
    "640c842f201352f04a000025_001": [
        {
            "text": "liver palms",
            "probability": 0.9712451091853908,
            "start_logit": 8.062989234924316,
            "end_logit": 8.429010391235352
        },
        {
            "text": "liver palms\"",
            "probability": 0.016520749417340403,
            "start_logit": 8.062989234924316,
            "end_logit": 4.355048656463623
        },
        {
            "text": "\"liver palms",
            "probability": 0.011048910146920034,
            "start_logit": 3.5867421627044678,
            "end_logit": 8.429010391235352
        },
        {
            "text": "Palmar erythema (\"liver palms",
            "probability": 0.0007790544830506695,
            "start_logit": 0.9347360730171204,
            "end_logit": 8.429010391235352
        },
        {
            "text": "\"liver palms\"",
            "probability": 0.00018794048396812382,
            "start_logit": 3.5867421627044678,
            "end_logit": 4.355048656463623
        },
        {
            "text": "palms",
            "probability": 8.619437718365335e-05,
            "start_logit": -1.2667399644851685,
            "end_logit": 8.429010391235352
        },
        {
            "text": "(\"liver palms",
            "probability": 8.12043219712732e-05,
            "start_logit": -1.3263764381408691,
            "end_logit": 8.429010391235352
        },
        {
            "text": "liver",
            "probability": 2.7020663269677332e-05,
            "start_logit": 8.062989234924316,
            "end_logit": -2.0607218742370605
        },
        {
            "text": "Palmar erythema (\"liver palms\"",
            "probability": 1.3251612569488936e-05,
            "start_logit": 0.9347360730171204,
            "end_logit": 4.355048656463623
        },
        {
            "text": "liver palms\")",
            "probability": 6.024279770964877e-06,
            "start_logit": 8.062989234924316,
            "end_logit": -3.561525821685791
        },
        {
            "text": "palms\"",
            "probability": 1.4661548286500028e-06,
            "start_logit": -1.2667399644851685,
            "end_logit": 4.355048656463623
        },
        {
            "text": "(\"liver palms\"",
            "probability": 1.381274656834703e-06,
            "start_logit": -1.3263764381408691,
            "end_logit": 4.355048656463623
        },
        {
            "text": "liver palms\") was seen in 32/100 consecutive patients with classical rheumatoid arthritis",
            "probability": 7.521510843500643e-07,
            "start_logit": 8.062989234924316,
            "end_logit": -5.642141819000244
        },
        {
            "text": "erythema (\"liver palms",
            "probability": 5.175622374658917e-07,
            "start_logit": -6.381970405578613,
            "end_logit": 8.429010391235352
        },
        {
            "text": "\"liver",
            "probability": 3.073877827063122e-07,
            "start_logit": 3.5867421627044678,
            "end_logit": -2.0607218742370605
        },
        {
            "text": "\"liver palms\")",
            "probability": 6.853236660838996e-08,
            "start_logit": 3.5867421627044678,
            "end_logit": -3.561525821685791
        },
        {
            "text": "Palmar erythema (\"liver",
            "probability": 2.1673796507351643e-08,
            "start_logit": 0.9347360730171204,
            "end_logit": -2.0607218742370605
        },
        {
            "text": "\"",
            "probability": 8.931656799602199e-09,
            "start_logit": -6.367536544799805,
            "end_logit": 4.355048656463623
        },
        {
            "text": "erythema (\"liver palms\"",
            "probability": 8.803664442875365e-09,
            "start_logit": -6.381970405578613,
            "end_logit": 4.355048656463623
        },
        {
            "text": "\"liver palms\") was seen in 32/100 consecutive patients with classical rheumatoid arthritis",
            "probability": 8.556490703837395e-09,
            "start_logit": 3.5867421627044678,
            "end_logit": -5.642141819000244
        }
    ],
    "64468b0757b1c7a315000070_001": [
        {
            "text": "poly[A]) binding protein nuclear 1 gene (11-18 repeats in OPMD instead of the normal 10 repeats).",
            "probability": 0.2613692630235592,
            "start_logit": -2.351818084716797,
            "end_logit": -2.2444844245910645
        },
        {
            "text": "Oculopharyngeal muscular dystrophy (OPMD) is a late-onset intractable myopathy,",
            "probability": 0.18734771819674045,
            "start_logit": -0.10222874581813812,
            "end_logit": -4.8270416259765625
        },
        {
            "text": "abnormal expansion of the alanine-encoding (GCN)n trinucleotide repeat",
            "probability": 0.1368463867377301,
            "start_logit": -1.178262710571289,
            "end_logit": -4.065114974975586
        },
        {
            "text": "Oculopharyngeal muscular dystrophy",
            "probability": 0.10839679994741751,
            "start_logit": -0.10222874581813812,
            "end_logit": -5.374209403991699
        },
        {
            "text": "Oculopharyngeal muscular dystrophy (OPMD) is a late-onset intractable myopathy",
            "probability": 0.0643375220851921,
            "start_logit": -0.10222874581813812,
            "end_logit": -5.895864963531494
        },
        {
            "text": "poly[A]) binding protein nuclear 1 gene",
            "probability": 0.05583851284128925,
            "start_logit": -2.351818084716797,
            "end_logit": -3.787954807281494
        },
        {
            "text": "polyadenosine (poly[A]) binding protein nuclear 1 gene",
            "probability": 0.035929141885024024,
            "start_logit": -2.7927331924438477,
            "end_logit": -3.787954807281494
        },
        {
            "text": "poly[A]) binding protein nuclear 1",
            "probability": 0.021499166608254662,
            "start_logit": -2.351818084716797,
            "end_logit": -4.742404460906982
        },
        {
            "text": "abnormal expansion of the alanine",
            "probability": 0.020169381285180303,
            "start_logit": -1.178262710571289,
            "end_logit": -5.979808330535889
        },
        {
            "text": "abnormal expansion of the alanine-encoding (GCN)n trinucleotide repeat in the exon 1",
            "probability": 0.017112300354062703,
            "start_logit": -1.178262710571289,
            "end_logit": -6.144176483154297
        },
        {
            "text": "abnormal expansion of the alanine-encoding (GCN",
            "probability": 0.01701293456745809,
            "start_logit": -1.178262710571289,
            "end_logit": -6.150000095367432
        },
        {
            "text": "polyadenosine (poly[A]) binding protein nuclear 1",
            "probability": 0.0138335813074623,
            "start_logit": -2.7927331924438477,
            "end_logit": -4.742404460906982
        },
        {
            "text": "the abnormal expansion of the alanine-encoding (GCN)n trinucleotide repeat",
            "probability": 0.012297636267480655,
            "start_logit": -3.587714672088623,
            "end_logit": -4.065114974975586
        },
        {
            "text": "It is caused by the abnormal expansion of the alanine-encoding (GCN)n trinucleotide repeat",
            "probability": 0.010935741537745267,
            "start_logit": -3.705085277557373,
            "end_logit": -4.065114974975586
        },
        {
            "text": "abnormal expansion of",
            "probability": 0.009023708167914766,
            "start_logit": -1.178262710571289,
            "end_logit": -6.78411865234375
        },
        {
            "text": "poly[A]) binding protein",
            "probability": 0.00691137384838051,
            "start_logit": -2.351818084716797,
            "end_logit": -5.8772501945495605
        },
        {
            "text": "expansion of the alanine-encoding (GCN)n trinucleotide repeat",
            "probability": 0.006502208348680465,
            "start_logit": -4.224979877471924,
            "end_logit": -4.065114974975586
        },
        {
            "text": "poly[A])",
            "probability": 0.0051955816352254255,
            "start_logit": -2.351818084716797,
            "end_logit": -6.162610054016113
        },
        {
            "text": "alanine-encoding (GCN)n trinucleotide repeat",
            "probability": 0.004971220477852373,
            "start_logit": -4.4934563636779785,
            "end_logit": -4.065114974975586
        },
        {
            "text": "poly[A]",
            "probability": 0.004469820877349952,
            "start_logit": -2.351818084716797,
            "end_logit": -6.313070297241211
        }
    ],
    "64468b0757b1c7a315000070_002": [
        {
            "text": "PABPN1 gene.",
            "probability": 0.4610042317680772,
            "start_logit": 1.790974736213684,
            "end_logit": -1.5100080966949463
        },
        {
            "text": "PABPN1",
            "probability": 0.28395177390338777,
            "start_logit": 1.790974736213684,
            "end_logit": -1.9946109056472778
        },
        {
            "text": "PABPN1 gene",
            "probability": 0.2137592516017539,
            "start_logit": 1.790974736213684,
            "end_logit": -2.278564929962158
        },
        {
            "text": "A common cause of OPMD is the short expansion of a GCG or GCA trinucleotide repeat",
            "probability": 0.013643581581155315,
            "start_logit": -1.3928951025009155,
            "end_logit": -1.8462762832641602
        },
        {
            "text": "the short expansion of a GCG or GCA trinucleotide repeat in PABPN1 gene.",
            "probability": 0.004475666622539509,
            "start_logit": -2.8437771797180176,
            "end_logit": -1.5100080966949463
        },
        {
            "text": "PABPN",
            "probability": 0.0032820033693870187,
            "start_logit": 1.790974736213684,
            "end_logit": -6.45496129989624
        },
        {
            "text": "the short expansion of a GCG or GCA trinucleotide repeat",
            "probability": 0.0031975571255202016,
            "start_logit": -2.8437771797180176,
            "end_logit": -1.8462762832641602
        },
        {
            "text": "the short expansion of a GCG or GCA trinucleotide repeat in PABPN1",
            "probability": 0.002756750132197552,
            "start_logit": -2.8437771797180176,
            "end_logit": -1.9946109056472778
        },
        {
            "text": "short expansion of a GCG or GCA trinucleotide repeat in PABPN1 gene.",
            "probability": 0.002631337023395062,
            "start_logit": -3.3749403953552246,
            "end_logit": -1.5100080966949463
        },
        {
            "text": "the short expansion of a GCG or GCA trinucleotide repeat in PABPN1 gene",
            "probability": 0.0020752849577621683,
            "start_logit": -2.8437771797180176,
            "end_logit": -2.278564929962158
        },
        {
            "text": "short expansion of a GCG or GCA trinucleotide repeat",
            "probability": 0.0018799100018821219,
            "start_logit": -3.3749403953552246,
            "end_logit": -1.8462762832641602
        },
        {
            "text": "short expansion of a GCG or GCA trinucleotide repeat in PABPN1",
            "probability": 0.0016207504487867196,
            "start_logit": -3.3749403953552246,
            "end_logit": -1.9946109056472778
        },
        {
            "text": "short expansion of a GCG or GCA trinucleotide repeat in PABPN1 gene",
            "probability": 0.0012201029710197648,
            "start_logit": -3.3749403953552246,
            "end_logit": -2.278564929962158
        },
        {
            "text": "expansion of a GCG or GCA trinucleotide repeat in PABPN1 gene.",
            "probability": 0.0012035724052366832,
            "start_logit": -4.157138347625732,
            "end_logit": -1.5100080966949463
        },
        {
            "text": "expansion of a GCG or GCA trinucleotide repeat",
            "probability": 0.0008598700137903471,
            "start_logit": -4.157138347625732,
            "end_logit": -1.8462762832641602
        },
        {
            "text": "expansion of a GCG or GCA trinucleotide repeat in PABPN1",
            "probability": 0.0007413305473951803,
            "start_logit": -4.157138347625732,
            "end_logit": -1.9946109056472778
        },
        {
            "text": "expansion of a GCG or GCA trinucleotide repeat in PABPN1 gene",
            "probability": 0.0005580745660515899,
            "start_logit": -4.157138347625732,
            "end_logit": -2.278564929962158
        },
        {
            "text": "GCG or GCA trinucleotide repeat in PABPN1 gene.",
            "probability": 0.0004465274512677738,
            "start_logit": -5.14868688583374,
            "end_logit": -1.5100080966949463
        },
        {
            "text": "OPMD is the short expansion of a GCG or GCA trinucleotide repeat in PABPN1 gene.",
            "probability": 0.00037194194481136655,
            "start_logit": -5.33144998550415,
            "end_logit": -1.5100080966949463
        },
        {
            "text": "A common cause of OPMD is the short expansion of a GCG or GCA trinucleotide repeat in",
            "probability": 0.00032048156458256127,
            "start_logit": -1.3928951025009155,
            "end_logit": -5.597476005554199
        }
    ],
    "63f0494cf36125a426000028_001": [
        {
            "text": "Respiratory Syncytial Virus",
            "probability": 0.5711874286737758,
            "start_logit": -1.8196247816085815,
            "end_logit": -1.7735509872436523
        },
        {
            "text": "Respiratory Syncytial Virus Inhibitor,",
            "probability": 0.12932118064519135,
            "start_logit": -1.8196247816085815,
            "end_logit": -3.258969306945801
        },
        {
            "text": "Respiratory Syncytial Virus Inhibitor, in a Human Virus Challenge.",
            "probability": 0.12278278461555878,
            "start_logit": -1.8196247816085815,
            "end_logit": -3.310851573944092
        },
        {
            "text": "Respiratory Syncytial Virus Inhibitor",
            "probability": 0.03780008915230385,
            "start_logit": -1.8196247816085815,
            "end_logit": -4.488956928253174
        },
        {
            "text": "Human Virus Challenge.",
            "probability": 0.03167828696201165,
            "start_logit": -3.174410104751587,
            "end_logit": -3.310851573944092
        },
        {
            "text": "Respiratory Syncytial Virus Inhibitor, in a Human Virus Challenge",
            "probability": 0.02886583216572981,
            "start_logit": -1.8196247816085815,
            "end_logit": -4.758609771728516
        },
        {
            "text": "EDP-938, a Respiratory Syncytial Virus",
            "probability": 0.023256540770812788,
            "start_logit": -5.020755767822266,
            "end_logit": -1.7735509872436523
        },
        {
            "text": "a Respiratory Syncytial Virus",
            "probability": 0.01385070906551927,
            "start_logit": -5.539005756378174,
            "end_logit": -1.7735509872436523
        },
        {
            "text": "Human Virus Challenge",
            "probability": 0.007447461935371205,
            "start_logit": -3.174410104751587,
            "end_logit": -4.758609771728516
        },
        {
            "text": "EDP-938, a Respiratory Syncytial Virus Inhibitor,",
            "probability": 0.005265457815112837,
            "start_logit": -5.020755767822266,
            "end_logit": -3.258969306945801
        },
        {
            "text": "EDP-938, a Respiratory Syncytial Virus Inhibitor, in a Human Virus Challenge.",
            "probability": 0.004999239641873386,
            "start_logit": -5.020755767822266,
            "end_logit": -3.310851573944092
        },
        {
            "text": "Respiratory Syncytial Vir",
            "probability": 0.003925945577566644,
            "start_logit": -1.8196247816085815,
            "end_logit": -6.753661155700684
        },
        {
            "text": "Respiratory Syncytial Virus Inhibitor, in a Human Virus",
            "probability": 0.0038240083318177905,
            "start_logit": -1.8196247816085815,
            "end_logit": -6.779969215393066
        },
        {
            "text": "a Respiratory Syncytial Virus Inhibitor,",
            "probability": 0.0031359059377145636,
            "start_logit": -5.539005756378174,
            "end_logit": -3.258969306945801
        },
        {
            "text": "a Respiratory Syncytial Virus Inhibitor, in a Human Virus Challenge.",
            "probability": 0.0029773565428655563,
            "start_logit": -5.539005756378174,
            "end_logit": -3.310851573944092
        },
        {
            "text": "Respiratory Syncytial V",
            "probability": 0.0026202090165945817,
            "start_logit": -1.8196247816085815,
            "end_logit": -7.158014297485352
        },
        {
            "text": "Virus Challenge.",
            "probability": 0.0018182199079546078,
            "start_logit": -6.032183647155762,
            "end_logit": -3.310851573944092
        },
        {
            "text": "Respiratory Syncytial",
            "probability": 0.0018020209576507405,
            "start_logit": -1.8196247816085815,
            "end_logit": -7.532359600067139
        },
        {
            "text": "Respiratory Syncyt",
            "probability": 0.0017347881765525323,
            "start_logit": -1.8196247816085815,
            "end_logit": -7.570383071899414
        },
        {
            "text": "Respiratory Syncytial Virus Inhibit",
            "probability": 0.0017065341080222452,
            "start_logit": -1.8196247816085815,
            "end_logit": -7.586803913116455
        }
    ],
    "63f0494cf36125a426000028_002": [
        {
            "text": "RSV",
            "probability": 0.9976285715419241,
            "start_logit": 9.402225494384766,
            "end_logit": 7.680700302124023
        },
        {
            "text": "RS",
            "probability": 0.002297375514117095,
            "start_logit": 9.402225494384766,
            "end_logit": 1.6070866584777832
        },
        {
            "text": "RSV,",
            "probability": 5.225516947582101e-05,
            "start_logit": 9.402225494384766,
            "end_logit": -2.176297187805176
        },
        {
            "text": "RSV, acts by modulating the viral nucleoprotein.",
            "probability": 1.9578970290991086e-05,
            "start_logit": 9.402225494384766,
            "end_logit": -3.157979965209961
        },
        {
            "text": "EDP-938, a nonfusion replication inhibitor of RSV",
            "probability": 9.413221101342165e-07,
            "start_logit": -4.471380710601807,
            "end_logit": 7.680700302124023
        },
        {
            "text": "RSV, acts by modulating the viral nucleoprotein",
            "probability": 6.42688533922106e-07,
            "start_logit": 9.402225494384766,
            "end_logit": -6.574531078338623
        },
        {
            "text": "nonfusion replication inhibitor of RSV",
            "probability": 2.0437663168420822e-07,
            "start_logit": -5.998701572418213,
            "end_logit": 7.680700302124023
        },
        {
            "text": "RSV, acts by modulating",
            "probability": 1.4670096809516468e-07,
            "start_logit": 9.402225494384766,
            "end_logit": -8.05179500579834
        },
        {
            "text": "RSV, acts by modulating the viral nucleoprote",
            "probability": 1.2641638851065876e-07,
            "start_logit": 9.402225494384766,
            "end_logit": -8.200610160827637
        },
        {
            "text": "a nonfusion replication inhibitor of RSV",
            "probability": 1.1545617183225287e-07,
            "start_logit": -6.569775104522705,
            "end_logit": 7.680700302124023
        },
        {
            "text": "replication inhibitor of RSV",
            "probability": 3.876134986937538e-08,
            "start_logit": -7.661242485046387,
            "end_logit": 7.680700302124023
        },
        {
            "text": "EDP-938, a nonfusion replication inhibitor of RS",
            "probability": 2.167710938126941e-09,
            "start_logit": -4.471380710601807,
            "end_logit": 1.6070866584777832
        },
        {
            "text": "nonfusion replication inhibitor of RS",
            "probability": 4.70645972541993e-10,
            "start_logit": -5.998701572418213,
            "end_logit": 1.6070866584777832
        },
        {
            "text": "a nonfusion replication inhibitor of RS",
            "probability": 2.658766896693345e-10,
            "start_logit": -6.569775104522705,
            "end_logit": 1.6070866584777832
        },
        {
            "text": "replication inhibitor of RS",
            "probability": 8.926105228361203e-11,
            "start_logit": -7.661242485046387,
            "end_logit": 1.6070866584777832
        },
        {
            "text": "EDP-938, a nonfusion replication inhibitor of RSV,",
            "probability": 4.930587174380444e-11,
            "start_logit": -4.471380710601807,
            "end_logit": -2.176297187805176
        },
        {
            "text": "EDP-938, a nonfusion replication inhibitor of RSV, acts by modulating the viral nucleoprotein.",
            "probability": 1.8473927225325424e-11,
            "start_logit": -4.471380710601807,
            "end_logit": -3.157979965209961
        },
        {
            "text": "nonfusion replication inhibitor of RSV,",
            "probability": 1.0705121956410355e-11,
            "start_logit": -5.998701572418213,
            "end_logit": -2.176297187805176
        },
        {
            "text": "a nonfusion replication inhibitor of RSV,",
            "probability": 6.047523094491034e-12,
            "start_logit": -6.569775104522705,
            "end_logit": -2.176297187805176
        },
        {
            "text": "nonfusion replication inhibitor of RSV, acts by modulating the viral nucleoprotein.",
            "probability": 4.010995789478331e-12,
            "start_logit": -5.998701572418213,
            "end_logit": -3.157979965209961
        }
    ],
    "63f0494cf36125a426000028_003": [
        {
            "text": "respiratory syncytial virus",
            "probability": 0.7148118914303216,
            "start_logit": 3.422478199005127,
            "end_logit": -2.5092973709106445
        },
        {
            "text": "respiratory syncytial virus.",
            "probability": 0.24460906614707428,
            "start_logit": 3.422478199005127,
            "end_logit": -3.581655502319336
        },
        {
            "text": "respiratory",
            "probability": 0.015265295209040144,
            "start_logit": 3.422478199005127,
            "end_logit": -6.355734825134277
        },
        {
            "text": "respiratory sync",
            "probability": 0.005817512023808046,
            "start_logit": 3.422478199005127,
            "end_logit": -7.320444107055664
        },
        {
            "text": "respiratory syncytial",
            "probability": 0.004961519620987925,
            "start_logit": 3.422478199005127,
            "end_logit": -7.479604721069336
        },
        {
            "text": "respiratory syncyt",
            "probability": 0.004505386410666367,
            "start_logit": 3.422478199005127,
            "end_logit": -7.576043128967285
        },
        {
            "text": "respiratory s",
            "probability": 0.004223034663335075,
            "start_logit": 3.422478199005127,
            "end_logit": -7.640762805938721
        },
        {
            "text": "antiviral with inhibitory activity against the nucleoprotein of the respiratory syncytial virus",
            "probability": 0.0036485474437356383,
            "start_logit": -1.8552120923995972,
            "end_logit": -2.5092973709106445
        },
        {
            "text": "antiviral with inhibitory activity against the nucleoprotein of the respiratory syncytial virus.",
            "probability": 0.0012485351652721706,
            "start_logit": -1.8552120923995972,
            "end_logit": -3.581655502319336
        },
        {
            "text": "antiviral",
            "probability": 0.0004965160045872765,
            "start_logit": -1.8552120923995972,
            "end_logit": -4.503766059875488
        },
        {
            "text": "antiviral with inhibitory activity against the nucleoprotein of the respiratory",
            "probability": 7.79172177751081e-05,
            "start_logit": -1.8552120923995972,
            "end_logit": -6.355734825134277
        },
        {
            "text": "EDP-938, a new antiviral",
            "probability": 5.980974614446471e-05,
            "start_logit": -3.9716591835021973,
            "end_logit": -4.503766059875488
        },
        {
            "text": "antivir",
            "probability": 5.177830721406054e-05,
            "start_logit": -1.8552120923995972,
            "end_logit": -6.764410495758057
        },
        {
            "text": "antiviral with inhibitory activity against the nucleoprotein",
            "probability": 4.004532123434108e-05,
            "start_logit": -1.8552120923995972,
            "end_logit": -7.021369934082031
        },
        {
            "text": "a new antiviral with inhibitory activity against the nucleoprotein of the respiratory syncytial virus",
            "probability": 3.331899252639349e-05,
            "start_logit": -6.551168918609619,
            "end_logit": -2.5092973709106445
        },
        {
            "text": "antiviral with inhibitory activity",
            "probability": 3.299559262329253e-05,
            "start_logit": -1.8552120923995972,
            "end_logit": -7.215007781982422
        },
        {
            "text": "inhibitory activity against the nucleoprotein of the respiratory syncytial virus",
            "probability": 3.216887801618799e-05,
            "start_logit": -6.586297035217285,
            "end_logit": -2.5092973709106445
        },
        {
            "text": "antiviral with inhibitory activity against the nucleoprotein of the respiratory sync",
            "probability": 2.969378220736441e-05,
            "start_logit": -1.8552120923995972,
            "end_logit": -7.320444107055664
        },
        {
            "text": "new antiviral with inhibitory activity against the nucleoprotein of the respiratory syncytial virus",
            "probability": 2.94265040106347e-05,
            "start_logit": -6.675400733947754,
            "end_logit": -2.5092973709106445
        },
        {
            "text": "the respiratory syncytial virus",
            "probability": 2.5541539419456553e-05,
            "start_logit": -6.816990375518799,
            "end_logit": -2.5092973709106445
        }
    ],
    "63f0494cf36125a426000028_004": [
        {
            "text": "RSV",
            "probability": 0.9947634179117361,
            "start_logit": 9.370903968811035,
            "end_logit": 6.830270767211914
        },
        {
            "text": "RS",
            "probability": 0.0052143374175423205,
            "start_logit": 9.370903968811035,
            "end_logit": 1.5791778564453125
        },
        {
            "text": "RSV.",
            "probability": 2.0953388672821454e-05,
            "start_logit": 9.370903968811035,
            "end_logit": -3.9376890659332275
        },
        {
            "text": "EDP-938 has shown high efficacy against RSV",
            "probability": 4.876060408151316e-07,
            "start_logit": -5.157603740692139,
            "end_logit": 6.830270767211914
        },
        {
            "text": "high efficacy against RSV",
            "probability": 2.581350337085414e-07,
            "start_logit": -5.793628692626953,
            "end_logit": 6.830270767211914
        },
        {
            "text": "has shown high efficacy against RSV",
            "probability": 2.0176650004321038e-07,
            "start_logit": -6.0400004386901855,
            "end_logit": 6.830270767211914
        },
        {
            "text": "shown high efficacy against RSV",
            "probability": 1.8648555860547117e-07,
            "start_logit": -6.118757724761963,
            "end_logit": 6.830270767211914
        },
        {
            "text": "against RSV",
            "probability": 1.067462291365712e-07,
            "start_logit": -6.676657199859619,
            "end_logit": 6.830270767211914
        },
        {
            "text": "efficacy against RSV",
            "probability": 4.378335773483608e-08,
            "start_logit": -7.56785774230957,
            "end_logit": 6.830270767211914
        },
        {
            "text": "EDP-938 has shown high efficacy against RS",
            "probability": 2.5559267438477566e-09,
            "start_logit": -5.157603740692139,
            "end_logit": 1.5791778564453125
        },
        {
            "text": "high efficacy against RS",
            "probability": 1.3530887252273532e-09,
            "start_logit": -5.793628692626953,
            "end_logit": 1.5791778564453125
        },
        {
            "text": "has shown high efficacy against RS",
            "probability": 1.057616908541379e-09,
            "start_logit": -6.0400004386901855,
            "end_logit": 1.5791778564453125
        },
        {
            "text": "shown high efficacy against RS",
            "probability": 9.775174765765955e-10,
            "start_logit": -6.118757724761963,
            "end_logit": 1.5791778564453125
        },
        {
            "text": "against RS",
            "probability": 5.595409388262776e-10,
            "start_logit": -6.676657199859619,
            "end_logit": 1.5791778564453125
        },
        {
            "text": "efficacy against RS",
            "probability": 2.2950301186352393e-10,
            "start_logit": -7.56785774230957,
            "end_logit": 1.5791778564453125
        },
        {
            "text": "EDP-938 has shown high efficacy against RSV.",
            "probability": 1.0270782689077167e-11,
            "start_logit": -5.157603740692139,
            "end_logit": -3.9376890659332275
        },
        {
            "text": "high efficacy against RSV.",
            "probability": 5.437276435759373e-12,
            "start_logit": -5.793628692626953,
            "end_logit": -3.9376890659332275
        },
        {
            "text": "has shown high efficacy against RSV.",
            "probability": 4.249947093385527e-12,
            "start_logit": -6.0400004386901855,
            "end_logit": -3.9376890659332275
        },
        {
            "text": "shown high efficacy against RSV.",
            "probability": 3.928074073664184e-12,
            "start_logit": -6.118757724761963,
            "end_logit": -3.9376890659332275
        },
        {
            "text": "against RSV.",
            "probability": 2.248469523690399e-12,
            "start_logit": -6.676657199859619,
            "end_logit": -3.9376890659332275
        }
    ],
    "63f0494cf36125a426000028_005": [
        {
            "text": "respiratory syncytial virus",
            "probability": 0.9960757538525451,
            "start_logit": 7.131365776062012,
            "end_logit": 3.9008588790893555
        },
        {
            "text": "respiratory syncytial virus,",
            "probability": 0.0019702404629352763,
            "start_logit": 7.131365776062012,
            "end_logit": -2.3248088359832764
        },
        {
            "text": "respiratory",
            "probability": 0.0009912089740338546,
            "start_logit": 7.131365776062012,
            "end_logit": -3.011794328689575
        },
        {
            "text": "respiratory syncytial virus, demonstrates potent antiviral activities in vitro and in a non-human primate model.",
            "probability": 0.0007109798100820227,
            "start_logit": 7.131365776062012,
            "end_logit": -3.3440756797790527
        },
        {
            "text": "respiratory syncytial virus, demonstrates potent antiviral",
            "probability": 6.007637435154541e-05,
            "start_logit": 7.131365776062012,
            "end_logit": -5.815103054046631
        },
        {
            "text": "respiratory syncytial virus, demonstrates potent antiviral activities",
            "probability": 4.989258392822949e-05,
            "start_logit": 7.131365776062012,
            "end_logit": -6.000847339630127
        },
        {
            "text": "respiratory syncytial",
            "probability": 2.3085832673599183e-05,
            "start_logit": 7.131365776062012,
            "end_logit": -6.771500587463379
        },
        {
            "text": "respiratory syncytial virus, demonstrates potent antiviral activities in vitro and in a non-human primate model",
            "probability": 1.8770474875528624e-05,
            "start_logit": 7.131365776062012,
            "end_logit": -6.9784345626831055
        },
        {
            "text": "respiratory sync",
            "probability": 1.771933680983637e-05,
            "start_logit": 7.131365776062012,
            "end_logit": -7.036063194274902
        },
        {
            "text": "respiratory s",
            "probability": 1.7159902139690987e-05,
            "start_logit": 7.131365776062012,
            "end_logit": -7.06814432144165
        },
        {
            "text": "respiratory syncyt",
            "probability": 1.7025177417899027e-05,
            "start_logit": 7.131365776062012,
            "end_logit": -7.076026439666748
        },
        {
            "text": "respiratory syncytial virus, demonstrates potent antiviral activities in vitro",
            "probability": 1.7004237136060204e-05,
            "start_logit": 7.131365776062012,
            "end_logit": -7.07725715637207
        },
        {
            "text": "respiratory syncytial virus, demonstrates potent antiviral activities in vitro and in a non-human primate",
            "probability": 1.295441289622927e-05,
            "start_logit": 7.131365776062012,
            "end_logit": -7.349283218383789
        },
        {
            "text": "EDP-938, a novel nucleoprotein inhibitor of respiratory syncytial virus",
            "probability": 1.0888052275952398e-05,
            "start_logit": -4.29254674911499,
            "end_logit": 3.9008588790893555
        },
        {
            "text": "a novel nucleoprotein inhibitor of respiratory syncytial virus",
            "probability": 1.7775917995272737e-06,
            "start_logit": -6.104953289031982,
            "end_logit": 3.9008588790893555
        },
        {
            "text": "virus",
            "probability": 1.6495215256033647e-06,
            "start_logit": -6.179727554321289,
            "end_logit": 3.9008588790893555
        },
        {
            "text": "nucleoprotein inhibitor of respiratory syncytial virus",
            "probability": 1.537123611383967e-06,
            "start_logit": -6.25029993057251,
            "end_logit": 3.9008588790893555
        },
        {
            "text": "novel nucleoprotein inhibitor of respiratory syncytial virus",
            "probability": 1.0170934674805172e-06,
            "start_logit": -6.66326379776001,
            "end_logit": 3.9008588790893555
        },
        {
            "text": "syncytial virus",
            "probability": 6.851991741643816e-07,
            "start_logit": -7.058258533477783,
            "end_logit": 3.9008588790893555
        },
        {
            "text": "inhibitor of respiratory syncytial virus",
            "probability": 5.739863209424215e-07,
            "start_logit": -7.235362529754639,
            "end_logit": 3.9008588790893555
        }
    ],
    "63f0494cf36125a426000028_006": [
        {
            "text": "respiratory syncytial virus",
            "probability": 0.9917182360736422,
            "start_logit": 5.797510147094727,
            "end_logit": 2.8847413063049316
        },
        {
            "text": "respiratory syncytial virus (RSV",
            "probability": 0.004791849242305027,
            "start_logit": 5.797510147094727,
            "end_logit": -2.4477813243865967
        },
        {
            "text": "respiratory syncytial virus (RSV).",
            "probability": 0.0018613034617182616,
            "start_logit": 5.797510147094727,
            "end_logit": -3.393420696258545
        },
        {
            "text": "respiratory syncytial virus (RSV)",
            "probability": 0.0007351828109639222,
            "start_logit": 5.797510147094727,
            "end_logit": -4.322333812713623
        },
        {
            "text": "respiratory",
            "probability": 0.0005784226959232611,
            "start_logit": 5.797510147094727,
            "end_logit": -4.562148094177246
        },
        {
            "text": "respiratory sync",
            "probability": 5.9904725657320916e-05,
            "start_logit": 5.797510147094727,
            "end_logit": -6.829697608947754
        },
        {
            "text": "EDP-938 is a novel non-fusion replication inhibitor of respiratory syncytial virus",
            "probability": 5.892811674056042e-05,
            "start_logit": -3.933365821838379,
            "end_logit": 2.8847413063049316
        },
        {
            "text": "respiratory syncyt",
            "probability": 4.047149259908786e-05,
            "start_logit": 5.797510147094727,
            "end_logit": -7.221855163574219
        },
        {
            "text": "respiratory s",
            "probability": 3.417204492166307e-05,
            "start_logit": 5.797510147094727,
            "end_logit": -7.391045093536377
        },
        {
            "text": "respiratory syncytial",
            "probability": 3.371027854080851e-05,
            "start_logit": 5.797510147094727,
            "end_logit": -7.4046502113342285
        },
        {
            "text": "respiratory syncytial virus (RS",
            "probability": 3.3126573005045885e-05,
            "start_logit": 5.797510147094727,
            "end_logit": -7.422117233276367
        },
        {
            "text": "respiratory syncytial virus (",
            "probability": 2.302238622611145e-05,
            "start_logit": 5.797510147094727,
            "end_logit": -7.785985946655273
        },
        {
            "text": "non-fusion replication inhibitor of respiratory syncytial virus",
            "probability": 1.3325281632573708e-05,
            "start_logit": -5.420021057128906,
            "end_logit": 2.8847413063049316
        },
        {
            "text": "virus",
            "probability": 4.078480947158358e-06,
            "start_logit": -6.603959560394287,
            "end_logit": 2.8847413063049316
        },
        {
            "text": "novel non-fusion replication inhibitor of respiratory syncytial virus",
            "probability": 3.8674464312788365e-06,
            "start_logit": -6.657089710235596,
            "end_logit": 2.8847413063049316
        },
        {
            "text": "a novel non-fusion replication inhibitor of respiratory syncytial virus",
            "probability": 3.3219709364494727e-06,
            "start_logit": -6.809125900268555,
            "end_logit": 2.8847413063049316
        },
        {
            "text": "fusion replication inhibitor of respiratory syncytial virus",
            "probability": 2.204895263898565e-06,
            "start_logit": -7.219004154205322,
            "end_logit": 2.8847413063049316
        },
        {
            "text": "syncytial virus",
            "probability": 2.107855062119469e-06,
            "start_logit": -7.264013290405273,
            "end_logit": 2.8847413063049316
        },
        {
            "text": "-fusion replication inhibitor of respiratory syncytial virus",
            "probability": 1.5186763408174678e-06,
            "start_logit": -7.5918450355529785,
            "end_logit": 2.8847413063049316
        },
        {
            "text": "RSV",
            "probability": 1.2454911423051064e-06,
            "start_logit": -2.4576315879821777,
            "end_logit": -2.4477813243865967
        }
    ],
    "640ddbe9201352f04a000027_001": [
        {
            "text": "durvalumab",
            "probability": 0.9984904416985362,
            "start_logit": 5.389049053192139,
            "end_logit": 2.348235607147217
        },
        {
            "text": "durvalumab (Imfinzi\u2122; AstraZeneca)",
            "probability": 0.0010337908824228537,
            "start_logit": 5.389049053192139,
            "end_logit": -4.524776458740234
        },
        {
            "text": "du",
            "probability": 0.0002218070791676286,
            "start_logit": 5.389049053192139,
            "end_logit": -6.063956260681152
        },
        {
            "text": "durvalumab (",
            "probability": 0.00013078751538346656,
            "start_logit": 5.389049053192139,
            "end_logit": -6.592190265655518
        },
        {
            "text": "durvalumab (Imfinzi\u2122;",
            "probability": 6.461587337874871e-05,
            "start_logit": 5.389049053192139,
            "end_logit": -7.297304153442383
        },
        {
            "text": "durvalumab (Imfinzi\u2122; AstraZeneca) is a fully human monoclonal antibody",
            "probability": 5.812614722176965e-05,
            "start_logit": 5.389049053192139,
            "end_logit": -7.403148651123047
        },
        {
            "text": "(Imfinzi\u2122; AstraZeneca)",
            "probability": 1.0902729757020235e-07,
            "start_logit": -3.7680957317352295,
            "end_logit": -4.524776458740234
        },
        {
            "text": "blocks programmed cell death ligand-1 binding to its receptors (PD-1 and CD80),",
            "probability": 4.7389986239343603e-08,
            "start_logit": -6.213680744171143,
            "end_logit": -2.9123787879943848
        },
        {
            "text": "programmed cell death ligand-1 binding to its receptors (PD-1 and CD80),",
            "probability": 4.684453219312773e-08,
            "start_logit": -6.225257396697998,
            "end_logit": -2.9123787879943848
        },
        {
            "text": "CD80),",
            "probability": 3.616974843411702e-08,
            "start_logit": -6.483868598937988,
            "end_logit": -2.9123787879943848
        },
        {
            "text": "AstraZeneca",
            "probability": 3.283552401047464e-08,
            "start_logit": -4.9681830406188965,
            "end_logit": -4.524776458740234
        },
        {
            "text": "antibody that blocks programmed cell death ligand-1 binding to its receptors (PD-1 and CD80),",
            "probability": 2.634256271604299e-08,
            "start_logit": -6.800905704498291,
            "end_logit": -2.9123787879943848
        },
        {
            "text": "monoclonal antibody that blocks programmed cell death ligand-1 binding to its receptors (PD-1 and CD80),",
            "probability": 2.0851415042370632e-08,
            "start_logit": -7.034669876098633,
            "end_logit": -2.9123787879943848
        },
        {
            "text": "PD-1 and CD80),",
            "probability": 2.083226420250464e-08,
            "start_logit": -7.03558874130249,
            "end_logit": -2.9123787879943848
        },
        {
            "text": ",",
            "probability": 1.9031755543074608e-08,
            "start_logit": -7.125982761383057,
            "end_logit": -2.9123787879943848
        },
        {
            "text": "that blocks programmed cell death ligand-1 binding to its receptors (PD-1 and CD80),",
            "probability": 1.7033765142864852e-08,
            "start_logit": -7.236894130706787,
            "end_logit": -2.9123787879943848
        },
        {
            "text": "(Imfinzi\u2122; AstraZeneca) is a fully human monoclonal antibody that blocks programmed cell death ligand-1",
            "probability": 1.5454240624098946e-08,
            "start_logit": -3.7680957317352295,
            "end_logit": -6.478491306304932
        },
        {
            "text": "AstraZeneca)",
            "probability": 1.4554565379790843e-08,
            "start_logit": -4.9681830406188965,
            "end_logit": -5.338382720947266
        },
        {
            "text": "(",
            "probability": 1.3793320874296575e-08,
            "start_logit": -3.7680957317352295,
            "end_logit": -6.592190265655518
        },
        {
            "text": "; AstraZeneca",
            "probability": 1.0642910860490988e-08,
            "start_logit": -6.094799995422363,
            "end_logit": -4.524776458740234
        }
    ],
    "640ddbe9201352f04a000027_002": [
        {
            "text": "durvalumab",
            "probability": 0.40218764994137174,
            "start_logit": 6.988178253173828,
            "end_logit": 7.265791416168213
        },
        {
            "text": "durvalumab (IMFINZI",
            "probability": 0.3725698562096092,
            "start_logit": 6.988178253173828,
            "end_logit": 7.189297199249268
        },
        {
            "text": "IMFINZI",
            "probability": 0.22392469480067057,
            "start_logit": 6.479063510894775,
            "end_logit": 7.189297199249268
        },
        {
            "text": "durvalumab (IMFINZI\u00ae",
            "probability": 0.0006356935573924452,
            "start_logit": 6.988178253173828,
            "end_logit": 0.8158339858055115
        },
        {
            "text": "IMFINZI\u00ae",
            "probability": 0.00038206925078171274,
            "start_logit": 6.479063510894775,
            "end_logit": 0.8158339858055115
        },
        {
            "text": "durvalumab (IMFINZ",
            "probability": 8.669885918720572e-05,
            "start_logit": 6.988178253173828,
            "end_logit": -1.1764419078826904
        },
        {
            "text": "durvalumab (IMFINZI\u00ae, Astra-Zeneca",
            "probability": 7.663094192148313e-05,
            "start_logit": 6.988178253173828,
            "end_logit": -1.2998816967010498
        },
        {
            "text": "IMFINZ",
            "probability": 5.210839057290495e-05,
            "start_logit": 6.479063510894775,
            "end_logit": -1.1764419078826904
        },
        {
            "text": "IMFINZI\u00ae, Astra-Zeneca",
            "probability": 4.605729635948322e-05,
            "start_logit": 6.479063510894775,
            "end_logit": -1.2998816967010498
        },
        {
            "text": "(IMFINZI\u00ae,",
            "probability": 1.148125318937709e-05,
            "start_logit": -3.3992860317230225,
            "end_logit": 7.189297199249268
        },
        {
            "text": "(IMFINZI",
            "probability": 1.0476010720274521e-05,
            "start_logit": -3.4909136295318604,
            "end_logit": 7.189297199249268
        },
        {
            "text": "durvalumab (IMFINZI\u00ae,",
            "probability": 5.90411487331909e-06,
            "start_logit": -4.064352035522461,
            "end_logit": 7.189297199249268
        },
        {
            "text": "durvalumab (I",
            "probability": 3.045632181205698e-06,
            "start_logit": 6.988178253173828,
            "end_logit": -4.525174140930176
        },
        {
            "text": "du",
            "probability": 2.6735572204102858e-06,
            "start_logit": 6.988178253173828,
            "end_logit": -4.655472755432129
        },
        {
            "text": "I",
            "probability": 1.8305084141533313e-06,
            "start_logit": 6.479063510894775,
            "end_logit": -4.525174140930176
        },
        {
            "text": "durvalumab (",
            "probability": 7.766513426536816e-07,
            "start_logit": 6.988178253173828,
            "end_logit": -5.891646385192871
        },
        {
            "text": "durvalumab (IMF",
            "probability": 7.52452689065166e-07,
            "start_logit": 6.988178253173828,
            "end_logit": -5.923299789428711
        },
        {
            "text": "IMFINZI\u00ae,",
            "probability": 7.036398757413582e-07,
            "start_logit": 6.479063510894775,
            "end_logit": -5.481256484985352
        },
        {
            "text": "IMF",
            "probability": 4.522446889961663e-07,
            "start_logit": 6.479063510894775,
            "end_logit": -5.923299789428711
        },
        {
            "text": "durvalumab (IMFIN",
            "probability": 4.446869382385221e-07,
            "start_logit": 6.988178253173828,
            "end_logit": -6.449267387390137
        }
    ],
    "640ddbe9201352f04a000027_003": [
        {
            "text": "durvalumab",
            "probability": 0.9999152009873719,
            "start_logit": 8.584052085876465,
            "end_logit": 8.785459518432617
        },
        {
            "text": "durvalumab (Imfinzi\u00ae)",
            "probability": 6.99419147999965e-05,
            "start_logit": 8.584052085876465,
            "end_logit": -0.782301127910614
        },
        {
            "text": "du",
            "probability": 1.1529368172674262e-05,
            "start_logit": 8.584052085876465,
            "end_logit": -2.585068702697754
        },
        {
            "text": "durvalumab (Imfinzi\u00ae",
            "probability": 1.832122825100652e-06,
            "start_logit": 8.584052085876465,
            "end_logit": -4.424490928649902
        },
        {
            "text": "durvalumab (",
            "probability": 1.0667499142467054e-06,
            "start_logit": 8.584052085876465,
            "end_logit": -4.9653496742248535
        },
        {
            "text": "durvalumab (Imfinzi",
            "probability": 2.6538606220752204e-07,
            "start_logit": 8.584052085876465,
            "end_logit": -6.356535911560059
        },
        {
            "text": "durvalum",
            "probability": 8.873658486987157e-08,
            "start_logit": 8.584052085876465,
            "end_logit": -7.452049255371094
        },
        {
            "text": "durva",
            "probability": 4.513923274816604e-08,
            "start_logit": 8.584052085876465,
            "end_logit": -8.127969741821289
        },
        {
            "text": "durvalumab (I",
            "probability": 2.4983372005578015e-08,
            "start_logit": 8.584052085876465,
            "end_logit": -8.719511032104492
        },
        {
            "text": "(Imfinzi\u00ae)",
            "probability": 3.0684758626413104e-09,
            "start_logit": -1.4501873254776,
            "end_logit": -0.782301127910614
        },
        {
            "text": "Imfinzi\u00ae)",
            "probability": 1.2895185985535985e-09,
            "start_logit": -2.3170993328094482,
            "end_logit": -0.782301127910614
        },
        {
            "text": "(Imfinzi\u00ae",
            "probability": 8.037847808844716e-11,
            "start_logit": -1.4501873254776,
            "end_logit": -4.424490928649902
        },
        {
            "text": ")",
            "probability": 7.461963434983042e-11,
            "start_logit": -5.166719913482666,
            "end_logit": -0.782301127910614
        },
        {
            "text": "(",
            "probability": 4.6800210899299926e-11,
            "start_logit": -1.4501873254776,
            "end_logit": -4.9653496742248535
        },
        {
            "text": "Imfinzi\u00ae",
            "probability": 3.377883583195766e-11,
            "start_logit": -2.3170993328094482,
            "end_logit": -4.424490928649902
        },
        {
            "text": "(Imfinzi",
            "probability": 1.1642957280964339e-11,
            "start_logit": -1.4501873254776,
            "end_logit": -6.356535911560059
        },
        {
            "text": "Imfinzi",
            "probability": 4.892920990111627e-12,
            "start_logit": -2.3170993328094482,
            "end_logit": -6.356535911560059
        },
        {
            "text": "(I",
            "probability": 1.096064844460172e-12,
            "start_logit": -1.4501873254776,
            "end_logit": -8.719511032104492
        },
        {
            "text": "I",
            "probability": 4.606182565619118e-13,
            "start_logit": -2.3170993328094482,
            "end_logit": -8.719511032104492
        }
    ],
    "644e81fa57b1c7a315000079_001": [
        {
            "text": "Tumor-suppressor genes (TSGs) or antioncogenes",
            "probability": 0.29660487048570716,
            "start_logit": 9.721759796142578,
            "end_logit": 10.345060348510742
        },
        {
            "text": "Tumor-suppressor genes",
            "probability": 0.20254722834206287,
            "start_logit": 9.721759796142578,
            "end_logit": 9.963632583618164
        },
        {
            "text": "antioncogenes",
            "probability": 0.17690946723398254,
            "start_logit": 9.204997062683105,
            "end_logit": 10.345060348510742
        },
        {
            "text": "TSGs) or antioncogenes",
            "probability": 0.1201410709389023,
            "start_logit": 8.818025588989258,
            "end_logit": 10.345060348510742
        },
        {
            "text": "Tumor-suppressor genes (TSGs",
            "probability": 0.09412182131429689,
            "start_logit": 9.721759796142578,
            "end_logit": 9.197249412536621
        },
        {
            "text": "Tumor-suppressor genes (TSGs)",
            "probability": 0.043393776937009736,
            "start_logit": 9.721759796142578,
            "end_logit": 8.422975540161133
        },
        {
            "text": "TSGs",
            "probability": 0.03812444614581789,
            "start_logit": 8.818025588989258,
            "end_logit": 9.197249412536621
        },
        {
            "text": "TSGs)",
            "probability": 0.017576834880556735,
            "start_logit": 8.818025588989258,
            "end_logit": 8.422975540161133
        },
        {
            "text": "Tumor-suppressor genes (TSGs) or antioncogene",
            "probability": 0.004544543933960622,
            "start_logit": 9.721759796142578,
            "end_logit": 6.166586875915527
        },
        {
            "text": "antioncogene",
            "probability": 0.002710585449462951,
            "start_logit": 9.204997062683105,
            "end_logit": 6.166586875915527
        },
        {
            "text": "TSGs) or antioncogene",
            "probability": 0.0018407869508711638,
            "start_logit": 8.818025588989258,
            "end_logit": 6.166586875915527
        },
        {
            "text": "(TSGs) or antioncogenes",
            "probability": 0.0009149157471612304,
            "start_logit": 3.9404356479644775,
            "end_logit": 10.345060348510742
        },
        {
            "text": "(TSGs",
            "probability": 0.0002903308240722076,
            "start_logit": 3.9404356479644775,
            "end_logit": 9.197249412536621
        },
        {
            "text": "(TSGs)",
            "probability": 0.00013385366795716586,
            "start_logit": 3.9404356479644775,
            "end_logit": 8.422975540161133
        },
        {
            "text": "genes (TSGs) or antioncogenes",
            "probability": 4.083503800628793e-05,
            "start_logit": 0.8311441540718079,
            "end_logit": 10.345060348510742
        },
        {
            "text": "Tumor-suppressor genes (TSG",
            "probability": 3.542212482976218e-05,
            "start_logit": 9.721759796142578,
            "end_logit": 1.3122408390045166
        },
        {
            "text": "genes",
            "probability": 2.7885664027944486e-05,
            "start_logit": 0.8311441540718079,
            "end_logit": 9.963632583618164
        },
        {
            "text": "TSG",
            "probability": 1.4347883111326667e-05,
            "start_logit": 8.818025588989258,
            "end_logit": 1.3122408390045166
        },
        {
            "text": "(TSGs) or antioncogene",
            "probability": 1.4018228365696984e-05,
            "start_logit": 3.9404356479644775,
            "end_logit": 6.166586875915527
        },
        {
            "text": "genes (TSGs",
            "probability": 1.2958209837540632e-05,
            "start_logit": 0.8311441540718079,
            "end_logit": 9.197249412536621
        }
    ],
    "644e81fa57b1c7a315000079_002": [
        {
            "text": "tumour suppressor proteins",
            "probability": 0.9921185234723352,
            "start_logit": 4.555968761444092,
            "end_logit": 5.795105934143066
        },
        {
            "text": "loss of function of tumour suppressor proteins",
            "probability": 0.004616093769411452,
            "start_logit": -0.8143249750137329,
            "end_logit": 5.795105934143066
        },
        {
            "text": "tumour suppressor proteins,",
            "probability": 0.0014790897731744874,
            "start_logit": 4.555968761444092,
            "end_logit": -0.7133097648620605
        },
        {
            "text": "tumour suppressor proteins, drives oncogenic proliferation.",
            "probability": 0.0007730075402814504,
            "start_logit": 4.555968761444092,
            "end_logit": -1.3622031211853027
        },
        {
            "text": "growth signalling networks, coupled to loss of function of tumour suppressor proteins",
            "probability": 0.000504566934651014,
            "start_logit": -3.027928590774536,
            "end_logit": 5.795105934143066
        },
        {
            "text": "hyperactivating mutations in growth signalling networks, coupled to loss of function of tumour suppressor proteins",
            "probability": 0.0001852436160897672,
            "start_logit": -4.029957294464111,
            "end_logit": 5.795105934143066
        },
        {
            "text": "cell cycle checkpoint control promotes genetic instability. During the past two decades, cancer genetics has shown that hyperactivating mutations in growth signalling networks",
            "probability": 7.663940047092488e-05,
            "start_logit": -2.3456966876983643,
            "end_logit": 3.2282848358154297
        },
        {
            "text": "proteins",
            "probability": 6.859801506519426e-05,
            "start_logit": -5.023365497589111,
            "end_logit": 5.795105934143066
        },
        {
            "text": "growth signalling networks",
            "probability": 3.874026149245794e-05,
            "start_logit": -3.027928590774536,
            "end_logit": 3.2282848358154297
        },
        {
            "text": "tumour suppressor",
            "probability": 3.432187943752723e-05,
            "start_logit": 4.555968761444092,
            "end_logit": -4.476708889007568
        },
        {
            "text": "cancer genetics has shown that hyperactivating mutations in growth signalling networks, coupled to loss of function of tumour suppressor proteins",
            "probability": 3.026192725316109e-05,
            "start_logit": -5.841738700866699,
            "end_logit": 5.795105934143066
        },
        {
            "text": "coupled to loss of function of tumour suppressor proteins",
            "probability": 1.817516508710206e-05,
            "start_logit": -6.3515729904174805,
            "end_logit": 5.795105934143066
        },
        {
            "text": "hyperactivating mutations in growth signalling networks",
            "probability": 1.4222862487193399e-05,
            "start_logit": -4.029957294464111,
            "end_logit": 3.2282848358154297
        },
        {
            "text": ", coupled to loss of function of tumour suppressor proteins",
            "probability": 1.102101975897576e-05,
            "start_logit": -6.851824760437012,
            "end_logit": 5.795105934143066
        },
        {
            "text": "cell cycle checkpoint control promotes genetic instability. During the past two decades, cancer genetics has shown that hyperactivating mutations in growth signalling networks,",
            "probability": 7.317619146010757e-06,
            "start_logit": -2.3456966876983643,
            "end_logit": 0.8794585466384888
        },
        {
            "text": "loss of function of tumour suppressor proteins,",
            "probability": 6.881856275049515e-06,
            "start_logit": -0.8143249750137329,
            "end_logit": -0.7133097648620605
        },
        {
            "text": "tumour suppressor proteins, drives oncogenic proliferation",
            "probability": 5.364573864498982e-06,
            "start_logit": 4.555968761444092,
            "end_logit": -6.332674980163574
        },
        {
            "text": "t",
            "probability": 4.634726485477868e-06,
            "start_logit": 4.555968761444092,
            "end_logit": -6.478914737701416
        },
        {
            "text": "growth signalling networks,",
            "probability": 3.698965251251168e-06,
            "start_logit": -3.027928590774536,
            "end_logit": 0.8794585466384888
        },
        {
            "text": "loss of function of tumour suppressor proteins, drives oncogenic proliferation.",
            "probability": 3.5966219821323344e-06,
            "start_logit": -0.8143249750137329,
            "end_logit": -1.3622031211853027
        }
    ],
    "644e81fa57b1c7a315000079_003": [
        {
            "text": "tumor suppressor genes",
            "probability": 0.9993756388375067,
            "start_logit": 7.530782699584961,
            "end_logit": 6.19199800491333
        },
        {
            "text": "We now recognize that tumor suppressor genes",
            "probability": 0.00027220445676302374,
            "start_logit": -0.6775498390197754,
            "end_logit": 6.19199800491333
        },
        {
            "text": "tumor suppressor",
            "probability": 0.00020892286297912986,
            "start_logit": 7.530782699584961,
            "end_logit": -2.2809228897094727
        },
        {
            "text": "tumor suppressor genes regulate diverse cellular activities,",
            "probability": 5.696342121018021e-05,
            "start_logit": 7.530782699584961,
            "end_logit": -3.5804786682128906
        },
        {
            "text": "genes",
            "probability": 3.546266313393032e-05,
            "start_logit": -2.715622901916504,
            "end_logit": 6.19199800491333
        },
        {
            "text": "tumor",
            "probability": 3.332665670801163e-05,
            "start_logit": 7.530782699584961,
            "end_logit": -4.116530418395996
        },
        {
            "text": "tumor suppressor genes regulate diverse cellular activities, including cell cycle checkpoint responses",
            "probability": 4.754896471301528e-06,
            "start_logit": 7.530782699584961,
            "end_logit": -6.063713073730469
        },
        {
            "text": "tumor suppressor genes regulate diverse cellular activities, including cell cycle checkpoint responses, detection and repair of DNA damage",
            "probability": 3.2170569582644153e-06,
            "start_logit": 7.530782699584961,
            "end_logit": -6.454421043395996
        },
        {
            "text": "tumor suppressor genes regulate diverse cellular activities, including cell cycle checkpoint responses,",
            "probability": 2.905742417631551e-06,
            "start_logit": 7.530782699584961,
            "end_logit": -6.556199073791504
        },
        {
            "text": "suppressor genes",
            "probability": 2.4082617097530426e-06,
            "start_logit": -5.405198097229004,
            "end_logit": 6.19199800491333
        },
        {
            "text": "tumor suppressor genes regulate diverse cellular activities",
            "probability": 2.2692866837438356e-06,
            "start_logit": 7.530782699584961,
            "end_logit": -6.803422451019287
        },
        {
            "text": "that tumor suppressor genes",
            "probability": 7.635723876278026e-07,
            "start_logit": -6.5538506507873535,
            "end_logit": 6.19199800491333
        },
        {
            "text": "now recognize that tumor suppressor genes",
            "probability": 6.928511366837507e-07,
            "start_logit": -6.65104341506958,
            "end_logit": 6.19199800491333
        },
        {
            "text": "recognize that tumor suppressor genes",
            "probability": 3.8207557990733735e-07,
            "start_logit": -7.246240139007568,
            "end_logit": 6.19199800491333
        },
        {
            "text": "We now recognize that tumor suppressor",
            "probability": 5.6905263859304867e-08,
            "start_logit": -0.6775498390197754,
            "end_logit": -2.2809228897094727
        },
        {
            "text": "We now recognize that tumor suppressor genes regulate diverse cellular activities,",
            "probability": 1.5515384329276763e-08,
            "start_logit": -0.6775498390197754,
            "end_logit": -3.5804786682128906
        },
        {
            "text": "We now recognize that tumor",
            "probability": 9.077332018503498e-09,
            "start_logit": -0.6775498390197754,
            "end_logit": -4.116530418395996
        },
        {
            "text": "We",
            "probability": 2.5439245923308825e-09,
            "start_logit": -0.6775498390197754,
            "end_logit": -5.3886027336120605
        },
        {
            "text": "genes regulate diverse cellular activities,",
            "probability": 2.02133666144053e-09,
            "start_logit": -2.715622901916504,
            "end_logit": -3.5804786682128906
        },
        {
            "text": "We now recognize that tumor suppressor genes regulate diverse cellular activities, including cell cycle checkpoint responses",
            "probability": 1.295112628961629e-09,
            "start_logit": -0.6775498390197754,
            "end_logit": -6.063713073730469
        }
    ],
    "6415c7fb690f196b51000016_001": [
        {
            "text": "September 4, 2014",
            "probability": 0.991777172209568,
            "start_logit": 8.186254501342773,
            "end_logit": 9.801507949829102
        },
        {
            "text": "2014",
            "probability": 0.0060888918150241835,
            "start_logit": 3.093222141265869,
            "end_logit": 9.801507949829102
        },
        {
            "text": "On September 4, 2014",
            "probability": 0.002006379019881328,
            "start_logit": 1.9830876588821411,
            "end_logit": 9.801507949829102
        },
        {
            "text": "September 4",
            "probability": 7.969674718095101e-05,
            "start_logit": 8.186254501342773,
            "end_logit": 0.3724829852581024
        },
        {
            "text": "4, 2014",
            "probability": 2.0160984356849663e-05,
            "start_logit": -2.6172499656677246,
            "end_logit": 9.801507949829102
        },
        {
            "text": "September 4,",
            "probability": 1.4616940112546675e-05,
            "start_logit": 8.186254501342773,
            "end_logit": -1.3235646486282349
        },
        {
            "text": "September",
            "probability": 1.0822184339372984e-05,
            "start_logit": 8.186254501342773,
            "end_logit": -1.624147653579712
        },
        {
            "text": "September 4, 2014,",
            "probability": 7.301650331430915e-07,
            "start_logit": 8.186254501342773,
            "end_logit": -4.320230484008789
        },
        {
            "text": ", 2014",
            "probability": 4.977718991972519e-07,
            "start_logit": -6.318612575531006,
            "end_logit": 9.801507949829102
        },
        {
            "text": "September 4, 2014, the FDA approved pembrolizumab",
            "probability": 4.133125377974677e-07,
            "start_logit": 8.186254501342773,
            "end_logit": -4.889297008514404
        },
        {
            "text": "September 4, 2014, the FDA approved pembrolizumab (KEYTRUDA",
            "probability": 3.921564603035829e-07,
            "start_logit": 8.186254501342773,
            "end_logit": -4.941840171813965
        },
        {
            "text": "On September 4",
            "probability": 1.6122762852103466e-07,
            "start_logit": 1.9830876588821411,
            "end_logit": 0.3724829852581024
        },
        {
            "text": "On September 4,",
            "probability": 2.957027324125432e-08,
            "start_logit": 1.9830876588821411,
            "end_logit": -1.3235646486282349
        },
        {
            "text": "On September",
            "probability": 2.1893429508395724e-08,
            "start_logit": 1.9830876588821411,
            "end_logit": -1.624147653579712
        },
        {
            "text": "2014,",
            "probability": 4.4827568313725905e-09,
            "start_logit": 3.093222141265869,
            "end_logit": -4.320230484008789
        },
        {
            "text": "2014, the FDA approved pembrolizumab",
            "probability": 2.5374805943911153e-09,
            "start_logit": 3.093222141265869,
            "end_logit": -4.889297008514404
        },
        {
            "text": "2014, the FDA approved pembrolizumab (KEYTRUDA",
            "probability": 2.4075955045744763e-09,
            "start_logit": 3.093222141265869,
            "end_logit": -4.941840171813965
        },
        {
            "text": "4",
            "probability": 1.6200865660451374e-09,
            "start_logit": -2.6172499656677246,
            "end_logit": 0.3724829852581024
        },
        {
            "text": "On",
            "probability": 1.477221364515945e-09,
            "start_logit": 1.9830876588821411,
            "end_logit": -4.320171356201172
        },
        {
            "text": "On September 4, 2014,",
            "probability": 1.4771340222375002e-09,
            "start_logit": 1.9830876588821411,
            "end_logit": -4.320230484008789
        }
    ],
    "64468e0d57b1c7a315000071_001": [
        {
            "text": "1 in 80,000 individuals worldwide",
            "probability": 0.9382311992903054,
            "start_logit": 6.591463565826416,
            "end_logit": 3.717057704925537
        },
        {
            "text": "1 in 80,000",
            "probability": 0.021935351835679486,
            "start_logit": 6.591463565826416,
            "end_logit": -0.03883912041783333
        },
        {
            "text": "1 in 80,000 individuals",
            "probability": 0.01807242559288472,
            "start_logit": 6.591463565826416,
            "end_logit": -0.23255136609077454
        },
        {
            "text": "1 in 80,000 individuals worldwide.",
            "probability": 0.005262583753606758,
            "start_logit": 6.591463565826416,
            "end_logit": -1.4663165807724
        },
        {
            "text": "1 in 80,000 individuals worldwide. However, it can affect as much as 1:600 individuals in some populations due to a strong founder effect.",
            "probability": 0.005247544519609631,
            "start_logit": 6.591463565826416,
            "end_logit": -1.4691784381866455
        },
        {
            "text": "approximately 1 in 80,000 individuals worldwide",
            "probability": 0.004312416815748298,
            "start_logit": 1.2089656591415405,
            "end_logit": 3.717057704925537
        },
        {
            "text": "1 in 80,000 individuals worldwide. However, it can affect as much as 1:600",
            "probability": 0.0035166912107959334,
            "start_logit": 6.591463565826416,
            "end_logit": -1.8694181442260742
        },
        {
            "text": "1",
            "probability": 0.0018907412812003478,
            "start_logit": 6.591463565826416,
            "end_logit": -2.4899697303771973
        },
        {
            "text": "late-onset rare muscle disease affecting approximately 1 in 80,000 individuals worldwide",
            "probability": 0.00035569640638069647,
            "start_logit": -1.286210536956787,
            "end_logit": 3.717057704925537
        },
        {
            "text": "1 in 80,000 individuals worldwide. However, it can affect as much as 1:600 individuals",
            "probability": 0.00026641903506592385,
            "start_logit": 6.591463565826416,
            "end_logit": -4.4496235847473145
        },
        {
            "text": "1 in",
            "probability": 0.00018384254101533947,
            "start_logit": 6.591463565826416,
            "end_logit": -4.820614337921143
        },
        {
            "text": "worldwide",
            "probability": 0.00015242164864285606,
            "start_logit": -2.1336374282836914,
            "end_logit": 3.717057704925537
        },
        {
            "text": "80,000 individuals worldwide",
            "probability": 0.00014761903749247187,
            "start_logit": -2.1656532287597656,
            "end_logit": 3.717057704925537
        },
        {
            "text": "approximately 1 in 80,000",
            "probability": 0.00010082203638835756,
            "start_logit": 1.2089656591415405,
            "end_logit": -0.03883912041783333
        },
        {
            "text": "approximately 1 in 80,000 individuals",
            "probability": 8.30667665785022e-05,
            "start_logit": 1.2089656591415405,
            "end_logit": -0.23255136609077454
        },
        {
            "text": "1 in 80,000 individuals worldwide. However, it can affect as much as 1:600 individuals in some populations due to a strong founder effect",
            "probability": 7.407434311480998e-05,
            "start_logit": 6.591463565826416,
            "end_logit": -5.7296247482299805
        },
        {
            "text": "1:600 individuals in some populations due to a strong founder effect.",
            "probability": 6.938784991470916e-05,
            "start_logit": 2.265659809112549,
            "end_logit": -1.4691784381866455
        },
        {
            "text": "1:600",
            "probability": 4.650091886199711e-05,
            "start_logit": 2.265659809112549,
            "end_logit": -1.8694181442260742
        },
        {
            "text": "1 in 80,",
            "probability": 2.5825936274206508e-05,
            "start_logit": 6.591463565826416,
            "end_logit": -6.7833147048950195
        },
        {
            "text": "1 in 80,000 individuals worldwide. However, it can affect as much as 1:600 individuals in some populations",
            "probability": 2.5369180439715697e-05,
            "start_logit": 6.591463565826416,
            "end_logit": -6.801158905029297
        }
    ],
    "63f04716f36125a426000025_001": [
        {
            "text": "angioedema",
            "probability": 0.9979938786134239,
            "start_logit": 9.466034889221191,
            "end_logit": 10.219493865966797
        },
        {
            "text": "Hereditary angioedema",
            "probability": 0.0019923969533608386,
            "start_logit": 3.2496261596679688,
            "end_logit": 10.219493865966797
        },
        {
            "text": "an",
            "probability": 5.107012063559391e-06,
            "start_logit": 9.466034889221191,
            "end_logit": -1.963394045829773
        },
        {
            "text": "BACKGROUND: Hereditary angioedema",
            "probability": 4.72525442038579e-06,
            "start_logit": -2.794546127319336,
            "end_logit": 10.219493865966797
        },
        {
            "text": "angioedema is characterized by recurrent and unpredictable swellings that are disabling and potentially fatal.",
            "probability": 3.844194793083083e-06,
            "start_logit": 9.466034889221191,
            "end_logit": -2.2474443912506104
        },
        {
            "text": "angioedema is",
            "probability": 2.99379676928118e-08,
            "start_logit": 9.466034889221191,
            "end_logit": -7.102636337280273
        },
        {
            "text": "Hereditary an",
            "probability": 1.0195648985693003e-08,
            "start_logit": 3.2496261596679688,
            "end_logit": -1.963394045829773
        },
        {
            "text": "Hereditary angioedema is characterized by recurrent and unpredictable swellings that are disabling and potentially fatal.",
            "probability": 7.674558088979157e-09,
            "start_logit": 3.2496261596679688,
            "end_logit": -2.2474443912506104
        },
        {
            "text": "Hereditary angioedema is",
            "probability": 5.976821792118267e-11,
            "start_logit": 3.2496261596679688,
            "end_logit": -7.102636337280273
        },
        {
            "text": "Here",
            "probability": 5.791658281735228e-11,
            "start_logit": 3.2496261596679688,
            "end_logit": -7.134106636047363
        },
        {
            "text": "BACKGROUND: Hereditary an",
            "probability": 2.418044022657292e-11,
            "start_logit": -2.794546127319336,
            "end_logit": -1.963394045829773
        },
        {
            "text": "angioedema is characterized by recurrent and unpredictable swellings that are disabling and potentially fatal. Selective inhibition of plasma prekallikrein",
            "probability": 1.1923288319739186e-11,
            "start_logit": -0.4404350519180298,
            "end_logit": -5.024555683135986
        },
        {
            "text": "antisense oligonucleotide treatment (donidalorsen) may reduce the frequency of attacks and the burden of disease.",
            "probability": 3.642253039722135e-12,
            "start_logit": -4.398930072784424,
            "end_logit": -2.2519516944885254
        },
        {
            "text": "BACKGROUND",
            "probability": 1.973391622906766e-12,
            "start_logit": -2.794546127319336,
            "end_logit": -4.469184398651123
        },
        {
            "text": "prekallikrein production by antisense oligonucleotide treatment",
            "probability": 1.4098282223990683e-12,
            "start_logit": -3.137756109237671,
            "end_logit": -4.4622602462768555
        },
        {
            "text": "prekallikrein",
            "probability": 8.034602484862268e-13,
            "start_logit": -3.137756109237671,
            "end_logit": -5.024555683135986
        },
        {
            "text": "donidalorsen) may reduce the frequency of attacks and the burden of disease.",
            "probability": 6.094564154351661e-13,
            "start_logit": -6.186720371246338,
            "end_logit": -2.2519516944885254
        },
        {
            "text": "prekallikrein production",
            "probability": 5.529197022807887e-13,
            "start_logit": -3.137756109237671,
            "end_logit": -5.398270606994629
        },
        {
            "text": "may reduce the frequency of attacks and the burden of disease.",
            "probability": 5.394216796099341e-13,
            "start_logit": -6.30879020690918,
            "end_logit": -2.2519516944885254
        },
        {
            "text": "BACKGROUND:",
            "probability": 4.4467184858961275e-13,
            "start_logit": -2.794546127319336,
            "end_logit": -5.959356784820557
        }
    ],
    "63f04716f36125a426000025_002": [
        {
            "text": "angioedema",
            "probability": 0.9988071083557262,
            "start_logit": 9.221641540527344,
            "end_logit": 9.87721061706543
        },
        {
            "text": "hereditary angioedema",
            "probability": 0.0011502070768190848,
            "start_logit": 2.455021858215332,
            "end_logit": 9.87721061706543
        },
        {
            "text": "angioedema,",
            "probability": 2.421643640649894e-05,
            "start_logit": -1.4056438207626343,
            "end_logit": 9.87721061706543
        },
        {
            "text": "an",
            "probability": 6.812052765596178e-06,
            "start_logit": 9.221641540527344,
            "end_logit": -2.0184128284454346
        },
        {
            "text": "Among patients with hereditary angioedema",
            "probability": 5.904469434057566e-06,
            "start_logit": -2.8169658184051514,
            "end_logit": 9.87721061706543
        },
        {
            "text": "CONCLUSIONS: Among patients with hereditary angioedema",
            "probability": 4.452363642093164e-06,
            "start_logit": -3.099240303039551,
            "end_logit": 9.87721061706543
        },
        {
            "text": "patients with hereditary angioedema",
            "probability": 5.768186053519159e-07,
            "start_logit": -5.142902851104736,
            "end_logit": 9.87721061706543
        },
        {
            "text": "CONCLUSIONS: Among patients with hereditary angioedema,",
            "probability": 3.425608324864686e-07,
            "start_logit": -5.6639814376831055,
            "end_logit": 9.87721061706543
        },
        {
            "text": "angioedema, donidalorsen treatment resulted in a significantly lower rate of angioedema attacks than placebo",
            "probability": 1.4627696935598735e-07,
            "start_logit": 9.221641540527344,
            "end_logit": -5.8593597412109375
        },
        {
            "text": "angioedema, donidalorsen treatment resulted in a significantly lower rate of angioedema",
            "probability": 8.135982039094842e-08,
            "start_logit": 9.221641540527344,
            "end_logit": -6.445980072021484
        },
        {
            "text": "angioedema, donidalorsen treatment resulted in a significantly lower rate of angioedema attacks",
            "probability": 5.298336330882364e-08,
            "start_logit": 9.221641540527344,
            "end_logit": -6.874883651733398
        },
        {
            "text": "angioede",
            "probability": 5.052254421649132e-08,
            "start_logit": 9.221641540527344,
            "end_logit": -6.9224419593811035
        },
        {
            "text": "angioedema, donidalorsen",
            "probability": 4.014338961789593e-08,
            "start_logit": 9.221641540527344,
            "end_logit": -7.152403831481934
        },
        {
            "text": "hereditary an",
            "probability": 7.844629091149003e-09,
            "start_logit": 2.455021858215332,
            "end_logit": -2.0184128284454346
        },
        {
            "text": "hereditary",
            "probability": 2.769823628415329e-10,
            "start_logit": 2.455021858215332,
            "end_logit": -5.362043380737305
        },
        {
            "text": "hereditary angioedema, donidalorsen treatment resulted in a significantly lower rate of angioedema attacks than placebo",
            "probability": 1.6844974762532736e-10,
            "start_logit": 2.455021858215332,
            "end_logit": -5.8593597412109375
        },
        {
            "text": "hereditary angioedema, donidalorsen treatment resulted in a significantly lower rate of angioedema",
            "probability": 9.369240607073223e-11,
            "start_logit": 2.455021858215332,
            "end_logit": -6.445980072021484
        },
        {
            "text": "angioedema, donidalorsen treatment resulted in a significantly lower rate of angioedema attacks than placebo in this small, phase 2 trial.",
            "probability": 7.673280346461837e-11,
            "start_logit": -1.4056438207626343,
            "end_logit": -2.7850022315979004
        },
        {
            "text": "hereditary angioedema, donidalorsen treatment resulted in a significantly lower rate of angioedema attacks",
            "probability": 6.101462326575783e-11,
            "start_logit": 2.455021858215332,
            "end_logit": -6.874883651733398
        },
        {
            "text": "hereditary angioede",
            "probability": 5.8180791276484406e-11,
            "start_logit": 2.455021858215332,
            "end_logit": -6.9224419593811035
        }
    ],
    "63f04716f36125a426000025_003": [
        {
            "text": "HAE",
            "probability": 0.9993397867208632,
            "start_logit": 5.631300449371338,
            "end_logit": 5.727758407592773
        },
        {
            "text": "HAE,",
            "probability": 0.0001668210926084488,
            "start_logit": -3.0666277408599854,
            "end_logit": 5.727758407592773
        },
        {
            "text": "Given the requirement of lifelong management for HAE",
            "probability": 0.00014505815620754898,
            "start_logit": -3.2064149379730225,
            "end_logit": 5.727758407592773
        },
        {
            "text": "H",
            "probability": 0.00012951015744925906,
            "start_logit": 5.631300449371338,
            "end_logit": -3.223332405090332
        },
        {
            "text": "HAE, further research is needed to determine how best to individualize optimal treatments for each patient.",
            "probability": 0.00012615199555864577,
            "start_logit": 5.631300449371338,
            "end_logit": -3.2496042251586914
        },
        {
            "text": "HA",
            "probability": 1.8849808030763626e-05,
            "start_logit": 5.631300449371338,
            "end_logit": -5.1505889892578125
        },
        {
            "text": "prophylaxis. Given the requirement of lifelong management for HAE",
            "probability": 1.5075561021477295e-05,
            "start_logit": -5.470474720001221,
            "end_logit": 5.727758407592773
        },
        {
            "text": "have shown promise as long-term prophylaxis. Given the requirement of lifelong management for HAE",
            "probability": 1.3466276571853533e-05,
            "start_logit": -5.5833611488342285,
            "end_logit": 5.727758407592773
        },
        {
            "text": "donidalorsen), have shown promise as long-term prophylaxis. Given the requirement of lifelong management for HAE",
            "probability": 1.0230792611807566e-05,
            "start_logit": -5.858147621154785,
            "end_logit": 5.727758407592773
        },
        {
            "text": "(donidalorsen), have shown promise as long-term prophylaxis. Given the requirement of lifelong management for HAE",
            "probability": 7.589401579788167e-06,
            "start_logit": -6.156796932220459,
            "end_logit": 5.727758407592773
        },
        {
            "text": "the requirement of lifelong management for HAE",
            "probability": 7.515410522590421e-06,
            "start_logit": -6.1665940284729,
            "end_logit": 5.727758407592773
        },
        {
            "text": "as long-term prophylaxis. Given the requirement of lifelong management for HAE",
            "probability": 6.84370756510722e-06,
            "start_logit": -6.260220050811768,
            "end_logit": 5.727758407592773
        },
        {
            "text": "shown promise as long-term prophylaxis. Given the requirement of lifelong management for HAE",
            "probability": 6.3114024402379805e-06,
            "start_logit": -6.34119176864624,
            "end_logit": 5.727758407592773
        },
        {
            "text": "HAE, further research is needed to determine how best to individualize optimal treatments",
            "probability": 3.375516126950134e-06,
            "start_logit": 5.631300449371338,
            "end_logit": -6.870543479919434
        },
        {
            "text": "HAE, further research is needed",
            "probability": 3.3600034211968026e-06,
            "start_logit": 5.631300449371338,
            "end_logit": -6.875149726867676
        },
        {
            "text": "Given the requirement of lifelong management for H",
            "probability": 1.8798915943678276e-08,
            "start_logit": -3.2064149379730225,
            "end_logit": -3.223332405090332
        },
        {
            "text": "Given the requirement of lifelong management for HAE, further research is needed to determine how best to individualize optimal treatments for each patient.",
            "probability": 1.831146535022473e-08,
            "start_logit": -3.2064149379730225,
            "end_logit": -3.2496042251586914
        },
        {
            "text": "Given the requirement of lifelong management for HAE,",
            "probability": 7.340305664011773e-09,
            "start_logit": -3.2064149379730225,
            "end_logit": -4.163751125335693
        },
        {
            "text": "prekallikrein messenger RNA (donidalorsen), have shown promise as long-term prophylaxis.",
            "probability": 6.810608888821566e-09,
            "start_logit": -4.197498321533203,
            "end_logit": -3.2475666999816895
        },
        {
            "text": "Given the requirement of lifelong management for HA",
            "probability": 2.7361248237508367e-09,
            "start_logit": -3.2064149379730225,
            "end_logit": -5.1505889892578125
        }
    ],
    "644ec7fe57b1c7a315000082_001": [
        {
            "text": "The lac operon",
            "probability": 0.6280655559066745,
            "start_logit": 3.00691819190979,
            "end_logit": -1.4930992126464844
        },
        {
            "text": "The lac operon is one of the best known gene regulatory circuits and constitutes a landmark example of how bacteria tune their metabolism to nutritional conditions.",
            "probability": 0.21907309522403368,
            "start_logit": 3.00691819190979,
            "end_logit": -2.5463383197784424
        },
        {
            "text": "lac operon",
            "probability": 0.09505886780693865,
            "start_logit": 1.1187700033187866,
            "end_logit": -1.4930992126464844
        },
        {
            "text": "lac operon is one of the best known gene regulatory circuits and constitutes a landmark example of how bacteria tune their metabolism to nutritional conditions.",
            "probability": 0.033157112666201846,
            "start_logit": 1.1187700033187866,
            "end_logit": -2.5463383197784424
        },
        {
            "text": "The lac",
            "probability": 0.010708470377200244,
            "start_logit": 3.00691819190979,
            "end_logit": -5.564708709716797
        },
        {
            "text": "The lac operon is one of the best known gene regulatory circuits",
            "probability": 0.006183898874793251,
            "start_logit": 3.00691819190979,
            "end_logit": -6.113794803619385
        },
        {
            "text": "The",
            "probability": 0.002669685637655743,
            "start_logit": 3.00691819190979,
            "end_logit": -6.95378303527832
        },
        {
            "text": "The lac operon is one of the best known gene regulatory",
            "probability": 0.0020392402179353255,
            "start_logit": 3.00691819190979,
            "end_logit": -7.223166465759277
        },
        {
            "text": "lac",
            "probability": 0.0016207465294467661,
            "start_logit": 1.1187700033187866,
            "end_logit": -5.564708709716797
        },
        {
            "text": "lac operon is one of the best known gene regulatory circuits",
            "probability": 0.0009359443773697341,
            "start_logit": 1.1187700033187866,
            "end_logit": -6.113794803619385
        },
        {
            "text": "lac operon is one of the best known gene regulatory",
            "probability": 0.0003086427276265268,
            "start_logit": 1.1187700033187866,
            "end_logit": -7.223166465759277
        },
        {
            "text": "operon",
            "probability": 4.958231249200003e-05,
            "start_logit": -6.439847469329834,
            "end_logit": -1.4930992126464844
        },
        {
            "text": "lactose, for species identification.",
            "probability": 3.474036276478221e-05,
            "start_logit": -5.7374467849731445,
            "end_logit": -2.551231861114502
        },
        {
            "text": "gene regulatory circuits and constitutes a landmark example of how bacteria tune their metabolism to nutritional conditions.",
            "probability": 2.4826450279506294e-05,
            "start_logit": -6.078332901000977,
            "end_logit": -2.5463383197784424
        },
        {
            "text": "Escherichia coli strains justifying the use of its phenotype, the ability to consume lactose, for species identification.",
            "probability": 1.7661179474201528e-05,
            "start_logit": -6.413980007171631,
            "end_logit": -2.551231861114502
        },
        {
            "text": "operon is one of the best known gene regulatory circuits and constitutes a landmark example of how bacteria tune their metabolism to nutritional conditions.",
            "probability": 1.7294612901207638e-05,
            "start_logit": -6.439847469329834,
            "end_logit": -2.5463383197784424
        },
        {
            "text": "one of the best known gene regulatory circuits and constitutes a landmark example of how bacteria tune their metabolism to nutritional conditions.",
            "probability": 1.4684964968630853e-05,
            "start_logit": -6.603418350219727,
            "end_logit": -2.5463383197784424
        },
        {
            "text": "the ability to consume lactose, for species identification.",
            "probability": 7.4869590122719505e-06,
            "start_logit": -7.272186279296875,
            "end_logit": -2.551231861114502
        },
        {
            "text": "lactose,",
            "probability": 6.5201170654513085e-06,
            "start_logit": -5.7374467849731445,
            "end_logit": -4.224241733551025
        },
        {
            "text": "ability to consume lactose, for species identification.",
            "probability": 5.942695166002639e-06,
            "start_logit": -7.503186225891113,
            "end_logit": -2.551231861114502
        }
    ],
    "644ec7fe57b1c7a315000082_002": [
        {
            "text": "colilac operon.",
            "probability": 0.453864259540419,
            "start_logit": 1.2258937358856201,
            "end_logit": -2.3436355590820312
        },
        {
            "text": "colilac operon. Most studies of lac operon regulation have focused on a few closely related strains.",
            "probability": 0.4526841468202178,
            "start_logit": 1.2258937358856201,
            "end_logit": -2.3462390899658203
        },
        {
            "text": "colilac",
            "probability": 0.06398952363656615,
            "start_logit": 1.2258937358856201,
            "end_logit": -4.3027143478393555
        },
        {
            "text": "Escherichia colilac operon.",
            "probability": 0.0073038804838998755,
            "start_logit": -2.903498649597168,
            "end_logit": -2.3436355590820312
        },
        {
            "text": "Escherichia colilac operon. Most studies of lac operon regulation have focused on a few closely related strains.",
            "probability": 0.007284889338233089,
            "start_logit": -2.903498649597168,
            "end_logit": -2.3462390899658203
        },
        {
            "text": "colilac operon. Most studies of lac operon",
            "probability": 0.0070977048433548155,
            "start_logit": 1.2258937358856201,
            "end_logit": -6.501662254333496
        },
        {
            "text": "Escherichia colilac operon",
            "probability": 0.0026966993180059656,
            "start_logit": -2.903498649597168,
            "end_logit": -3.340012788772583
        },
        {
            "text": "Transcription of bacterial genes is controlled by the coordinated action of cis- and trans-acting regulators.",
            "probability": 0.0010830980255155584,
            "start_logit": -4.813843250274658,
            "end_logit": -2.3418712615966797
        },
        {
            "text": "Escherichia colilac",
            "probability": 0.001029761262401283,
            "start_logit": -2.903498649597168,
            "end_logit": -4.3027143478393555
        },
        {
            "text": "the Escherichia colilac operon.",
            "probability": 0.0004962715512168917,
            "start_logit": -5.592536449432373,
            "end_logit": -2.3436355590820312
        },
        {
            "text": "the Escherichia colilac operon. Most studies of lac operon regulation have focused on a few closely related strains.",
            "probability": 0.000494981173404684,
            "start_logit": -5.592536449432373,
            "end_logit": -2.3462390899658203
        },
        {
            "text": "lac operon regulation have focused on a few closely related strains.",
            "probability": 0.0003851958940097671,
            "start_logit": -5.84330415725708,
            "end_logit": -2.3462390899658203
        },
        {
            "text": "Most studies of lac operon regulation have focused on a few closely related strains.",
            "probability": 0.00030958459389856586,
            "start_logit": -6.061824798583984,
            "end_logit": -2.3462390899658203
        },
        {
            "text": "lactose to control the Escherichia colilac operon.",
            "probability": 0.0002206275027566953,
            "start_logit": -6.403183937072754,
            "end_logit": -2.3436355590820312
        },
        {
            "text": "cis- and trans-acting regulators.",
            "probability": 0.00021234229592833505,
            "start_logit": -6.4432244300842285,
            "end_logit": -2.3418712615966797
        },
        {
            "text": "the regulatory function that integrates the environmental availability of glucose and lactose to control the Escherichia colilac operon.",
            "probability": 0.00021087658127543908,
            "start_logit": -6.4483866691589355,
            "end_logit": -2.3436355590820312
        },
        {
            "text": "the Escherichia colilac operon",
            "probability": 0.0001832307027288291,
            "start_logit": -5.592536449432373,
            "end_logit": -3.340012788772583
        },
        {
            "text": "bacterial genes is controlled by the coordinated action of cis- and trans-acting regulators.",
            "probability": 0.00017774616303772717,
            "start_logit": -6.621067523956299,
            "end_logit": -2.3418712615966797
        },
        {
            "text": "Transcription of bacterial genes is controlled by the coordinated action of cis- and trans-acting regulators",
            "probability": 0.00016095936501415897,
            "start_logit": -4.813843250274658,
            "end_logit": -4.248300075531006
        },
        {
            "text": "Escherichia colilac operon. Most studies of lac operon",
            "probability": 0.00011422090811546744,
            "start_logit": -2.903498649597168,
            "end_logit": -6.501662254333496
        }
    ],
    "63fa16d8201352f04a000002_001": [
        {
            "text": "colorectal cancer",
            "probability": 0.9980027262861682,
            "start_logit": 9.513215065002441,
            "end_logit": 8.600942611694336
        },
        {
            "text": "colorectal",
            "probability": 0.001636259065259171,
            "start_logit": 9.513215065002441,
            "end_logit": 2.1875991821289062
        },
        {
            "text": "cancer",
            "probability": 0.00021579919390785453,
            "start_logit": 1.074052095413208,
            "end_logit": 8.600942611694336
        },
        {
            "text": "color",
            "probability": 0.0001337852241528979,
            "start_logit": 9.513215065002441,
            "end_logit": -0.31633296608924866
        },
        {
            "text": "colorectal cancer.",
            "probability": 8.15384760969575e-06,
            "start_logit": 9.513215065002441,
            "end_logit": -3.1140787601470947
        },
        {
            "text": "RBFOX2 and PTBP1 is associated with metastasis in colorectal cancer",
            "probability": 9.522243869177409e-07,
            "start_logit": -4.349250793457031,
            "end_logit": 8.600942611694336
        },
        {
            "text": "Alternative microexon splicing by RBFOX2 and PTBP1 is associated with metastasis in colorectal cancer",
            "probability": 7.685145869972034e-07,
            "start_logit": -4.563591957092285,
            "end_logit": 8.600942611694336
        },
        {
            "text": "colorec",
            "probability": 7.186132091092108e-07,
            "start_logit": 9.513215065002441,
            "end_logit": -5.5430006980896
        },
        {
            "text": "PTBP1 is associated with metastasis in colorectal cancer",
            "probability": 2.8759951457576847e-07,
            "start_logit": -5.546482563018799,
            "end_logit": 8.600942611694336
        },
        {
            "text": "metastasis in colorectal cancer",
            "probability": 2.4614697397888373e-07,
            "start_logit": -5.702122688293457,
            "end_logit": 8.600942611694336
        },
        {
            "text": "in colorectal cancer",
            "probability": 1.614845598172933e-07,
            "start_logit": -6.1236419677734375,
            "end_logit": 8.600942611694336
        },
        {
            "text": "associated with metastasis in colorectal cancer",
            "probability": 9.805627461802886e-08,
            "start_logit": -6.622509956359863,
            "end_logit": 8.600942611694336
        },
        {
            "text": "is associated with metastasis in colorectal cancer",
            "probability": 3.785845015350255e-08,
            "start_logit": -7.574197292327881,
            "end_logit": 8.600942611694336
        },
        {
            "text": "cancer.",
            "probability": 1.7631151649933289e-09,
            "start_logit": 1.074052095413208,
            "end_logit": -3.1140787601470947
        },
        {
            "text": "RBFOX2 and PTBP1 is associated with metastasis in colorectal",
            "probability": 1.5612039368399913e-09,
            "start_logit": -4.349250793457031,
            "end_logit": 2.1875991821289062
        },
        {
            "text": "Alternative microexon splicing by RBFOX2 and PTBP1 is associated with metastasis in colorectal",
            "probability": 1.260005535693806e-09,
            "start_logit": -4.563591957092285,
            "end_logit": 2.1875991821289062
        },
        {
            "text": "PTBP1 is associated with metastasis in colorectal",
            "probability": 4.715290855365876e-10,
            "start_logit": -5.546482563018799,
            "end_logit": 2.1875991821289062
        },
        {
            "text": "metastasis in colorectal",
            "probability": 4.0356624982162023e-10,
            "start_logit": -5.702122688293457,
            "end_logit": 2.1875991821289062
        },
        {
            "text": "in colorectal",
            "probability": 2.6475937183428827e-10,
            "start_logit": -6.1236419677734375,
            "end_logit": 2.1875991821289062
        },
        {
            "text": "associated with metastasis in colorectal",
            "probability": 1.6076656307979482e-10,
            "start_logit": -6.622509956359863,
            "end_logit": 2.1875991821289062
        }
    ],
    "63fa16d8201352f04a000002_002": [
        {
            "text": "CRC",
            "probability": 0.997102427559721,
            "start_logit": 9.832874298095703,
            "end_logit": 9.451995849609375
        },
        {
            "text": "CR",
            "probability": 0.002888885547120751,
            "start_logit": 9.832874298095703,
            "end_logit": 3.608013153076172
        },
        {
            "text": "we found that changes in the pattern of microexon splicing were associated with CRC",
            "probability": 3.3813317714901452e-06,
            "start_logit": -2.761464834213257,
            "end_logit": 9.451995849609375
        },
        {
            "text": "CRC metastasis.",
            "probability": 3.215368175786821e-06,
            "start_logit": 9.832874298095703,
            "end_logit": -3.192671060562134
        },
        {
            "text": "CRC metastasis. Our data thus suggest that altered expression of RBFOX2 and PTBP1 might influence CRC",
            "probability": 6.560030826959718e-07,
            "start_logit": 9.832874298095703,
            "end_logit": -4.78220272064209
        },
        {
            "text": "CRC metastasis",
            "probability": 3.5584219663144947e-07,
            "start_logit": 9.832874298095703,
            "end_logit": -5.393880844116211
        },
        {
            "text": "Finally, we found that changes in the pattern of microexon splicing were associated with CRC",
            "probability": 2.0650765646988026e-07,
            "start_logit": -5.557152271270752,
            "end_logit": 9.451995849609375
        },
        {
            "text": "CRC metastasis. Our data thus suggest that altered expression of RBFOX2 and PTBP1",
            "probability": 1.534647033957799e-07,
            "start_logit": 9.832874298095703,
            "end_logit": -6.234897613525391
        },
        {
            "text": "CRC metastasis. Our data thus suggest that altered expression of RBFOX2",
            "probability": 1.3051654233206093e-07,
            "start_logit": 9.832874298095703,
            "end_logit": -6.3968682289123535
        },
        {
            "text": "changes in the pattern of microexon splicing were associated with CRC",
            "probability": 9.603598639115168e-08,
            "start_logit": -6.3227667808532715,
            "end_logit": 9.451995849609375
        },
        {
            "text": "CRC metastasis. Our data",
            "probability": 9.340704450210343e-08,
            "start_logit": 9.832874298095703,
            "end_logit": -6.731401443481445
        },
        {
            "text": "CRC metastasis. Our data thus suggest",
            "probability": 8.315816390931989e-08,
            "start_logit": 9.832874298095703,
            "end_logit": -6.847623825073242
        },
        {
            "text": "CRC metastasis. Our data thus suggest that altered expression of RBFOX2 and PTBP1 might influence CRC metastasis",
            "probability": 7.723721143092641e-08,
            "start_logit": 9.832874298095703,
            "end_logit": -6.921486854553223
        },
        {
            "text": "CRC metastasis. Our",
            "probability": 7.639738225368955e-08,
            "start_logit": 9.832874298095703,
            "end_logit": -6.932419776916504
        },
        {
            "text": "CRC metastasis. Our data thus",
            "probability": 6.039998336545402e-08,
            "start_logit": 9.832874298095703,
            "end_logit": -7.167379379272461
        },
        {
            "text": "microexon splicing were associated with CRC",
            "probability": 4.863201586915039e-08,
            "start_logit": -7.003207683563232,
            "end_logit": 9.451995849609375
        },
        {
            "text": "found that changes in the pattern of microexon splicing were associated with CRC",
            "probability": 4.1918021033349304e-08,
            "start_logit": -7.151773929595947,
            "end_logit": 9.451995849609375
        },
        {
            "text": "we found that changes in the pattern of microexon splicing were associated with CR",
            "probability": 9.796667037091352e-09,
            "start_logit": -2.761464834213257,
            "end_logit": 3.608013153076172
        },
        {
            "text": "Finally, we found that changes in the pattern of microexon splicing were associated with CR",
            "probability": 5.98310632545203e-10,
            "start_logit": -5.557152271270752,
            "end_logit": 3.608013153076172
        },
        {
            "text": "changes in the pattern of microexon splicing were associated with CR",
            "probability": 2.7824320292537475e-10,
            "start_logit": -6.3227667808532715,
            "end_logit": 3.608013153076172
        }
    ],
    "6451060c57b1c7a315000096_001": [
        {
            "text": "Kennedy's disease is nearly exclusively caused by mutations in the androgen receptor encoding gene (AR).",
            "probability": 0.34443198370595146,
            "start_logit": 4.757884502410889,
            "end_logit": 0.6249831914901733
        },
        {
            "text": "Kennedy",
            "probability": 0.29340711781396495,
            "start_logit": 4.757884502410889,
            "end_logit": 0.46464768052101135
        },
        {
            "text": "Kennedy's disease",
            "probability": 0.26771365043156015,
            "start_logit": 4.757884502410889,
            "end_logit": 0.3730044960975647
        },
        {
            "text": "androgen receptor encoding gene (AR).",
            "probability": 0.04273720425237813,
            "start_logit": 2.67105770111084,
            "end_logit": 0.6249831914901733
        },
        {
            "text": "Kennedy's disease is nearly exclusively caused by mutations in the androgen receptor encoding gene (AR)",
            "probability": 0.030692365879570475,
            "start_logit": 4.757884502410889,
            "end_logit": -1.792899489402771
        },
        {
            "text": "Kennedy's disease is nearly exclusively caused by mutations in the androgen receptor encoding gene",
            "probability": 0.007070540251947533,
            "start_logit": 4.757884502410889,
            "end_logit": -3.260976552963257
        },
        {
            "text": "androgen receptor encoding gene (AR)",
            "probability": 0.0038083162181121793,
            "start_logit": 2.67105770111084,
            "end_logit": -1.792899489402771
        },
        {
            "text": "Kennedy's disease is nearly exclusively caused by mutations in the androgen",
            "probability": 0.0024810931690631335,
            "start_logit": 4.757884502410889,
            "end_logit": -4.30821418762207
        },
        {
            "text": "Kennedy's disease is nearly exclusively caused by mutations in the androgen receptor encoding gene (AR",
            "probability": 0.0019042550340502735,
            "start_logit": 4.757884502410889,
            "end_logit": -4.572822570800781
        },
        {
            "text": "Kennedy's disease is nearly exclusively caused by mutations",
            "probability": 0.001210581495266285,
            "start_logit": 4.757884502410889,
            "end_logit": -5.02581262588501
        },
        {
            "text": "Kennedy's disease is nearly exclusively caused by mutations in the androgen receptor",
            "probability": 0.001044550816506684,
            "start_logit": 4.757884502410889,
            "end_logit": -5.17332649230957
        },
        {
            "text": "androgen receptor encoding gene",
            "probability": 0.0008773143529554327,
            "start_logit": 2.67105770111084,
            "end_logit": -3.260976552963257
        },
        {
            "text": "Kennedy's disease is nearly exclusively caused by mutations in the and",
            "probability": 0.000783560321593151,
            "start_logit": 4.757884502410889,
            "end_logit": -5.46082067489624
        },
        {
            "text": "mutations in the androgen receptor encoding gene (AR).",
            "probability": 0.0003933549473134924,
            "start_logit": -2.017055034637451,
            "end_logit": 0.6249831914901733
        },
        {
            "text": "Kennedy's",
            "probability": 0.0003609316805116733,
            "start_logit": 4.757884502410889,
            "end_logit": -6.235980033874512
        },
        {
            "text": "androgen",
            "probability": 0.00030785464344668844,
            "start_logit": 2.67105770111084,
            "end_logit": -4.30821418762207
        },
        {
            "text": "androgen receptor encoding gene (AR",
            "probability": 0.00023628042745386777,
            "start_logit": 2.67105770111084,
            "end_logit": -4.572822570800781
        },
        {
            "text": "Kennedy's disease is nearly exclusively caused by mutations in the androgen receptor encoding",
            "probability": 0.00020669890947691097,
            "start_logit": 4.757884502410889,
            "end_logit": -6.793405532836914
        },
        {
            "text": "Kennedy's disease is nearly exclusively caused by mutations in",
            "probability": 0.00020273752968728428,
            "start_logit": 4.757884502410889,
            "end_logit": -6.812756538391113
        },
        {
            "text": "androgen receptor",
            "probability": 0.00012960811919007382,
            "start_logit": 2.67105770111084,
            "end_logit": -5.17332649230957
        }
    ],
    "6451060c57b1c7a315000096_002": [
        {
            "text": "androgen receptor (AR) gene, and mutant AR is presumed to act in motoneurons to cause SBMA.",
            "probability": 0.317742492060714,
            "start_logit": 8.032177925109863,
            "end_logit": -0.5365789532661438
        },
        {
            "text": "androgen receptor (AR) gene,",
            "probability": 0.3104722152865952,
            "start_logit": 8.032177925109863,
            "end_logit": -0.559725821018219
        },
        {
            "text": "androgen receptor",
            "probability": 0.12669428644959813,
            "start_logit": 8.032177925109863,
            "end_logit": -1.4560432434082031
        },
        {
            "text": "and",
            "probability": 0.06763375413491204,
            "start_logit": 8.032177925109863,
            "end_logit": -2.0837130546569824
        },
        {
            "text": "androgen receptor (AR) gene",
            "probability": 0.06224465477382736,
            "start_logit": 8.032177925109863,
            "end_logit": -2.166747570037842
        },
        {
            "text": "androgen receptor (AR)",
            "probability": 0.06082281087442544,
            "start_logit": 8.032177925109863,
            "end_logit": -2.1898553371429443
        },
        {
            "text": "androgen receptor (AR",
            "probability": 0.0335098056727738,
            "start_logit": 8.032177925109863,
            "end_logit": -2.785982131958008
        },
        {
            "text": "androgen",
            "probability": 0.01127947277316314,
            "start_logit": 8.032177925109863,
            "end_logit": -3.874835729598999
        },
        {
            "text": "androgen receptor (AR) gene, and mutant AR is presumed to act in motoneurons",
            "probability": 0.007823782632940248,
            "start_logit": 8.032177925109863,
            "end_logit": -4.240652084350586
        },
        {
            "text": "androgen receptor (AR) gene, and",
            "probability": 0.0008486810051392151,
            "start_logit": 8.032177925109863,
            "end_logit": -6.461892127990723
        },
        {
            "text": "Spinal bulbar muscular atrophy (SBMA) is caused by a CAG repeat expansion mutation",
            "probability": 0.00033667020292292425,
            "start_logit": 1.3965040445327759,
            "end_logit": -0.7507978081703186
        },
        {
            "text": "Spinal bulbar muscular atrophy (SBMA) is caused by a CAG repeat expansion mutation in the androgen receptor",
            "probability": 0.00016631081041789127,
            "start_logit": 1.3965040445327759,
            "end_logit": -1.4560432434082031
        },
        {
            "text": "Spinal bulbar muscular atrophy (SBMA) is caused by a CAG repeat expansion mutation in the and",
            "probability": 8.878241298005516e-05,
            "start_logit": 1.3965040445327759,
            "end_logit": -2.0837130546569824
        },
        {
            "text": "Spinal bulbar muscular atrophy (SBMA) is caused by a CAG repeat expansion mutation in the androgen receptor (AR)",
            "probability": 7.984172966192913e-05,
            "start_logit": 1.3965040445327759,
            "end_logit": -2.1898553371429443
        },
        {
            "text": "a CAG repeat expansion mutation in the androgen receptor (AR) gene,",
            "probability": 7.971999612738923e-05,
            "start_logit": -0.23515132069587708,
            "end_logit": -0.559725821018219
        },
        {
            "text": "a CAG repeat expansion mutation",
            "probability": 6.585454587627461e-05,
            "start_logit": -0.23515132069587708,
            "end_logit": -0.7507978081703186
        },
        {
            "text": "Spinal bulbar muscular atrophy (SBMA) is caused by a CAG repeat expansion mutation in the androgen receptor (AR",
            "probability": 4.3988115759285986e-05,
            "start_logit": 1.3965040445327759,
            "end_logit": -2.785982131958008
        },
        {
            "text": "a CAG repeat expansion mutation in the androgen receptor",
            "probability": 3.2531310461391815e-05,
            "start_logit": -0.23515132069587708,
            "end_logit": -1.4560432434082031
        },
        {
            "text": "a CAG repeat expansion mutation in the and",
            "probability": 1.7366328941025778e-05,
            "start_logit": -0.23515132069587708,
            "end_logit": -2.0837130546569824
        },
        {
            "text": "Spinal bulbar muscular atrophy (SBMA",
            "probability": 1.6978882763025448e-05,
            "start_logit": 1.3965040445327759,
            "end_logit": -3.737931251525879
        }
    ],
    "6451060c57b1c7a315000096_003": [
        {
            "text": "androgen receptor (AR) gene.",
            "probability": 0.6612248333051612,
            "start_logit": 5.390405178070068,
            "end_logit": -0.7285488247871399
        },
        {
            "text": "androgen receptor (AR) gene",
            "probability": 0.1813869618562618,
            "start_logit": 5.390405178070068,
            "end_logit": -2.022010087966919
        },
        {
            "text": "androgen receptor",
            "probability": 0.05278121645309748,
            "start_logit": 5.390405178070068,
            "end_logit": -3.2564873695373535
        },
        {
            "text": "a CAG trinucleotide repeat expansion",
            "probability": 0.04399426631188174,
            "start_logit": -0.5343824028968811,
            "end_logit": 2.486204147338867
        },
        {
            "text": "and",
            "probability": 0.028204517406540258,
            "start_logit": 5.390405178070068,
            "end_logit": -3.8831605911254883
        },
        {
            "text": "androgen receptor (AR",
            "probability": 0.013993801813047308,
            "start_logit": 5.390405178070068,
            "end_logit": -4.584028244018555
        },
        {
            "text": "SBMA), an inherited neuromuscular disorder caused by a CAG trinucleotide repeat expansion",
            "probability": 0.005884603900648032,
            "start_logit": -2.546102285385132,
            "end_logit": 2.486204147338867
        },
        {
            "text": "androgen receptor (AR)",
            "probability": 0.0055280065563903455,
            "start_logit": 5.390405178070068,
            "end_logit": -5.512815475463867
        },
        {
            "text": "androgen",
            "probability": 0.002917898230852808,
            "start_logit": 5.390405178070068,
            "end_logit": -6.1517791748046875
        },
        {
            "text": "a CAG trinucleotide repeat expansion in the androgen receptor (AR) gene.",
            "probability": 0.0017670409045265046,
            "start_logit": -0.5343824028968811,
            "end_logit": -0.7285488247871399
        },
        {
            "text": "a CAG trinucleotide repeat expansion in the androgen receptor (AR) gene",
            "probability": 0.00048473403448215824,
            "start_logit": -0.5343824028968811,
            "end_logit": -2.022010087966919
        },
        {
            "text": "expansion",
            "probability": 0.0003522815302818592,
            "start_logit": -5.361766338348389,
            "end_logit": 2.486204147338867
        },
        {
            "text": "CAG trinucleotide repeat expansion",
            "probability": 0.000283299902586871,
            "start_logit": -5.579690933227539,
            "end_logit": 2.486204147338867
        },
        {
            "text": "an inherited neuromuscular disorder caused by a CAG trinucleotide repeat expansion",
            "probability": 0.00027114138000825525,
            "start_logit": -5.623556613922119,
            "end_logit": 2.486204147338867
        },
        {
            "text": "spinal and bulbar muscular atrophy (SBMA)",
            "probability": 0.00020607796589244674,
            "start_logit": -0.5368071794509888,
            "end_logit": -2.8749310970306396
        },
        {
            "text": "(SBMA), an inherited neuromuscular disorder caused by a CAG trinucleotide repeat expansion",
            "probability": 0.00016304547996039145,
            "start_logit": -6.132167816162109,
            "end_logit": 2.486204147338867
        },
        {
            "text": "by a CAG trinucleotide repeat expansion",
            "probability": 0.0001543461296112062,
            "start_logit": -6.186999320983887,
            "end_logit": 2.486204147338867
        },
        {
            "text": "a CAG trinucleotide repeat expansion in the androgen receptor",
            "probability": 0.00014105121853499297,
            "start_logit": -0.5343824028968811,
            "end_logit": -3.2564873695373535
        },
        {
            "text": "neuromuscular disorder caused by a CAG trinucleotide repeat expansion",
            "probability": 0.00013413738012353507,
            "start_logit": -6.327332496643066,
            "end_logit": 2.486204147338867
        },
        {
            "text": "spinal and bulbar muscular atrophy (SBMA),",
            "probability": 0.00012673824011072868,
            "start_logit": -0.5368071794509888,
            "end_logit": -3.3610618114471436
        }
    ],
    "61f7c904882a024a10000027_001": [
        {
            "text": "asthma",
            "probability": 0.9997990561999152,
            "start_logit": 9.268304824829102,
            "end_logit": 9.380263328552246
        },
        {
            "text": "as",
            "probability": 0.00015449600456716726,
            "start_logit": 9.268304824829102,
            "end_logit": 0.6051219701766968
        },
        {
            "text": "asthma that is effective also in nontype 2 asthma",
            "probability": 3.16379193994986e-05,
            "start_logit": 9.268304824829102,
            "end_logit": -0.9806898832321167
        },
        {
            "text": "asthma that is effective also in nontype 2 asthma.",
            "probability": 4.593766308999342e-06,
            "start_logit": 9.268304824829102,
            "end_logit": -2.910346031188965
        },
        {
            "text": "TSLP monoclonal antibody, is a promising alternative treatment for asthma",
            "probability": 4.465591220736582e-06,
            "start_logit": -3.050603151321411,
            "end_logit": 9.380263328552246
        },
        {
            "text": "asth",
            "probability": 4.4460736981492935e-06,
            "start_logit": 9.268304824829102,
            "end_logit": -2.9430248737335205
        },
        {
            "text": "tezepelumab, an anti-TSLP monoclonal antibody, is a promising alternative treatment for asthma",
            "probability": 2.8835480865647333e-07,
            "start_logit": -5.7905683517456055,
            "end_logit": 9.380263328552246
        },
        {
            "text": "anti-TSLP monoclonal antibody, is a promising alternative treatment for asthma",
            "probability": 2.0091753812487253e-07,
            "start_logit": -6.151865482330322,
            "end_logit": 9.380263328552246
        },
        {
            "text": "asthma that",
            "probability": 1.913789980892202e-07,
            "start_logit": 9.268304824829102,
            "end_logit": -6.088545799255371
        },
        {
            "text": "demonstrated that tezepelumab, an anti-TSLP monoclonal antibody, is a promising alternative treatment for asthma",
            "probability": 1.3592550309905435e-07,
            "start_logit": -6.5426530838012695,
            "end_logit": 9.380263328552246
        },
        {
            "text": "an anti-TSLP monoclonal antibody, is a promising alternative treatment for asthma",
            "probability": 1.115081798613377e-07,
            "start_logit": -6.740662097930908,
            "end_logit": 9.380263328552246
        },
        {
            "text": "for asthma",
            "probability": 9.062205610004904e-08,
            "start_logit": -6.948062419891357,
            "end_logit": 9.380263328552246
        },
        {
            "text": "treatment for asthma",
            "probability": 8.2675567101753e-08,
            "start_logit": -7.0398359298706055,
            "end_logit": 9.380263328552246
        },
        {
            "text": "alternative treatment for asthma",
            "probability": 7.982437455841752e-08,
            "start_logit": -7.0749311447143555,
            "end_logit": 9.380263328552246
        },
        {
            "text": "a promising alternative treatment for asthma",
            "probability": 7.565126625088627e-08,
            "start_logit": -7.128625869750977,
            "end_logit": 9.380263328552246
        },
        {
            "text": "asthma that is effective also in nontype 2",
            "probability": 4.666374308187728e-08,
            "start_logit": 9.268304824829102,
            "end_logit": -7.499834060668945
        },
        {
            "text": "TSLP monoclonal antibody, is a promising alternative treatment for as",
            "probability": 6.900546638404394e-10,
            "start_logit": -3.050603151321411,
            "end_logit": 0.6051219701766968
        },
        {
            "text": "TSLP monoclonal antibody, is a promising alternative treatment for asthma that is effective also in nontype 2 asthma",
            "probability": 1.4131041056366278e-10,
            "start_logit": -3.050603151321411,
            "end_logit": -0.9806898832321167
        },
        {
            "text": "nontype 2 asthma",
            "probability": 4.693147688377578e-11,
            "start_logit": -4.152873516082764,
            "end_logit": -0.9806898832321167
        },
        {
            "text": "tezepelumab, an anti-TSLP monoclonal antibody, is a promising alternative treatment for as",
            "probability": 4.4558619613506816e-11,
            "start_logit": -5.7905683517456055,
            "end_logit": 0.6051219701766968
        }
    ],
    "61f7c904882a024a10000027_002": [
        {
            "text": "asthma",
            "probability": 0.9997489730973265,
            "start_logit": 8.773038864135742,
            "end_logit": 8.504335403442383
        },
        {
            "text": "as",
            "probability": 0.00019614098932895174,
            "start_logit": 8.773038864135742,
            "end_logit": -0.032090362161397934
        },
        {
            "text": "asthma.",
            "probability": 3.963080496535972e-05,
            "start_logit": -1.3626139163970947,
            "end_logit": 8.504335403442383
        },
        {
            "text": "severe, uncontrolled asthma",
            "probability": 6.9489234951687305e-06,
            "start_logit": -3.1036338806152344,
            "end_logit": 8.504335403442383
        },
        {
            "text": "Tezepelumab in adults and adolescents with severe, uncontrolled asthma",
            "probability": 5.139747437235209e-06,
            "start_logit": -3.405216693878174,
            "end_logit": 8.504335403442383
        },
        {
            "text": "asth",
            "probability": 2.3673453983200454e-06,
            "start_logit": 8.773038864135742,
            "end_logit": -4.449154853820801
        },
        {
            "text": "with severe, uncontrolled asthma",
            "probability": 2.385413247679077e-07,
            "start_logit": -6.475433349609375,
            "end_logit": 8.504335403442383
        },
        {
            "text": "uncontrolled asthma",
            "probability": 1.9204705969580207e-07,
            "start_logit": -6.692235469818115,
            "end_logit": 8.504335403442383
        },
        {
            "text": "in adults and adolescents with severe, uncontrolled asthma",
            "probability": 1.3270906115890273e-07,
            "start_logit": -7.061816692352295,
            "end_logit": 8.504335403442383
        },
        {
            "text": "adolescents with severe, uncontrolled asthma",
            "probability": 8.114071488505741e-08,
            "start_logit": -7.553791046142578,
            "end_logit": 8.504335403442383
        },
        {
            "text": "adults and adolescents with severe, uncontrolled asthma",
            "probability": 8.020794067173911e-08,
            "start_logit": -7.5653533935546875,
            "end_logit": 8.504335403442383
        },
        {
            "text": "and adolescents with severe, uncontrolled asthma",
            "probability": 7.184960970630468e-08,
            "start_logit": -7.675400733947754,
            "end_logit": 8.504335403442383
        },
        {
            "text": "severe, uncontrolled as",
            "probability": 1.3633109568404683e-09,
            "start_logit": -3.1036338806152344,
            "end_logit": -0.032090362161397934
        },
        {
            "text": "Tezepelumab in adults and adolescents with severe, uncontrolled as",
            "probability": 1.0083682748050366e-09,
            "start_logit": -3.405216693878174,
            "end_logit": -0.032090362161397934
        },
        {
            "text": "severe, uncontrolled asthma.",
            "probability": 5.615518047494483e-11,
            "start_logit": -3.1036338806152344,
            "end_logit": -3.2216429710388184
        },
        {
            "text": "with severe, uncontrolled as",
            "probability": 4.679947936416771e-11,
            "start_logit": -6.475433349609375,
            "end_logit": -0.032090362161397934
        },
        {
            "text": "Tezepelumab in adults and adolescents with severe, uncontrolled asthma.",
            "probability": 4.153498669747121e-11,
            "start_logit": -3.405216693878174,
            "end_logit": -3.2216429710388184
        },
        {
            "text": "uncontrolled as",
            "probability": 3.7677758417446084e-11,
            "start_logit": -6.692235469818115,
            "end_logit": -0.032090362161397934
        },
        {
            "text": "in adults and adolescents with severe, uncontrolled as",
            "probability": 2.6036222340875093e-11,
            "start_logit": -7.061816692352295,
            "end_logit": -0.032090362161397934
        },
        {
            "text": "severe, uncontrolled asth",
            "probability": 1.645463261502572e-11,
            "start_logit": -3.1036338806152344,
            "end_logit": -4.449154853820801
        }
    ],
    "61f7c904882a024a10000027_003": [
        {
            "text": "asthma",
            "probability": 0.9998269809268084,
            "start_logit": 8.613444328308105,
            "end_logit": 8.669942855834961
        },
        {
            "text": "as",
            "probability": 0.00010581071026534573,
            "start_logit": 8.613444328308105,
            "end_logit": -0.48374292254447937
        },
        {
            "text": "asthma,",
            "probability": 3.9246125218774196e-05,
            "start_logit": -1.5320404767990112,
            "end_logit": 8.669942855834961
        },
        {
            "text": "In severe, uncontrolled asthma",
            "probability": 1.3297160365775145e-05,
            "start_logit": -2.61434268951416,
            "end_logit": 8.669942855834961
        },
        {
            "text": "severe, uncontrolled asthma",
            "probability": 8.593303177126442e-06,
            "start_logit": -3.050909996032715,
            "end_logit": 8.669942855834961
        },
        {
            "text": "asthma, tezepelumab reduced exacerbations and improved asthma control at 1 y.",
            "probability": 3.636653497548727e-06,
            "start_logit": 8.613444328308105,
            "end_logit": -3.8543307781219482
        },
        {
            "text": "asth",
            "probability": 1.3885046628926695e-06,
            "start_logit": 8.613444328308105,
            "end_logit": -4.817167282104492
        },
        {
            "text": "uncontrolled asthma",
            "probability": 2.157453005575489e-07,
            "start_logit": -6.7355499267578125,
            "end_logit": 8.669942855834961
        },
        {
            "text": "asthma, tezepelumab reduced exacerbations and improved asthma control at 1 y",
            "probability": 1.8932248714579427e-07,
            "start_logit": 8.613444328308105,
            "end_logit": -6.809698104858398
        },
        {
            "text": "asthma, tezepelumab reduced exacerbations",
            "probability": 1.7212267245675107e-07,
            "start_logit": 8.613444328308105,
            "end_logit": -6.904942512512207
        },
        {
            "text": "asthma, tezepelumab",
            "probability": 1.2777086852110807e-07,
            "start_logit": 8.613444328308105,
            "end_logit": -7.202911376953125
        },
        {
            "text": "asthma, tezepelumab reduced exacerbations and improved asthma",
            "probability": 1.2046608422063554e-07,
            "start_logit": 8.613444328308105,
            "end_logit": -7.261781692504883
        },
        {
            "text": "asthma, tezepelumab reduced exacerbations and improved asthma control",
            "probability": 8.995343465587822e-08,
            "start_logit": 8.613444328308105,
            "end_logit": -7.553857803344727
        },
        {
            "text": "asthma, tezepelumab reduced exacerbations and",
            "probability": 7.00065833687992e-08,
            "start_logit": 8.613444328308105,
            "end_logit": -7.804560661315918
        },
        {
            "text": "asthma, tezepelumab reduced exacerbations and improved asthma control at",
            "probability": 5.883937235243034e-08,
            "start_logit": 8.613444328308105,
            "end_logit": -7.978338718414307
        },
        {
            "text": "In severe, uncontrolled as",
            "probability": 1.4072254596596745e-09,
            "start_logit": -2.61434268951416,
            "end_logit": -0.48374292254447937
        },
        {
            "text": "severe, uncontrolled as",
            "probability": 9.094208598515136e-10,
            "start_logit": -3.050909996032715,
            "end_logit": -0.48374292254447937
        },
        {
            "text": "severe, uncontrolled asthma, tezepelumab reduced exacerbations and improved asthma control at 1 y.",
            "probability": 3.125627398614997e-11,
            "start_logit": -3.050909996032715,
            "end_logit": -3.8543307781219482
        },
        {
            "text": "uncontrolled as",
            "probability": 2.283211387958719e-11,
            "start_logit": -6.7355499267578125,
            "end_logit": -0.48374292254447937
        },
        {
            "text": "In severe, uncontrolled asth",
            "probability": 1.8466364204330236e-11,
            "start_logit": -2.61434268951416,
            "end_logit": -4.817167282104492
        }
    ],
    "61f7c904882a024a10000027_004": [
        {
            "text": "asthma",
            "probability": 0.9991898879764768,
            "start_logit": 9.072813034057617,
            "end_logit": 8.251805305480957
        },
        {
            "text": "as",
            "probability": 0.0007566883974597521,
            "start_logit": 9.072813034057617,
            "end_logit": 1.066056728363037
        },
        {
            "text": "asthma.",
            "probability": 4.0041717450699624e-05,
            "start_logit": -1.0519652366638184,
            "end_logit": 8.251805305480957
        },
        {
            "text": "severe asthma",
            "probability": 5.92134847372478e-06,
            "start_logit": -2.963322877883911,
            "end_logit": 8.251805305480957
        },
        {
            "text": "asth",
            "probability": 5.278112156568284e-06,
            "start_logit": 9.072813034057617,
            "end_logit": -3.8993263244628906
        },
        {
            "text": "uncontrolled severe asthma",
            "probability": 7.195881106870273e-07,
            "start_logit": -5.070963382720947,
            "end_logit": 8.251805305480957
        },
        {
            "text": "the biological treatment of uncontrolled severe asthma",
            "probability": 5.009665227444993e-07,
            "start_logit": -5.433103084564209,
            "end_logit": 8.251805305480957
        },
        {
            "text": "alarmins are thus likely to become, in the near future, valuable therapeutic options for the biological treatment of uncontrolled severe asthma",
            "probability": 2.9141845871487677e-07,
            "start_logit": -5.974882125854492,
            "end_logit": 8.251805305480957
        },
        {
            "text": "biological treatment of uncontrolled severe asthma",
            "probability": 2.119954672771175e-07,
            "start_logit": -6.29307746887207,
            "end_logit": 8.251805305480957
        },
        {
            "text": "in the near future, valuable therapeutic options for the biological treatment of uncontrolled severe asthma",
            "probability": 1.628548255636551e-07,
            "start_logit": -6.556783199310303,
            "end_logit": 8.251805305480957
        },
        {
            "text": "the near future, valuable therapeutic options for the biological treatment of uncontrolled severe asthma",
            "probability": 1.1070595180921002e-07,
            "start_logit": -6.942764759063721,
            "end_logit": 8.251805305480957
        },
        {
            "text": "treatment of uncontrolled severe asthma",
            "probability": 9.424981630307111e-08,
            "start_logit": -7.10369348526001,
            "end_logit": 8.251805305480957
        },
        {
            "text": "near future, valuable therapeutic options for the biological treatment of uncontrolled severe asthma",
            "probability": 8.443722411756553e-08,
            "start_logit": -7.213634014129639,
            "end_logit": 8.251805305480957
        },
        {
            "text": "severe as",
            "probability": 4.484248430953934e-09,
            "start_logit": -2.963322877883911,
            "end_logit": 1.066056728363037
        },
        {
            "text": "uncontrolled severe as",
            "probability": 5.449454411609059e-10,
            "start_logit": -5.070963382720947,
            "end_logit": 1.066056728363037
        },
        {
            "text": "the biological treatment of uncontrolled severe as",
            "probability": 3.793828979236466e-10,
            "start_logit": -5.433103084564209,
            "end_logit": 1.066056728363037
        },
        {
            "text": "anti-alarmins are thus likely to become, in the near future, valuable therapeutic options for the biological treatment of uncontrolled severe as",
            "probability": 3.1846190928164367e-10,
            "start_logit": -5.6081461906433105,
            "end_logit": 1.066056728363037
        },
        {
            "text": "alarmins are thus likely to become, in the near future, valuable therapeutic options for the biological treatment of uncontrolled severe as",
            "probability": 2.206917515565794e-10,
            "start_logit": -5.974882125854492,
            "end_logit": 1.066056728363037
        },
        {
            "text": "biological treatment of uncontrolled severe as",
            "probability": 1.605445694887075e-10,
            "start_logit": -6.29307746887207,
            "end_logit": 1.066056728363037
        },
        {
            "text": "in the near future, valuable therapeutic options for the biological treatment of uncontrolled severe as",
            "probability": 1.2333026830756995e-10,
            "start_logit": -6.556783199310303,
            "end_logit": 1.066056728363037
        }
    ],
    "61f7c904882a024a10000027_005": [
        {
            "text": "asthma",
            "probability": 0.9998380807269326,
            "start_logit": 9.690119743347168,
            "end_logit": 9.099287033081055
        },
        {
            "text": "as",
            "probability": 0.00011960500558607174,
            "start_logit": 9.690119743347168,
            "end_logit": 0.06813310086727142
        },
        {
            "text": "asthma,",
            "probability": 2.995086622558823e-05,
            "start_logit": -0.7256706357002258,
            "end_logit": 9.099287033081055
        },
        {
            "text": "asth",
            "probability": 9.303201618919926e-06,
            "start_logit": 9.690119743347168,
            "end_logit": -2.4857029914855957
        },
        {
            "text": "asthma, by specifically blocking the interaction between IgE, IL-4, and TSLP,",
            "probability": 1.6860402571433278e-06,
            "start_logit": 9.690119743347168,
            "end_logit": -4.193678855895996
        },
        {
            "text": "asthma, by specifically blocking the interaction between IgE, IL-4, and TSLP",
            "probability": 2.2070429801222402e-07,
            "start_logit": 9.690119743347168,
            "end_logit": -6.226993083953857
        },
        {
            "text": "asthma, by specifically blocking the interaction between IgE, IL-4",
            "probability": 2.0582754735547943e-07,
            "start_logit": 9.690119743347168,
            "end_logit": -6.296778202056885
        },
        {
            "text": "Omalizumab, dupilumab, and tezepelumab can directly modulate the ASM in asthma",
            "probability": 1.7175441151450274e-07,
            "start_logit": -5.886918544769287,
            "end_logit": 9.099287033081055
        },
        {
            "text": "asthma, by specifically blocking the interaction between IgE",
            "probability": 1.365968727843362e-07,
            "start_logit": 9.690119743347168,
            "end_logit": -6.706782817840576
        },
        {
            "text": "ASM in asthma",
            "probability": 1.2997608640184852e-07,
            "start_logit": -6.165633678436279,
            "end_logit": 9.099287033081055
        },
        {
            "text": "asthma, by specifically blocking the interaction between IgE, IL-4,",
            "probability": 1.1240375016069845e-07,
            "start_logit": 9.690119743347168,
            "end_logit": -6.901719570159912
        },
        {
            "text": "dupilumab, and tezepelumab can directly modulate the ASM in asthma",
            "probability": 8.514639605881889e-08,
            "start_logit": -6.588612079620361,
            "end_logit": 9.099287033081055
        },
        {
            "text": "tezepelumab can directly modulate the ASM in asthma",
            "probability": 8.2075879268799e-08,
            "start_logit": -6.625339984893799,
            "end_logit": 9.099287033081055
        },
        {
            "text": "asthma, by specifically blocking the interaction between IgE, IL-4, and TSLP, and their receptors",
            "probability": 6.201095941469949e-08,
            "start_logit": 9.690119743347168,
            "end_logit": -7.4965057373046875
        },
        {
            "text": "modulate the ASM in asthma",
            "probability": 4.60670112600883e-08,
            "start_logit": -7.202887058258057,
            "end_logit": 9.099287033081055
        },
        {
            "text": "in asthma",
            "probability": 4.47754698822586e-08,
            "start_logit": -7.231323719024658,
            "end_logit": 9.099287033081055
        },
        {
            "text": "directly modulate the ASM in asthma",
            "probability": 4.354081226490054e-08,
            "start_logit": -7.2592854499816895,
            "end_logit": 9.099287033081055
        },
        {
            "text": "can directly modulate the ASM in asthma",
            "probability": 3.324379082302772e-08,
            "start_logit": -7.529116153717041,
            "end_logit": 9.099287033081055
        },
        {
            "text": "Omalizumab, dupilumab, and tezepelumab can directly modulate the ASM in as",
            "probability": 2.0546014144299237e-11,
            "start_logit": -5.886918544769287,
            "end_logit": 0.06813310086727142
        },
        {
            "text": "ASM in as",
            "probability": 1.554830811089558e-11,
            "start_logit": -6.165633678436279,
            "end_logit": 0.06813310086727142
        }
    ],
    "61f7c904882a024a10000027_006": [
        {
            "text": "eosinophilic asthma",
            "probability": 0.9622225691189743,
            "start_logit": 8.988980293273926,
            "end_logit": 9.791708946228027
        },
        {
            "text": "asthma",
            "probability": 0.037698393083455614,
            "start_logit": 5.749351978302002,
            "end_logit": 9.791708946228027
        },
        {
            "text": "eosinophilic asthma,",
            "probability": 4.482188620883236e-05,
            "start_logit": 8.988980293273926,
            "end_logit": -0.18259556591510773
        },
        {
            "text": "asthma,",
            "probability": 2.1473430288812203e-05,
            "start_logit": -1.721204400062561,
            "end_logit": 9.791708946228027
        },
        {
            "text": "e",
            "probability": 5.864118398399413e-06,
            "start_logit": 8.988980293273926,
            "end_logit": -2.216439962387085
        },
        {
            "text": "AHR has been suggested as the main treatable trait towards precision medicine in patients suffering from eosinophilic asthma",
            "probability": 4.0846099705095684e-06,
            "start_logit": -3.3807945251464844,
            "end_logit": 9.791708946228027
        },
        {
            "text": "eosinophilic as",
            "probability": 2.0600403109312853e-06,
            "start_logit": 8.988980293273926,
            "end_logit": -3.262566566467285
        },
        {
            "text": "eosinophilic",
            "probability": 3.1309921029895484e-07,
            "start_logit": 8.988980293273926,
            "end_logit": -5.146527290344238
        },
        {
            "text": "precision medicine in patients suffering from eosinophilic asthma",
            "probability": 1.1178331778981205e-07,
            "start_logit": -6.979213714599609,
            "end_logit": 9.791708946228027
        },
        {
            "text": "patients suffering from eosinophilic asthma",
            "probability": 1.0071912936882424e-07,
            "start_logit": -7.08344030380249,
            "end_logit": 9.791708946228027
        },
        {
            "text": "eosinophilic asth",
            "probability": 9.607763124844188e-08,
            "start_logit": 8.988980293273926,
            "end_logit": -6.327890872955322
        },
        {
            "text": "as",
            "probability": 8.070919546229162e-08,
            "start_logit": 5.749351978302002,
            "end_logit": -3.262566566467285
        },
        {
            "text": "eosinophilic asthma, therefore, well-designed head-to-head trials are needed",
            "probability": 2.5391928057193127e-08,
            "start_logit": 8.988980293273926,
            "end_logit": -7.658616065979004
        },
        {
            "text": "asth",
            "probability": 3.7641730983793005e-09,
            "start_logit": 5.749351978302002,
            "end_logit": -6.327890872955322
        },
        {
            "text": "asthma, therefore, well-designed head-to-head trials are needed",
            "probability": 9.948164964820464e-10,
            "start_logit": 5.749351978302002,
            "end_logit": -7.658616065979004
        },
        {
            "text": "asthma, therefore, well-designed head-to-head trials are needed to compare the efficacy of those mAbs",
            "probability": 9.438780857860816e-10,
            "start_logit": 5.749351978302002,
            "end_logit": -7.711177349090576
        },
        {
            "text": "AHR has been suggested as the main treatable trait towards precision medicine in patients suffering from eosinophilic asthma,",
            "probability": 1.9026775008330222e-10,
            "start_logit": -3.3807945251464844,
            "end_logit": -0.18259556591510773
        },
        {
            "text": "AHR has been suggested as the main treatable trait towards precision medicine in patients suffering from e",
            "probability": 2.4893031245652705e-11,
            "start_logit": -3.3807945251464844,
            "end_logit": -2.216439962387085
        },
        {
            "text": "AHR has been suggested as the main treatable trait towards precision medicine in patients suffering from eosinophilic as",
            "probability": 8.744817949329508e-12,
            "start_logit": -3.3807945251464844,
            "end_logit": -3.262566566467285
        },
        {
            "text": "precision medicine in patients suffering from eosinophilic asthma,",
            "probability": 5.2070480477383155e-12,
            "start_logit": -6.979213714599609,
            "end_logit": -0.18259556591510773
        }
    ],
    "61f7c904882a024a10000027_007": [
        {
            "text": "asthma",
            "probability": 0.9994282331943254,
            "start_logit": 9.763860702514648,
            "end_logit": 9.241938591003418
        },
        {
            "text": "as",
            "probability": 0.0005575505476963271,
            "start_logit": 9.763860702514648,
            "end_logit": 1.7505531311035156
        },
        {
            "text": "thymic stromal lymphopoietin, an epithelial cytokine involved in asthma",
            "probability": 7.462186282637711e-06,
            "start_logit": -2.041229486465454,
            "end_logit": 9.241938591003418
        },
        {
            "text": "asthma pathogenesis.",
            "probability": 3.380025292506308e-06,
            "start_logit": 9.763860702514648,
            "end_logit": -3.355116844177246
        },
        {
            "text": "asth",
            "probability": 1.571239505466371e-06,
            "start_logit": 9.763860702514648,
            "end_logit": -4.121135234832764
        },
        {
            "text": "asthma pathogenesis. In the phase 2b PATHWAY",
            "probability": 6.59246761998981e-07,
            "start_logit": 9.763860702514648,
            "end_logit": -4.989657402038574
        },
        {
            "text": "asthma pathogenesis",
            "probability": 4.5775612358430033e-07,
            "start_logit": 9.763860702514648,
            "end_logit": -5.354418754577637
        },
        {
            "text": "asthma pathogenesis. In the phase 2b PATHWAY study",
            "probability": 3.15517539544939e-07,
            "start_logit": 9.763860702514648,
            "end_logit": -5.726541042327881
        },
        {
            "text": "asthma pathogenesis. In the phase 2b",
            "probability": 1.7363521953457806e-07,
            "start_logit": 9.763860702514648,
            "end_logit": -6.323798656463623
        },
        {
            "text": "asthma pathogenesis. In the phase 2b PATHWAY study (ClinicalTrials.gov",
            "probability": 1.3188858556934543e-07,
            "start_logit": 9.763860702514648,
            "end_logit": -6.598797798156738
        },
        {
            "text": "blocks thymic stromal lymphopoietin, an epithelial cytokine involved in asthma",
            "probability": 5.83585867968031e-08,
            "start_logit": -6.892226696014404,
            "end_logit": 9.241938591003418
        },
        {
            "text": "thymic stromal lymphopoietin, an epithelial cytokine involved in as",
            "probability": 4.162926271953448e-09,
            "start_logit": -2.041229486465454,
            "end_logit": 1.7505531311035156
        },
        {
            "text": "asthma.",
            "probability": 1.7681421239385055e-09,
            "start_logit": 2.210214376449585,
            "end_logit": -3.357179641723633
        },
        {
            "text": "severe, uncontrolled asthma",
            "probability": 2.0045536385298972e-10,
            "start_logit": -5.275875568389893,
            "end_logit": 1.951817274093628
        },
        {
            "text": "tezepelumab significantly reduced exacerbations in adults with severe, uncontrolled asthma",
            "probability": 7.44371932276789e-11,
            "start_logit": -6.2665114402771,
            "end_logit": 1.951817274093628
        },
        {
            "text": "with severe, uncontrolled asthma",
            "probability": 6.463891930780444e-11,
            "start_logit": -6.407650470733643,
            "end_logit": 1.951817274093628
        },
        {
            "text": "adults with severe, uncontrolled asthma",
            "probability": 3.835266481241365e-11,
            "start_logit": -6.929643154144287,
            "end_logit": 1.951817274093628
        },
        {
            "text": "significantly reduced exacerbations in adults with severe, uncontrolled asthma",
            "probability": 3.733461302770567e-11,
            "start_logit": -6.956546306610107,
            "end_logit": 1.951817274093628
        },
        {
            "text": "blocks thymic stromal lymphopoietin, an epithelial cytokine involved in as",
            "probability": 3.255647674405317e-11,
            "start_logit": -6.892226696014404,
            "end_logit": 1.7505531311035156
        },
        {
            "text": "thymic stromal lymphopoietin, an epithelial cytokine involved in asthma pathogenesis.",
            "probability": 2.523680794177138e-11,
            "start_logit": -2.041229486465454,
            "end_logit": -3.355116844177246
        }
    ],
    "61f7c904882a024a10000027_008": [
        {
            "text": "Asthma",
            "probability": 0.9740693400649243,
            "start_logit": 4.899068355560303,
            "end_logit": 7.43295955657959
        },
        {
            "text": "Severe Asthma",
            "probability": 0.025317089827794237,
            "start_logit": 1.2490655183792114,
            "end_logit": 7.43295955657959
        },
        {
            "text": "Asthma.",
            "probability": 0.0003344004078730722,
            "start_logit": -3.0778303146362305,
            "end_logit": 7.43295955657959
        },
        {
            "text": "Patients With Severe Asthma",
            "probability": 0.00010338628903944554,
            "start_logit": -4.251697063446045,
            "end_logit": 7.43295955657959
        },
        {
            "text": "As",
            "probability": 0.00010049893717149912,
            "start_logit": 4.899068355560303,
            "end_logit": -1.7461310625076294
        },
        {
            "text": "With Severe Asthma",
            "probability": 1.9750200213070494e-05,
            "start_logit": -5.907005786895752,
            "end_logit": 7.43295955657959
        },
        {
            "text": "Tezepelumab to Guide Phase 3 Dose Selection for Patients With Severe Asthma",
            "probability": 1.8518091512034984e-05,
            "start_logit": -5.971421241760254,
            "end_logit": 7.43295955657959
        },
        {
            "text": "Phase 3 Dose Selection for Patients With Severe Asthma",
            "probability": 8.25925276315213e-06,
            "start_logit": -6.778835296630859,
            "end_logit": 7.43295955657959
        },
        {
            "text": "Pharmacodynamic Modeling of Tezepelumab to Guide Phase 3 Dose Selection for Patients With Severe Asthma",
            "probability": 7.89135266104589e-06,
            "start_logit": -6.82440185546875,
            "end_logit": 7.43295955657959
        },
        {
            "text": "Severe Asthma.",
            "probability": 6.092756264399936e-06,
            "start_logit": -7.08306884765625,
            "end_logit": 7.43295955657959
        },
        {
            "text": "Dose Selection for Patients With Severe Asthma",
            "probability": 4.8004636470405195e-06,
            "start_logit": -7.3214569091796875,
            "end_logit": 7.43295955657959
        },
        {
            "text": "Patients With Severe Asthma.",
            "probability": 4.585907959947201e-06,
            "start_logit": -7.367181301116943,
            "end_logit": 7.43295955657959
        },
        {
            "text": "Asth",
            "probability": 2.6579257094453267e-06,
            "start_logit": 4.899068355560303,
            "end_logit": -5.378732204437256
        },
        {
            "text": "Severe As",
            "probability": 2.6120734072166826e-06,
            "start_logit": 1.2490655183792114,
            "end_logit": -1.7461310625076294
        },
        {
            "text": "Severe Asth",
            "probability": 6.908229339930352e-08,
            "start_logit": 1.2490655183792114,
            "end_logit": -5.378732204437256
        },
        {
            "text": "Se",
            "probability": 1.7023204412110598e-08,
            "start_logit": 1.2490655183792114,
            "end_logit": -6.779453277587891
        },
        {
            "text": "Severe",
            "probability": 1.572844801027631e-08,
            "start_logit": 1.2490655183792114,
            "end_logit": -6.858559608459473
        },
        {
            "text": "Patients With Severe As",
            "probability": 1.0666809578337772e-08,
            "start_logit": -4.251697063446045,
            "end_logit": -1.7461310625076294
        },
        {
            "text": "With Severe As",
            "probability": 2.037713383120757e-09,
            "start_logit": -5.907005786895752,
            "end_logit": -1.7461310625076294
        },
        {
            "text": "Tezepelumab to Guide Phase 3 Dose Selection for Patients With Severe As",
            "probability": 1.9105914115724364e-09,
            "start_logit": -5.971421241760254,
            "end_logit": -1.7461310625076294
        }
    ],
    "61f7c904882a024a10000027_009": [
        {
            "text": "asthma",
            "probability": 0.9991318693703302,
            "start_logit": 8.346634864807129,
            "end_logit": 8.296957015991211
        },
        {
            "text": "severe asthma",
            "probability": 0.0004910817486471437,
            "start_logit": 0.7286034226417542,
            "end_logit": 8.296957015991211
        },
        {
            "text": "as",
            "probability": 0.0002622995546300241,
            "start_logit": 8.346634864807129,
            "end_logit": 0.05180215463042259
        },
        {
            "text": "asthma.",
            "probability": 0.00010113735005996866,
            "start_logit": -0.8515276908874512,
            "end_logit": 8.296957015991211
        },
        {
            "text": "asth",
            "probability": 1.0216543561242727e-05,
            "start_logit": 8.346634864807129,
            "end_logit": -3.193676710128784
        },
        {
            "text": "with severe asthma",
            "probability": 1.2811987414499904e-06,
            "start_logit": -5.220211029052734,
            "end_logit": 8.296957015991211
        },
        {
            "text": "tezepelumab in adults and adolescents with severe asthma",
            "probability": 5.600696246151542e-07,
            "start_logit": -6.047701358795166,
            "end_logit": 8.296957015991211
        },
        {
            "text": "phase 3 studies of tezepelumab in adults and adolescents with severe asthma",
            "probability": 5.134554436205682e-07,
            "start_logit": -6.134599208831787,
            "end_logit": 8.296957015991211
        },
        {
            "text": "adults and adolescents with severe asthma",
            "probability": 3.0795738010421945e-07,
            "start_logit": -6.645801067352295,
            "end_logit": 8.296957015991211
        },
        {
            "text": "in adults and adolescents with severe asthma",
            "probability": 2.740228874187454e-07,
            "start_logit": -6.7625508308410645,
            "end_logit": 8.296957015991211
        },
        {
            "text": "subcutaneously as the dose for phase 3 studies of tezepelumab in adults and adolescents with severe asthma",
            "probability": 1.7722999122499715e-07,
            "start_logit": -7.198314189910889,
            "end_logit": 8.296957015991211
        },
        {
            "text": "adolescents with severe asthma",
            "probability": 1.4289097273396303e-07,
            "start_logit": -7.413680553436279,
            "end_logit": 8.296957015991211
        },
        {
            "text": "severe as",
            "probability": 1.2892244548085308e-07,
            "start_logit": 0.7286034226417542,
            "end_logit": 0.05180215463042259
        },
        {
            "text": "severe asth",
            "probability": 5.021517410256059e-09,
            "start_logit": 0.7286034226417542,
            "end_logit": -3.193676710128784
        },
        {
            "text": "severe asthma.",
            "probability": 3.2078672933991913e-09,
            "start_logit": 0.7286034226417542,
            "end_logit": -3.6418025493621826
        },
        {
            "text": "severe",
            "probability": 7.231431249129147e-10,
            "start_logit": 0.7286034226417542,
            "end_logit": -5.131556987762451
        },
        {
            "text": "with severe as",
            "probability": 3.3634985488619154e-10,
            "start_logit": -5.220211029052734,
            "end_logit": 0.05180215463042259
        },
        {
            "text": "tezepelumab in adults and adolescents with severe as",
            "probability": 1.4703365752004521e-10,
            "start_logit": -6.047701358795166,
            "end_logit": 0.05180215463042259
        },
        {
            "text": "phase 3 studies of tezepelumab in adults and adolescents with severe as",
            "probability": 1.3479615485482766e-10,
            "start_logit": -6.134599208831787,
            "end_logit": 0.05180215463042259
        },
        {
            "text": "210 mg every 4 weeks subcutaneously as the dose for phase 3 studies of tezepelumab in adults and adolescents with severe as",
            "probability": 1.1457716313211168e-10,
            "start_logit": -6.297114372253418,
            "end_logit": 0.05180215463042259
        }
    ],
    "644ef78f57b1c7a315000084_001": [
        {
            "text": "nucleoprotein complex called chromatin in a manner that enables it to be rapidly accessed during genomic processes.",
            "probability": 0.6609917284970046,
            "start_logit": 0.8685916662216187,
            "end_logit": -2.1534461975097656
        },
        {
            "text": "nucleoprotein complex",
            "probability": 0.15933880986982327,
            "start_logit": 0.8685916662216187,
            "end_logit": -3.5761547088623047
        },
        {
            "text": "nucleosome",
            "probability": 0.09448389740971694,
            "start_logit": -1.4629148244857788,
            "end_logit": -1.7672516107559204
        },
        {
            "text": "the nucleosome",
            "probability": 0.021894737350900285,
            "start_logit": -2.925097942352295,
            "end_logit": -1.7672516107559204
        },
        {
            "text": "nucleosome,",
            "probability": 0.012922765595003978,
            "start_logit": -1.4629148244857788,
            "end_logit": -3.756690502166748
        },
        {
            "text": "chromatin in a manner that enables it to be rapidly accessed during genomic processes. Formation of the nucleosome",
            "probability": 0.007671528902794056,
            "start_logit": -3.9738283157348633,
            "end_logit": -1.7672516107559204
        },
        {
            "text": "nucleoprotein",
            "probability": 0.006465162770544993,
            "start_logit": 0.8685916662216187,
            "end_logit": -6.780759334564209
        },
        {
            "text": "nucleoprotein complex called",
            "probability": 0.006453461701440767,
            "start_logit": 0.8685916662216187,
            "end_logit": -6.782570838928223
        },
        {
            "text": "a rather ingenious nucleoprotein complex",
            "probability": 0.005664282010179172,
            "start_logit": -2.4682610034942627,
            "end_logit": -3.5761547088623047
        },
        {
            "text": "chromatin in a manner that enables it to be rapidly accessed during genomic processes.",
            "probability": 0.005213864587323758,
            "start_logit": -3.9738283157348633,
            "end_logit": -2.1534461975097656
        },
        {
            "text": "nucleoprotein complex called chromatin",
            "probability": 0.004371661953230018,
            "start_logit": 0.8685916662216187,
            "end_logit": -7.172044277191162
        },
        {
            "text": "the nucleosome,",
            "probability": 0.002994590256188611,
            "start_logit": -2.925097942352295,
            "end_logit": -3.756690502166748
        },
        {
            "text": "nucleoprotein complex called chromatin in a manner that enables it to be rapidly accessed during genomic processes",
            "probability": 0.002595619684780762,
            "start_logit": 0.8685916662216187,
            "end_logit": -7.693362236022949
        },
        {
            "text": "n",
            "probability": 0.002241735434791987,
            "start_logit": 0.8685916662216187,
            "end_logit": -7.839937210083008
        },
        {
            "text": "nucleoprotein complex called chromatin in",
            "probability": 0.0022395515802278955,
            "start_logit": 0.8685916662216187,
            "end_logit": -7.840911865234375
        },
        {
            "text": "nucleosome, which is the fundamental unit of chromatin,",
            "probability": 0.001155771735764231,
            "start_logit": -1.4629148244857788,
            "end_logit": -6.170912742614746
        },
        {
            "text": "chromatin in a manner that enables it to be rapidly accessed during genomic processes. Formation of the nucleosome,",
            "probability": 0.0010492514860623236,
            "start_logit": -3.9738283157348633,
            "end_logit": -3.756690502166748
        },
        {
            "text": "chromatin, occurs via a stepwise process that is reversed to enable the disassembly of nucleosomes.",
            "probability": 0.0008438413198507979,
            "start_logit": -5.793101787567139,
            "end_logit": -2.155284881591797
        },
        {
            "text": "Formation of the nucleosome",
            "probability": 0.0007977827545657865,
            "start_logit": -6.237263202667236,
            "end_logit": -1.7672516107559204
        },
        {
            "text": "nucleosome, which is the fundamental unit of chromatin",
            "probability": 0.0006099550998055934,
            "start_logit": -1.4629148244857788,
            "end_logit": -6.810050964355469
        }
    ],
    "644ef78f57b1c7a315000084_002": [
        {
            "text": "chromatin fibres, and tethering of chromosomal regions to nuclear structures.",
            "probability": 0.18829474805001234,
            "start_logit": -4.116919994354248,
            "end_logit": -2.3207039833068848
        },
        {
            "text": "DNA in eukaryotes is packed into chromatin.",
            "probability": 0.15882798890553262,
            "start_logit": -4.307684898376465,
            "end_logit": -2.30012583732605
        },
        {
            "text": "Inside the cell nucleus, chromatin is folded into higher-order structures",
            "probability": 0.11904198077287996,
            "start_logit": -2.950275421142578,
            "end_logit": -3.945880889892578
        },
        {
            "text": "nucleosome consisting of DNA wrapped around a histone octamer.",
            "probability": 0.08417320428011765,
            "start_logit": -4.92520809173584,
            "end_logit": -2.3175477981567383
        },
        {
            "text": "Inside the cell nucleus, chromatin is folded into higher-order structures through various mechanisms,",
            "probability": 0.04850309471157523,
            "start_logit": -2.950275421142578,
            "end_logit": -4.843729496002197
        },
        {
            "text": "higher-order structures",
            "probability": 0.046291621436966836,
            "start_logit": -3.8947906494140625,
            "end_logit": -3.945880889892578
        },
        {
            "text": "chromatin fibres,",
            "probability": 0.0448749201459872,
            "start_logit": -4.116919994354248,
            "end_logit": -3.754833459854126
        },
        {
            "text": "nuclear structures.",
            "probability": 0.03782163181890685,
            "start_logit": -5.722047328948975,
            "end_logit": -2.3207039833068848
        },
        {
            "text": "chromatin is folded into higher-order structures",
            "probability": 0.03546451118808071,
            "start_logit": -4.161219120025635,
            "end_logit": -3.945880889892578
        },
        {
            "text": "chromatin fibres",
            "probability": 0.034688963187345045,
            "start_logit": -4.116919994354248,
            "end_logit": -4.012290954589844
        },
        {
            "text": "Inside the cell nucleus",
            "probability": 0.03263287239438381,
            "start_logit": -2.950275421142578,
            "end_logit": -5.240036964416504
        },
        {
            "text": "looping of chromatin fibres, and tethering of chromosomal regions to nuclear structures.",
            "probability": 0.032139725456796796,
            "start_logit": -5.884835720062256,
            "end_logit": -2.3207039833068848
        },
        {
            "text": "chromatin is the nucleosome consisting of DNA wrapped around a histone octamer.",
            "probability": 0.022499637755231516,
            "start_logit": -6.2445855140686035,
            "end_logit": -2.3175477981567383
        },
        {
            "text": "chromatin.",
            "probability": 0.02027691696442392,
            "start_logit": -6.366023540496826,
            "end_logit": -2.30012583732605
        },
        {
            "text": "chromatin. The basic component of chromatin is the nucleosome consisting of DNA wrapped around a histone octamer.",
            "probability": 0.019926712790923153,
            "start_logit": -6.366023540496826,
            "end_logit": -2.3175477981567383
        },
        {
            "text": "higher-order structures through various mechanisms,",
            "probability": 0.018861303250601726,
            "start_logit": -3.8947906494140625,
            "end_logit": -4.843729496002197
        },
        {
            "text": "The basic component of chromatin is the nucleosome consisting of DNA wrapped around a histone octamer.",
            "probability": 0.01654810506643793,
            "start_logit": -6.551813125610352,
            "end_logit": -2.3175477981567383
        },
        {
            "text": "chromatin is folded into higher-order structures through various mechanisms,",
            "probability": 0.014449848145059415,
            "start_logit": -4.161219120025635,
            "end_logit": -4.843729496002197
        },
        {
            "text": "the nucleosome consisting of DNA wrapped around a histone octamer.",
            "probability": 0.012362174038869843,
            "start_logit": -6.843443393707275,
            "end_logit": -2.3175477981567383
        },
        {
            "text": "histone octamer.",
            "probability": 0.012320039639867095,
            "start_logit": -6.84685754776001,
            "end_logit": -2.3175477981567383
        }
    ],
    "644298cc57b1c7a315000062_001": [
        {
            "text": "Facial-scapular-humeral myodystrophy Landouzy-Dejerine",
            "probability": 0.9531427907474816,
            "start_logit": 1.0561455488204956,
            "end_logit": 1.939139485359192
        },
        {
            "text": "Landouzy-Dejerine",
            "probability": 0.03942775374010723,
            "start_logit": -2.1291491985321045,
            "end_logit": 1.939139485359192
        },
        {
            "text": "ectopic expression of the transcription factor DUX4 in skeletal muscle.",
            "probability": 0.0012636170734930095,
            "start_logit": -2.12664794921875,
            "end_logit": -1.503853440284729
        },
        {
            "text": "autosomal dominant",
            "probability": 0.0012599493255337584,
            "start_logit": -1.4458836317062378,
            "end_logit": -2.1875245571136475
        },
        {
            "text": "Facial-scapular-humeral myodystrophy Landouzy-Dejerine (FSHD)",
            "probability": 0.0008471408720550033,
            "start_logit": 1.0561455488204956,
            "end_logit": -5.086513519287109
        },
        {
            "text": "Facial-scapular-humeral myodystrophy",
            "probability": 0.000840376842580323,
            "start_logit": 1.0561455488204956,
            "end_logit": -5.09453010559082
        },
        {
            "text": "Landouzy-Dejerine (FSHD) is an autosomal dominant",
            "probability": 0.0006362306879524071,
            "start_logit": -2.1291491985321045,
            "end_logit": -2.1875245571136475
        },
        {
            "text": "autosomal dominant disease,",
            "probability": 0.0005452026972986332,
            "start_logit": -1.4458836317062378,
            "end_logit": -3.025193691253662
        },
        {
            "text": "Dejerine",
            "probability": 0.0004565542203906894,
            "start_logit": -6.587666988372803,
            "end_logit": 1.939139485359192
        },
        {
            "text": "myodystrophy Landouzy-Dejerine",
            "probability": 0.0003385773259800388,
            "start_logit": -6.886621952056885,
            "end_logit": 1.939139485359192
        },
        {
            "text": "Facial-scapular-humeral myodystrophy Landouzy-Dejerine (FSHD",
            "probability": 0.0002813907340215874,
            "start_logit": 1.0561455488204956,
            "end_logit": -6.188636302947998
        },
        {
            "text": "Landouzy-Dejerine (FSHD) is an autosomal dominant disease,",
            "probability": 0.0002753084430827161,
            "start_logit": -2.1291491985321045,
            "end_logit": -3.025193691253662
        },
        {
            "text": "the basis of its pathogenesis is ectopic expression of the transcription factor DUX4 in skeletal muscle.",
            "probability": 0.00016090771229953626,
            "start_logit": -4.1875505447387695,
            "end_logit": -1.503853440284729
        },
        {
            "text": "autosomal dominant disease, the basis of its pathogenesis is ectopic expression of the transcription factor DUX4",
            "probability": 0.00013213032661060756,
            "start_logit": -1.4458836317062378,
            "end_logit": -4.442562580108643
        },
        {
            "text": "FSHD) is an autosomal dominant",
            "probability": 0.0001317436511871848,
            "start_logit": -3.703852415084839,
            "end_logit": -2.1875245571136475
        },
        {
            "text": "autosomal dominant disease, the basis of its pathogenesis is ectopic expression of the transcription factor DUX4 in skeletal muscle",
            "probability": 6.73114752765503e-05,
            "start_logit": -1.4458836317062378,
            "end_logit": -5.117020606994629
        },
        {
            "text": "ectopic expression of the transcription factor DUX4",
            "probability": 6.688832520697912e-05,
            "start_logit": -2.12664794921875,
            "end_logit": -4.442562580108643
        },
        {
            "text": "FSHD) is an autosomal dominant disease,",
            "probability": 5.700784350894035e-05,
            "start_logit": -3.703852415084839,
            "end_logit": -3.025193691253662
        },
        {
            "text": "Landouzy-Dejerine (FSHD)",
            "probability": 3.504287291557905e-05,
            "start_logit": -2.1291491985321045,
            "end_logit": -5.086513519287109
        },
        {
            "text": "ectopic expression of the transcription factor DUX4 in skeletal muscle",
            "probability": 3.407508301805694e-05,
            "start_logit": -2.12664794921875,
            "end_logit": -5.117020606994629
        }
    ],
    "644298cc57b1c7a315000062_002": [
        {
            "text": "FSHD2 is caused by the mutations in the protein regulating the methylation status of chromatin - SMCHD1.",
            "probability": 0.3271063207162416,
            "start_logit": 0.6232019662857056,
            "end_logit": -1.0953762531280518
        },
        {
            "text": "SMCHD1.",
            "probability": 0.2858034426477166,
            "start_logit": 0.48822101950645447,
            "end_logit": -1.0953762531280518
        },
        {
            "text": "FSHD2 is caused by the mutations in the protein regulating the methylation status of chromatin - SMCHD1",
            "probability": 0.1618333837907552,
            "start_logit": 0.6232019662857056,
            "end_logit": -1.7990942001342773
        },
        {
            "text": "SMCHD1",
            "probability": 0.14139909654283384,
            "start_logit": 0.48822101950645447,
            "end_logit": -1.7990942001342773
        },
        {
            "text": "FSHD2 is caused by the mutations in the protein regulating the methylation status of chromatin -",
            "probability": 0.036018010069854695,
            "start_logit": 0.6232019662857056,
            "end_logit": -3.301642417907715
        },
        {
            "text": "FSHD2 is caused by the mutations in the protein regulating the methylation status of chromatin",
            "probability": 0.018114767161561456,
            "start_logit": 0.6232019662857056,
            "end_logit": -3.98893404006958
        },
        {
            "text": "mutations in the protein regulating the methylation status of chromatin - SMCHD1.",
            "probability": 0.009380749355355844,
            "start_logit": -2.9284236431121826,
            "end_logit": -1.0953762531280518
        },
        {
            "text": "mutations in the protein regulating the methylation status of chromatin - SMCHD1",
            "probability": 0.00464105495530036,
            "start_logit": -2.9284236431121826,
            "end_logit": -1.7990942001342773
        },
        {
            "text": "FSHD2 is caused by the mutations",
            "probability": 0.003154604793338243,
            "start_logit": 0.6232019662857056,
            "end_logit": -5.736798286437988
        },
        {
            "text": "the mutations in the protein regulating the methylation status of chromatin - SMCHD1.",
            "probability": 0.0020221044660385544,
            "start_logit": -4.462944507598877,
            "end_logit": -1.0953762531280518
        },
        {
            "text": "FSHD2",
            "probability": 0.001962437047285658,
            "start_logit": 0.6232019662857056,
            "end_logit": -6.211474418640137
        },
        {
            "text": "FSHD2 is caused by the mutations in",
            "probability": 0.0012085923941571137,
            "start_logit": 0.6232019662857056,
            "end_logit": -6.696205139160156
        },
        {
            "text": "FSHD2 is caused by the mutations in the protein regulating the methylation status of chromatin - SMCHD",
            "probability": 0.0011294542236234982,
            "start_logit": 0.6232019662857056,
            "end_logit": -6.763926982879639
        },
        {
            "text": "the protein regulating the methylation status of chromatin - SMCHD1.",
            "probability": 0.001096850115493383,
            "start_logit": -5.07464075088501,
            "end_logit": -1.0953762531280518
        },
        {
            "text": "mutations in the protein regulating the methylation status of chromatin -",
            "probability": 0.001032923864033464,
            "start_logit": -2.9284236431121826,
            "end_logit": -3.301642417907715
        },
        {
            "text": "the mutations in the protein regulating the methylation status of chromatin - SMCHD1",
            "probability": 0.0010004209255292727,
            "start_logit": -4.462944507598877,
            "end_logit": -1.7990942001342773
        },
        {
            "text": "SMCHD",
            "probability": 0.0009868409290220476,
            "start_logit": 0.48822101950645447,
            "end_logit": -6.763926982879639
        },
        {
            "text": "FSHD2 is caused by the mutations in the protein regulating the methylation status",
            "probability": 0.0008955392374530213,
            "start_logit": 0.6232019662857056,
            "end_logit": -6.995990753173828
        },
        {
            "text": "by the mutations in the protein regulating the methylation status of chromatin - SMCHD1.",
            "probability": 0.0006707484467284657,
            "start_logit": -5.566444396972656,
            "end_logit": -1.0953762531280518
        },
        {
            "text": "the protein regulating the methylation status of chromatin - SMCHD1",
            "probability": 0.0005426583176775685,
            "start_logit": -5.07464075088501,
            "end_logit": -1.7990942001342773
        }
    ],
    "6442933f57b1c7a315000060_001": [
        {
            "text": "partial deletion of the D4Z4 repeats on the 4th chromosome affects the expression of DUX4",
            "probability": 0.3945411492274824,
            "start_logit": -3.9102396965026855,
            "end_logit": -3.2329325675964355
        },
        {
            "text": "deletion of the D4Z4 repeats on the 4th chromosome affects the expression of DUX4",
            "probability": 0.19144286352497072,
            "start_logit": -4.633373737335205,
            "end_logit": -3.2329325675964355
        },
        {
            "text": "In FSHD1, partial deletion of the D4Z4 repeats on the 4th chromosome affects the expression of DUX4",
            "probability": 0.04714072781354328,
            "start_logit": -6.034825801849365,
            "end_logit": -3.2329325675964355
        },
        {
            "text": "FSHD1, partial deletion of the D4Z4 repeats on the 4th chromosome affects the expression of DUX4",
            "probability": 0.040857191465242956,
            "start_logit": -6.17788028717041,
            "end_logit": -3.2329325675964355
        },
        {
            "text": "different genetic causes but are phenotypically indistinguishable.",
            "probability": 0.03356893704858471,
            "start_logit": -6.699036121368408,
            "end_logit": -2.9082584381103516
        },
        {
            "text": "D4Z4 repeats on the 4th chromosome affects the expression of DUX4",
            "probability": 0.030096654536199037,
            "start_logit": -6.483549118041992,
            "end_logit": -3.2329325675964355
        },
        {
            "text": "partial deletion of the D4Z4 repeats",
            "probability": 0.028229328036561314,
            "start_logit": -3.9102396965026855,
            "end_logit": -5.870294570922852
        },
        {
            "text": "which have different genetic causes but are phenotypically indistinguishable.",
            "probability": 0.027206649091622345,
            "start_logit": -6.909175872802734,
            "end_logit": -2.9082584381103516
        },
        {
            "text": "DUX4",
            "probability": 0.02607670634341077,
            "start_logit": -6.626920700073242,
            "end_logit": -3.2329325675964355
        },
        {
            "text": "have different genetic causes but are phenotypically indistinguishable.",
            "probability": 0.025041540744147134,
            "start_logit": -6.992101192474365,
            "end_logit": -2.9082584381103516
        },
        {
            "text": "partial deletion of the D4Z4",
            "probability": 0.02501879203835098,
            "start_logit": -3.9102396965026855,
            "end_logit": -5.991028785705566
        },
        {
            "text": "genetic causes but are phenotypically indistinguishable.",
            "probability": 0.023642156756338475,
            "start_logit": -7.049605846405029,
            "end_logit": -2.9082584381103516
        },
        {
            "text": "partial deletion of the D4Z4 repeats on the 4th chromosome",
            "probability": 0.01967833446508967,
            "start_logit": -3.9102396965026855,
            "end_logit": -6.231137752532959
        },
        {
            "text": "FSHD2 (MIM: 158901),",
            "probability": 0.017336961825311078,
            "start_logit": -5.164559841156006,
            "end_logit": -5.103495121002197
        },
        {
            "text": "partial deletion",
            "probability": 0.016219917210629098,
            "start_logit": -3.9102396965026855,
            "end_logit": -6.4244160652160645
        },
        {
            "text": "deletion of the D4Z4 repeats",
            "probability": 0.013697692636843447,
            "start_logit": -4.633373737335205,
            "end_logit": -5.870294570922852
        },
        {
            "text": "deletion of the D4Z4",
            "probability": 0.01213984700743103,
            "start_logit": -4.633373737335205,
            "end_logit": -5.991028785705566
        },
        {
            "text": "FSHD1 (MIM:158900) and FSHD2 (MIM: 158901),",
            "probability": 0.010532360327388827,
            "start_logit": -5.662948131561279,
            "end_logit": -5.103495121002197
        },
        {
            "text": "deletion of the D4Z4 repeats on the 4th chromosome",
            "probability": 0.009548501358540866,
            "start_logit": -4.633373737335205,
            "end_logit": -6.231137752532959
        },
        {
            "text": "FSHD2",
            "probability": 0.007983688542311868,
            "start_logit": -5.164559841156006,
            "end_logit": -5.87893533706665
        }
    ],
    "6442933f57b1c7a315000060_002": [
        {
            "text": "Facial-scapular-humeral myodystrophy Landouzy-Dejerine",
            "probability": 0.967689970952753,
            "start_logit": 1.7075694799423218,
            "end_logit": 2.4940173625946045
        },
        {
            "text": "Landouzy-Dejerine",
            "probability": 0.027641770224469245,
            "start_logit": -1.848014235496521,
            "end_logit": 2.4940173625946045
        },
        {
            "text": "autosomal dominant",
            "probability": 0.0009625748751636754,
            "start_logit": -1.077721357345581,
            "end_logit": -1.6337469816207886
        },
        {
            "text": "Facial-scapular-humeral myodystrophy Landouzy-Dejerine (FSHD)",
            "probability": 0.0006855321182134717,
            "start_logit": 1.7075694799423218,
            "end_logit": -4.758454322814941
        },
        {
            "text": "ectopic expression of the transcription factor DUX4 in skeletal muscle.",
            "probability": 0.0005635670575837726,
            "start_logit": -1.8360295295715332,
            "end_logit": -1.4107643365859985
        },
        {
            "text": "Facial-scapular-humeral myodystrophy",
            "probability": 0.0005330984888417398,
            "start_logit": 1.7075694799423218,
            "end_logit": -5.00994348526001
        },
        {
            "text": "Landouzy-Dejerine (FSHD) is an autosomal dominant",
            "probability": 0.0004455542342174149,
            "start_logit": -1.848014235496521,
            "end_logit": -1.6337469816207886
        },
        {
            "text": "autosomal dominant disease,",
            "probability": 0.00031580917512411455,
            "start_logit": -1.077721357345581,
            "end_logit": -2.748220682144165
        },
        {
            "text": "Dejerine",
            "probability": 0.0002922335095927444,
            "start_logit": -6.3975443840026855,
            "end_logit": 2.4940173625946045
        },
        {
            "text": "Facial-scapular-humeral myodystrophy Landouzy-Dejerine (FSHD",
            "probability": 0.0002149903592416329,
            "start_logit": 1.7075694799423218,
            "end_logit": -5.918056488037109
        },
        {
            "text": "myodystrophy Landouzy-Dejerine",
            "probability": 0.0001830331349960222,
            "start_logit": -6.8654303550720215,
            "end_logit": 2.4940173625946045
        },
        {
            "text": "Landouzy-Dejerine (FSHD) is an autosomal dominant disease,",
            "probability": 0.00014618095569690837,
            "start_logit": -1.848014235496521,
            "end_logit": -2.748220682144165
        },
        {
            "text": "FSHD) is an autosomal dominant",
            "probability": 8.038854506439244e-05,
            "start_logit": -3.5604615211486816,
            "end_logit": -1.6337469816207886
        },
        {
            "text": "autosomal dominant disease, the basis of its pathogenesis is ectopic expression of the transcription factor DUX4",
            "probability": 6.260207208752484e-05,
            "start_logit": -1.077721357345581,
            "end_logit": -4.366560459136963
        },
        {
            "text": "the basis of its pathogenesis is ectopic expression of the transcription factor DUX4 in skeletal muscle.",
            "probability": 6.040428396733259e-05,
            "start_logit": -4.069255828857422,
            "end_logit": -1.4107643365859985
        },
        {
            "text": "autosomal dominant disease, the basis of its pathogenesis is ectopic expression of the transcription factor DUX4 in skeletal muscle",
            "probability": 3.201114103788849e-05,
            "start_logit": -1.077721357345581,
            "end_logit": -5.0372748374938965
        },
        {
            "text": "ectopic expression of the transcription factor DUX4",
            "probability": 2.9326460750772137e-05,
            "start_logit": -1.8360295295715332,
            "end_logit": -4.366560459136963
        },
        {
            "text": "FSHD) is an autosomal dominant disease,",
            "probability": 2.6374509413510952e-05,
            "start_logit": -3.5604615211486816,
            "end_logit": -2.748220682144165
        },
        {
            "text": "Landouzy-Dejerine (FSHD)",
            "probability": 1.958201682558893e-05,
            "start_logit": -1.848014235496521,
            "end_logit": -4.758454322814941
        },
        {
            "text": "ectopic expression of the transcription factor DUX4 in skeletal muscle",
            "probability": 1.499588495924792e-05,
            "start_logit": -1.8360295295715332,
            "end_logit": -5.0372748374938965
        }
    ]
}
